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Pathogenesis and virology of rotavirus 
In this thesis I shall focus on rotavirus. Rotavirus is a member of the so-called Reoviridae family 
and  was discovered as a novel pathogen by Dr. Ruth Bishop together with colleagues at the 
Royal Children’s Hospital (RCH) in 1973(1). The name rotavirus was first coined one year later 
by Thomas Henry Flewett and in 1978 rotavirus was officially defined(2). Since, it has become 
clear that it constitutes a major health concern. 
Indeed data from 2015 show that diarrheal disease is the fourth leading cause of death among 
children under 5 years old, responsible for almost 500 000 deaths in that year (3). As one of 
the leading causal factors for pediatric diarrhea globally,  it is estimated that rotavirus 
infection develops in 25% of cases in moderate-to-severe illnesses (4) and associates with 
approximately 125,000-200,000 deaths each year(3, 5), contributing to 30% of all death due 
to diarrhea for the first two years after birth (6).  
Though among young children, diarrhea-associated mortality number has decreased since 
1990 by approximately 65% (7), due to limited resources and poor hygiene practices, 
situations are still unsatisfactory in many developing countries and especially India, Nigeria, 
Pakistan, and the Democratic Republic of the Congo need to be named in this respect as they 
together account for half of the global mortally due to pediatric diarrhea (8). 
Although primarily a health concern in infants, it is important to realize that rotavirus infection 
is not restricted by age. Especially orthotopic organ transplantation patients are effected, the 
average incidence of rotavirus infection is 3.03% among them, with intestinal transplant 
recipients, liver transplant recipients and hematopoietic stem cell transplant patients being 
under the highest risk for suffering from rotavirus infection-caused chronic diarrhea (9). 
Improved treatment options are called for. 
Rational novel avenues for the treatment of rotavirus may be designed following an 
understanding of rotavirus biology. Rotavirus is a non-enveloped virus which has a double-
stranded RNA genome containing 11 segments and is surrounded by multilayered icosahedral 
protein capsid. Its genome encodes 12 proteins including 6 viral proteins and 6 non-structural 
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proteins (10).  VP1, VP2 and VP3 proteins make up the rotavirus core particle. VP1 protein is 
the RNA-dependent RNA polymerase (RdRP) of rotavirus catalyzing viral RNA synthesis (11). 
VP2 protein consists of 120 molecules and VP3 is a guanylyl transferase (12, 13). There is also 
a VP4 protein, with a length of 775 or 776 amino acids and this constitutes an 84 KDa spike 
protein, part of the outer capsid. VP4 needs to be cleaved into VP5* and VP8* before the virus 
is infectious. This process will activate the virus, and it helps the virus to penetrate the target 
cell’s interior (14). VP6 forms the bulk of the capsid. It is highly antigenic and constitutes the 
intermediate shell of the virions (15). VP7 forms as trimers the icosahedral lattice of the 
rotavirus outer capsid, in addition it also plays an important role in the virus’ uncoating 
process once it enters host cells (16). Although there is a lot of information on the biology of 
the virus, this has still to be translated into improved therapeutic strategies. 
Vaccination and treatment against rotavirus infection 
Up to 2019, there were four rotavirus vaccines that had been prequalified by the WHO for 
global use: Rotarix (GlaxoSmithKline Biologicals SA, Rixensart, Belgium; prequalified in 2009), 
RotaTeq (Merck & Co., Inc. , West point, PA, USA; prequalified in 2008), Rotavac (Bharat 
Biotech, Hyderabad, India; prequalified in 2018), and ROTASIIL (Serum Institute of India PVT. 
LTD., Pune, India; prequalified in 2018) (17). Among these vaccines, Rotarix and RotaTeq were  
used in 97 countries in the end of 2018, while Rotavac and ROTASIIL were only used in India 
and the Palestine district. Besides these vaccines, which are used on international scale, two 
additional rotavirus vaccines have come available for nationwide-restricted use only: Rotavin-
M1 (Center of Research and Production of Vaccines and Biologicals, Hanoi, Vietnam) is 
available in Vietnam only and the Lanzhou Lamb Rotavirus (LLR) vaccine (Lanzhou Institute of 
Biological Products Co., Ltd., Lanzhou, China), which now serves the private market in China 
(17). More widespread use of the latter two vaccines is hampered by the unique 
immunological profiles elicited, In past decade, rotavirus vaccines have made a remarkable 
impact on the global burden of disease (18). Nevertheless, initial optimism has recently 
subsided.  
Though rotavirus vaccination programs have generated a huge breakthrough in preventing 
young children to contract rotavirus-related diarrhea, for patients who have already been 
infected by rotavirus, vaccination is not effective and specific medical treatment 
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counteracting ongoing rotavirus-mediated disease is still lacking. Indeed, even in developed 
countries, treatment is largely confined to supportive care and mainly involves rehydration 
and maintenance of fluid and electrolyte balance (19, 20). Even for many developing countries, 
the lack of coverage of rotavirus vaccination precludes efficient protection of the population 
at large. In addition, in severe cases, which include immunocompromised patients subject to 
rotavirus infection, virus-specific treatment is needed. Therefore, further steps should be 
taken to reduce the burden of mortality and morbidity and especially more research on the 
development of novel antiviral therapies is required and might even be considered urgent (21). 
Furthermore, as rotavirus is especially a scourge for resource-limited regions, cost efficacy 
should also be taken into account. An obvious solution is to investigate the potential for 
effective treatment based on the existing approved reagents, especially broad-spectrum 
antiviral agents come to mind in this respect. 
Viral-host interaction 
Evolutionary pressure and especially the need for efficient production of novel viral particles 
as well as the fight with the cell-autonomous innate immune system has shaped viral biology. 
Many viral mRNAs have acquired a variety of sophisticated strategies to compete with cellular 
mRNAs that are already present in the cytoplasm. This allows the selective translation of viral 
mRNAs, since they circumvent the need to possess the required components to initiate the 
translation of mRNA (22, 23). In this the eukaryotic translation initiation factor 4F (eIF4F) is 
important to consider. eIF4F is a protein complex containing three constituent proteins: a 
eukaryotic translation initiation factor 4A (eIF4A), a eukaryotic translation initiation factor 4E 
(eIF4E), and a eukaryotic translation initiation factor 4G (eIF4G)(24). This complex plays a 
pivotal role in cap-dependent mRNA protein translation initiated by recruiting mRNA to a 
ribosome (25). Moreover, it is essential in the regulation of interferon (INF) signaling(26), 
which closely relates to anti-viral immunity. 
Innate immune responses are at the front line of this battle, playing a critical role against 
rotavirus infection and the critical role of INF signaling in this fight is well-established (27). 
Cytokine production, a broad term that includes the production of IFNs , are induced following 
the recognition of rotavirus viral proteins and/or RNA by the infected host cell (28). IFNs 
constitute a group of related humoral factors that exert potent antiviral activities and are 
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further subclassified into three groups: type I INFs (IFN-α, IFN-β, IFN-δ and others), type II INFs 
(IFN-γ) and type Ⅲ INFs (IFN-λ1, IFN-λ2 and IFN-λ3)(29, 30). They bind to distinct cognate but 
evolutionary related receptors and all signal through the Janus kinase signal transducer and 
activator of transcription (JAK-STAT) pathway (30, 31). Following engagement of IFNs with 
their receptors, STAT1 and STAT2 are activated through phosphorylation and subsequently 
form complexes of STAT proteins that will translocate to the nucleus and bind to IFN 
regulatory factor 9 (IRF9) to form the  IFN-stimulated gene factor 3 complex (ISGF3). ISGF3 
induces transcription of numerous IFN-stimulated genes (ISGs) which cooperatively exert 
antiviral effect against various kinds of viruses (32). Moreover, recognition of rotavirus and 
IFN induction are indispensable to promote the development of adaptive B-cell mediated 
immune response and thus links innate immunity to adaptive immunity (33). The resulting 
evolutionary pressure on rotavirus has fostered the pathogen in developing its own strategies 
to evade such host immune responses. For instance, rotavirus can inhibit the production of 
IFNs in infected cells by blocking the activation of STAT1 and STAT2 proteins (34). Although 
many details are still unclear, one of the viral nonstructural proteins, NSP1, was reported to 
mediate this inhibition of IFN signaling in rotavirus infected primary mouse cells (35). Further 
understanding of the interaction of rotavirus with the host innate immune machinery may 
well be essential for developing novel rational avenues for managing rotavirus-provoked 
disease. 
Nucleotide biosynthesis and viral infection 
Cellular nucleotides, which are classified as either purines or pyrimidines, are the building 
blocks of RNA and DNA. Cellular demand for nucleotides is met either through the activity of 
the de novo synthesis pathway or through the salvage pathway (36) and also viruses require 
these pathways to obtain the nucleotides essential for their replication. Therefore, host 
enzymes or other molecules involved in nucleoside biosynthesis pathways represent potential 
targets for antiviral strategies. 
Pyrimidine biosynthesis is a relatively linear sequential process in which the enzyme 
dihydroorotate dehydrogenase (DHODH) represents the fourth and, importantly, rate-limiting 
step. The enzyme is located in the inner membrane of mitochondria where it catalyzes the 
conversion of dihydroorotate to orotate (37). The thus produced orotate is then a substrate 
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for uridine monophosphate (UMP) synthase and the UMP resulting from the reaction serves 
as an essential precursor for synthesis of all other pyrimidine nucleotides. Several studies have 
reported that the inhibition of DHODH enzyme suppresses a range of different viruses’ 
replication (6, 38-40). Apparently viral replication is more dependent on pyrimidine 
biosynthesis relative to host demands for these nucleotides. 
Gemcitabine is a cytidine analogue, it has been reported to inhibit pyrimidine biosynthesis 
resulting in depletion of nucleotide pool (43) and might thus be useful for combating viral 
replication. By inference from the dependency of viral replication on pyrimidine biosynthesis, 
also purine biosynthesis might be target for anti-viral therapy. A common strategy for 
interfering with purine biosynthesis is the use of poorly-metabolizable analogues of 
intermediate products its biosynthetic pathway. 6-thioguanine (6-TG), a thio analogue of the 
naturally occurring purine base guanine, has been used clinically since 1950s (41). Metabolized 
6-TG can bind to Rac1 to form a 6-TGNP•Rac1 complex that inhibits the activation of Rac1, an 
important regulator of cell physiology (42). The usefulness for interfering with nucleotide 
biosynthesis for combating rotavirus infection, however, remains largely obscure at best, 
prompting studies in this respect. 
Organoid models for studying rotavirus infection 
Lack of insight into the biology of rotavirus was also due to the absence of appropriate cellular 
model systems that truly recapitulated the infection process in vivo. An exciting development 
in this respect is advent of organoid technology. In 2009, the group of Prof. dr. Hans Clevers 
from Hubrecht institute (Utrecht, Netherlands) established primary intestinal organoids from 
intestinal stem cells (ISCs) (44). Subsequently the same research team generated liver 
organoids as well. Organoid technology is largely possible through exploiting the properties of 
the Lgr5-positive (Lgr5+) stem cells (45, 46). Compared to conventional 2D cultured 
immortalized cell lines, organoids model systems are superior in various respects: 1. 2D 
cultured immortalized cells are cancer cells, which by definition involves genetic alterations 
and thus never truly mimic the situation in healthy cells in vivo; although there are certainly 
differences between organoids and real body structures, at least the genetic dimension is 
absent in organoid models. 2. As organoids have the capacity to form different types of stem 
cell-derived progeny they allow study of the interactions between these different cell types, 
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at least more so as compared to conventional model systems. 3. Organoids are 3D structures, 
hence studying spatial effects is greatly facilitated compared to 2D cultures. 4. Establishing 
immortalized cell lines is cumbersome and does not really allow personalized medicine. 
Indeed, much of the knowledge on intestinal cell biology generated in the last century 
depended on the use of a handful of cell lines. Organoids models perform much better in this 
respect and might allow precision medicine, also potentially with respect to rotavirus-
mediated disease. Overall, for rotavirus research the organoid model appears highly 
promising and I decided in the course of this thesis research to grab the momentum and 
opportunity involved. 
Biliary atresia and rotavirus infection 
Effective research into rotavirus-mediated disease requires full understanding of the entire 
spectrum of clinical manifestations associated with rotavirus infection. In this case biliary 
atresia (BA) has been overlooked. BA is a neonatal disease of the liver and bile duct and is 
characterized by a progressive fibro-inflammatory obliteration of both the intrahepatic and 
extrahepatic bile duct. If untreated, patients have a high risk for developing chronic cholestasis 
and biliary cirrhosis. Also, in infants BA is one of the leading causes of end-stage liver disease 
requiring liver transplantation (47, 48). The pathogenesis of BA remains unknown, however 
the evidence points to multiple pathogenic mechanisms being involved in the development of 
BA, including gene mutation (49), exposure to environmental toxins (50), dysregulation of the 
immune system, and most importantly, viral factors (51-56). 
Various lines of evidence led me to speculate that rotavirus is one of the viral factors causing 
biliary atresia. In rodents experimental rotavirus infection provokes aspects of neonate biliary 
atresia. Remarkable findings in respect are that both blood-borne viral antigens (antigenemia) 
and infectious virus (viremia) have been detected in this mouse model while other data 
indicates as well that rotavirus infection is not limited to the intestinal mucosa but may escape 
into the circulation, thus potentially reaching bile duct structures (57-61). If rotavirus indeed 
causes biliary atresia in children, this will constitute an important extra-intestinal clinical 
manifestation of rotavirus-mediated pathology and would have important consequences with 
respect to our thinking on how rotavirus infection should be managed and prevented. 
Aim of this thesis  
Chapter 1 
 
9 | P a g e  
 
Following the introduction of rotavirus vaccines on a global scale the burden provoked by this 
virus to mankind has been decreasing. Nevertheless, especially in developing countries, the 
rotavirus-associated misery is still depressingly common, in particular with respect to infants. 
In addition, persistent rotavirus infection commonly occurs in immunocompromised patients, 
irrespective whether this concerns pediatric or adult patients and whether they hail from 
developing or developed countries. Finally, the full amount of clinical manifestations caused 
by rotavirus infections may be underestimated, for instance rotavirus may be one of the 
causative agents of biliary atresia in neonates. Overall, there is clear need for obtaining better 
insight into the role of rotavirus in pathophysiology and to define novel ways of dealing with 
rotavirus-induced disease, especially for patients in which disease has already manifested 
itself and thus vaccination is no longer an option. Excitingly, the advent of the 3D organoid 
model also opens new possibilities to perform research into rotavirus, previously impossible. 
In conjunction, I considered the case for investigating rotavirus biology imperative.  
Outline of this thesis 
Although it is well-recognized that rotavirus infection causes thousands of deaths among 
children under 5 years old, the full spectrum of rotavirus-mediated disease may still be 
underestimated. There is substantial evidence indicating the possible involvement of rotavirus 
in BA development, at least in a subset of patients, but in lieu of concrete proof this issue 
remains largely ignored both by medical professionals as well as by policy decision makers. 
Therefore, in Chapter 2, exploiting the novel possibilities offered by the recently developed 
organoid technology, I investigated the role of rotavirus in BA development and I 
demonstrated that human biliary organoids are susceptible to rotavirus infection, and this 
leads to active virus-host interactions and causes severe cytopathogenesis. Furthermore, I 
demonstrated that antiviral drugs and neutralizing antibodies can counteract the infection 
and BA-like morphological changes, suggesting their potential for mitigating BA in patients.  
Thus, encouraged to further identify novel avenues for treating rotavirus infection, I 
investigated the viral mRNA translation process. In Chapter 3, I investigated the function of 
eukaryotic translation initiation factor 4F (eIF4F) complex in rotavirus replication. I dissect the 
effects of loss-of-function of the three components of eIF4F, including eIF4A, eIF4E and eIF4G, 
and establish the resulting consequences on the levels of rotavirus genomic RNA and viral 
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protein VP4. Consistent with the observations made, I observe that knockdown of the 
negative regulator of eIF4F and programmed cell death protein 4 (PDCD4) inhibits the 
expression of viral mRNA and the VP4 protein. More importantly, I established that eIF4F 
complex can regulate the IFN signaling pathway in the context of rotavirus infection. In 
Chapter 4 I further extend these observations. Host immune responses determine the 
outcome of viral infections, and IFNs are produced as the first and the main anti-viral cytokines 
to combat the virus infection. In this chapter I show that rotavirus predominantly induces type 
III IFNs (IFN-λ1), and to a lesser degree type I IFNs (IFN-α and IFN-β) in human intestinal cells 
on the RNA level. However, I was not able to detect IFN protein and thus this interferon 
response is not sufficient to effectively inhibit rotavirus replication. In contrast, however, I 
establish a significant role of constitutive IFN signaling for limiting rotavirus replication, as for 
instance evident from experiments involving the silencing of STAT1, STAT2 and IRF9 genes. In 
addition, exogenous IFN treatment impaired rotavirus replication irrespective of IFN type used. 
Again making this observation was also facilitated by the use of organoid technology. IFNs 
significantly upregulated a panel of well-known anti-viral ISGs and inhibition of the JAK-STAT 
cascade abrogated ISG induction and the anti-rotavirus effects of IFNs. Thus overall, I was able 
to substantially advance our understanding of the interaction between rotavirus infection and 
intestinal epithelial innate immunity. 
Viral replication heavily relies on the host to supply nucleosides. So, limiting nucleoside 
availability might inhibit rotavirus replication. In Chapter 5, I demonstrate that two specific 
DHODH enzyme inhibitors, brequinar (BQR) and leflunomide (LFM) robustly inhibit rotavirus 
replication in the conventional human intestinal Caco2 cell line model as well as in human 
primary intestinal organoids. These antiviral effects are evident both when using the 
laboratory strain SA11 as well as when using the rotavirus strain 2011K which was isolated 
from clinical sample in my host institution. Mechanistic studies indicated that BQR and LFM 
exerted their anti-rotavirus effect through targeting DHODH and by depleting the pyrimidine 
nucleotide pool. Therefore, targeting pyrimidine biosynthesis represents a potential approach 
for developing antiviral strategies against rotavirus. In Chapter 6, I aimed at testing on the 
other side of the nucleoside coin, in casu purine biosynthesis, by testing another 
immunosuppressive drug 6-TG, a purine biosynthesis inhibitor. I observed, however, that 6-
TG although significantly inhibits rotavirus replication, gene knockdown or knockout of Rac1, 
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an alternative cellular target of 6-TG, also significantly inhibited rotavirus replication, 
indicating a previously not-suspected accessory role for Rac1 in rotavirus infection. I further 
demonstrated that 6-Thioguanine (6-TG) can effectively inhibit the active form of Rac1 (GTP-
Rac1) and essentially mediates the anti-rotavirus effect of 6-TG. Consistently, ectopic over-
expression of GTP-Rac1 facilitates but an inactive Rac1 (N17) or a specific Rac1 inhibitor 
(NSC23766) inhibits rotavirus replication. In conclusion, I identified 6-TG as an effective 
inhibitor of rotavirus replication but that unexpectedly acts through inhibition of Rac1 
activation. In Chapter 7, I screened a library of safe-in-man broad-spectrum antivirals and 
identified gemcitabine, a widely used anticancer drug, as a potent inhibitor of rotavirus 
infection. I confirmed this effect in 2D cell cultures and 3D cultured human intestinal organoids 
with both laboratory-adapted rotavirus strains and five clinical isolates. Supplementation of 
UTP or uridine largely abolished the anti-rotavirus activity of gemcitabine, suggesting its 
function through inhibition of pyrimidine biosynthesis pathway.  
Overall, I feel I have been able to significantly advance our understanding of rotavirus disease 
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Biliary atresia (BA) is a neonatal liver disease characterized by progressive fibro-inflammatory 
obliteration of both intrahepatic and extrahepatic bile duct. The etiologies of BA remain 
largely unknown, but rotavirus infection has been implicated at least for a subset of patients 
and this causal relation has been well-demonstrated in mouse models. In this study, we aim 
to further consolidate this evidence in human biliary organoids. We obtained seven batches 
of human biliary organoids cultured from fetal liver, adult liver and bile duct tissues. We found 
that these organoids are highly susceptible and support the full life cycle of rotavirus infection 
in 3D culture. The robust infection triggers active virus-host interactions, including interferon-
based host defense mechanisms and injury response. We have observed direct 
cytopathogenesis in organoids upon rotavirus infection, which may partially recapitulate the 
development of BA. Importantly, we have demonstrated the efficacy of mycophenolic acid 
and interferon-alpha but not ribavirin in inhibiting rotavirus in biliary organoids. Furthermore, 
a neutralizing antibody targeting rotavirus VP7 protein effectively inhibits the infection in 
organoids. Thus, we have substantiated the causal evidence of rotavirus inducing BA in 
humans and provided potential strategies to combat the disease.  
Importance 
There are substantial evidence indicating the possible involvement of rotavirus in biliary 
atresia (BA) development at least in a subset of patients, but concrete proof remains lacking. 
In mouse model, it has been well-demonstrated that rotavirus can infect the biliary epithelium 
to cause biliary inflammation and obstruction, representing the pathogenesis of BA in 
humans. By using the recently developed organoids technology, we now have demonstrated 
that human biliary organoids are susceptible to rotavirus infection, and this provokes active 
virus-host interactions and causes severe cytopathogenesis. Thus, our model recapitulates 
some essential aspects of BA development. Furthermore, we have demonstrated that antiviral 
drugs and neutralizing antibodies are capable of counteracting the infection and BA-like 
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Biliary atresia, Rotavirus infection, Human organoids 
Observation 
Biliary atresia (BA) is characterized by progressive fibro-inflammatory obliteration of the bile 
ducts, resulting in chronic cholestasis and biliary cirrhosis. It is one of the leading causes for 
liver transplantation in infants (1, 2). Exposure to rotavirus in mice has demonstrated the 
infection in biliary epithelium, resulting in BA-like biliary inflammation and obstruction (3). 
Nevertheless, whether rotavirus is a causal agent for BA in patients remains controversial, also 
because of a paucity of preclinical models. Organoid technology provides an excellent way 
forward here. These 3D cultured organoids are superior in recapitulating the architecture, 
composition, diversity, organization and functionality of cell types of the tissue/organ of 
origin. Human organoids have been increasingly explored to advance the research in disease 
modeling (4, 5). Although it is feasible to culture hepatocyte-like organoids from liver tissue, 
it remains technically challenging with stringent requirement of experimental protocols (6). In 
contrast, organoids resembling cholangiocyte-phenotype are relatively easy to be cultured 
from the hepatic and extrahepatic bile duct compartments (7-9). In this study, we explored 
the feasibility of employing human biliary organoids cultured from fetal liver, adult liver and 
bile duct for recapitulating BA development.  
The canonical compartment for rotavirus infection is the small intestinal enterocyte. We have 
previously shown that human intestinal organoids (HIOs) sustain rotavirus infection (4) and 
we now again confirmed these results (see Fig. S1A-C in the supplemental material). BA is a 
disorder that typically first manifests itself during mid-gestation and murine experimentation 
has demonstrated rotavirus-induced BA development. Hence, we first tested if biliary fetal 
liver organoids (FLOs) support rotavirus infection. Inoculation of FLOs with rotavirus resulted 
in an increase of cellular viral RNA by a factor of 103-105 at 24 hours and 104-106 fold at 48 
hours post-inoculation (Fig. 1A) with a concomitant increase in levels of rotavirus VP4 protein 
(Fig. 1B). Thus the human fetal biliary epithelium is highly permissive for rotavirus infection, 
comparable to the level in intestinal epithelium (Fig. S1A). In apparent agreement, 
supernatant harvested from infected FLOs effectively infected and replicated in Caco2 
intestinal epithelial model as shown by qRT-PCR quantification of viral RNA (Fig 1C). Next, we 
performed TCID50 assay to compare the level of infectious viral particles between the baseline 
Chapter 2 
 
19 | P a g e  
 
of inoculation and five batches of organoids at 48 hours post-inoculation. We harvested 
rotavirus from the organoids through repeated freezing and thawing and demonstrated 102-
103 times increase of infectious virus titers (Fig. 1D). This was further confirmed by cytopathic 
effects in Caco2 cells at 48 hours post-inoculation with rotavirus harvested from these five 
batches of organoids and the control (see Fig. S2 in the supplemental material). Collectively, 
these results convincingly showed effective replication and production of infectious viral 
particles by infected fetal biliary organoids. Similar results were obtained in biliary organoids 
derived from adult human liver and bile duct (Fig. 1A-C). Thus, the human biliary epithelium 
is highly susceptible to rotavirus infection and supports its full life cycle.  
To better understand the consequences of rotavirus infection in biliary epithelium, we 
performed a genome-wide transcriptomic analysis of FLOs upon infection. Volcano plots of 
the results showed significant down-regulation of 103 and up-regulation of 512 genes in 
response to rotavirus, compared to uninfected organoids (Fig. 1E). Most of the highly up-
regulated genes, including IFIT2, IFITM3, OASL, DDX58, MX2, IFI35, HERC5 and BST2, are 
interferon-stimulated genes (ISGs). Other genes, such as CXCL11 and NLRC5 are related to 
inflammatory response. Gene ontology (GO) enrichment analysis of these differentially 
expressed genes confirmed the essential involvement of “immune system process” (Fig. 1F). 
Interestingly, “response to stress”, “cell death” and “extracellular space” were also identified 
as the top regulated processes, with obvious relations to the development and pathogenesis 
of BA (Fig. 1E).  
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Figure 1. Characterizing rotavirus infection in human biliary organoids. (A) The dynamics of cellular viral 
RNA levels upon inoculation of SA11 rotavirus at different time points of post-inoculation. The level at post-
inoculation 1 hour (hr) was set as 1. Three batches of human fetal liver organoids (FLOs), two adult liver 
(LiOs) and two bile duct organoids (BDOs) were tested. (B) Expression of rotavirus VP4 protein in the 
organoids determined by Western blotting. (C) Inoculation of human intestinal Caco2 cell line with 
supernatant from rotavirus infected organoids for 48 hrs. Relative cellular viral RNA levels were quantified. 
(D) TCID50 of five batches of rotavirus infected organoids at 48 hrs post-inoculation compared with the basal 
level at incubation. Organoids after inoculation were thoroughly washed to remove free viruses and 
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subjected to repeated freezing and thawing to harvest the attached and entered rotaviruses. The total 
amount of rotaviruses in organoids incubated for 48 hrs were harvested by repeated freezing and thawing 
of entire well. (E) Volcano plots of differentially expressed genes in rotavirus infected (for 48 hrs) compared 
to un-infected fetal liver organoids. (F) Gene ontology (GO) enrichment analysis of differentially expressed 
genes. All the data represent as means ± SEM. For each organoids batch, experiments were repeated 3-6 
times. Mann-Whitney test; *P < 0.05, **P < 0.01. 
This is in line with the observations that naïve organoids grow and become hyaline in a 
spheroidal shape, whereas rotavirus-infected organoids are opaque, shriveled and 
disorganized (Fig. 2A; upper panel). Propidium iodide (PI) staining marked the wide-spread of 
dead cells in infected organoids (Fig. 2A; middle panel). Confocal analysis after 
immunostaining of viral VP6 protein further visualized the disruption of infected organoid cells 
(Fig. 2A; lower panel). Quantitative analysis demonstrated significant increase of the 
percentage of deteriorated biliary organoids at 12-, 24- and 48-hours post-infection of 
rotavirus (Fig. 2B). Thus, rotavirus infection causes severe cytopathogenesis in human biliary 
organoids.  
Next, we evaluated a monoclonal neutralizing antibody targeting rotavirus VP7 protein (10) 
using three representative batches of biliary organoids. It effectively inhibited rotavirus 
infection in a dose-dependent manner (Fig. 2C). Finally, the effects of the known broad 
antiviral drugs were tested in all bathes of organoids. Similar as in HIOs (see Fig. S1D in the 
supplemental material), mycophenolic acid (MPA) and interferon-alpha (IFN-α) potently 
inhibited rotavirus in all batches of biliary organoids (Fig. 2D). Surprisingly, ribavirin is effective 
in intestinal (Fig. S1D) but not in biliary organoids (Fig. 2D). Therefore, antiviral drugs and 
neutralizing antibodies are potential therapeutics to combat rotavirus infection in the human 
biliary epithelium compartment.  
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Figure 2. Cytopathogenesis of rotavirus infected human biliary organoids, and efficacy of antiviral 
treatment/neutralizing antibody. (A) Organoids from 50 µm -150 µm diameter were selected to capture 
images. Optical microscopy images of infected and un-infected organoids (upper). Fluorescence staining of 
dead cells (PI; red), live cells (Calcein; green) and nuclei (Hoechst; blue) (middle). Confocal immunostaining 
of rotavirus structural protein VP6 (red), Epcam (green) and nuclei (blue) (lower). These are representative 
images of one FLO batch from the tested seven biliary organoids batches. (B) Quantitative analysis of the 
percentage of deteriorated organoids with or without rotavirus infection at indicated time points and 
calculated based on the live/dead cell staining (A, middle). (C) The inhibitory activities of neutralizing 
monoclonal antibody HS-1 against rotavirus infection in three representative batches of biliary organoids. 
(D) The effects of the broad-spectrum antiviral drugs on rotavirus in biliary organoids. Ribavirin: Rib; 
mycophenolic acid: MPA; interferon alpha: IFN-α. All the data represent as means ± SEM. For each 
organoids batch, experiments were repeated 3-6 times. Mann-Whitney test; *P < 0.05, **P < 0.01. 
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Discussion and conclusions 
Although the etiologies and pathogenesis of BA remain largely unknown, multiple pathogenic 
mechanisms are likely involved, including genetic mutations (11), exposure of environmental 
toxins (12), dysregulation of immune system, and most intriguingly, viral factors in particular 
rotavirus (3, 13-18). Previous studies have attempted to detect rotavirus in liver or biliary 
tissues and the antibody in serum of BA patients, but results are inconclusive (19). Since the 
wide implementation of vaccines that have substantially counteracted rotavirus-mediated 
diarrheal disease, more direct investigation on causality of rotavirus infection for BA has 
become possible. A survey of the national registry system in Taiwan found decreased 
incidence of BA from 2004 to 2009 mirroring the increased uptake of rotavirus vaccination 
(20). A nationwide population-based study in Korea has shown that rotavirus infection in 
neonates is a risk factor for BA, although vaccination did not impact disease incidence (21).  
Unfortunately, detection of rotavirus in tissue is often not feasible, as advanced disease is 
usually diagnosed in children of 4-6 weeks old and the virus likely has been cleared by that 
time. Here we show, however, using organoid technology that the human biliary epithelium 
supports the full life cycle of rotavirus infection and results in cellular and morphological 
changes consistent with BA development, even in the absence of immune cell components in 
our model. Furthermore, we identify therapeutic strategies potentially useful for combating 
rotavirus infection in the biliary epithelium.  
Interestingly, a study in mice has demonstrated that maternal vaccination can prevent 
rotavirus-induced BA in newborn pups (22). This is in line with our findings that neutralizing 
antibodies inhibit rotavirus infection in organoids. Thus, we have substantiated the causal 
evidence of rotavirus inducing BA in humans and provided potential strategies to combat the 
disease.  
 
Materials and methods 
Human fetal liver organoids (FLOs, n=3 batches) were initiated from 17-week-old human fetal 
livers collected at abortion, from adult liver (LiOs, n=2 batches), and from adult bile duct 
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(BDOs, n=2 batches). Human intestinal organoids (HIOs, n=1 batch) were cultured to serve as 
standard model for rotavirus infection. Detailed methods are described in the Text S1 of 
supplemental materials and methods.  
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Text S1 – Supplemental Materials and Methods 
Reagents 
Propidium iodide (PI) (Method Detection Limit [MDL] no. MFCD00011921), calcein-AM (MDL 
no. MFCD05861516), ribavirin (MDL no. MFCD00058564) and mycophenolic acid (MPA) 
(MDL no. MFCD00036814) were purchased from Sigma. All the reagents above were 
dissolved in dimethyl sulfoxide (DMSO). Hoechst 33342 (Catalog number: H3570) and Type I 
human recombinant IFN alpha 2a (IFN-α) were purchased from Thermo Fisher, and IFN-α 
was dissolved in culture medium. 
Viruses 
Simian rotavirus SA11, a widely used laboratory strain(1), was gifted by Karen Knipping from 
Nutricia Research Utrecht, The Netherland. Rotavirus SA11 was prepared as previously 
described(2).  
Cell lines and human organoids 
Human colon cancer cell line Caco2 was cultured as previous study(3). Cells were analyzed 
by genotyping and confirmed to be mycoplasma negative. 
Human primary small intestinal organoids (HIOs) were cultured as described previously(4). 
three batches of human fetal liver organoids (FLO P, FLO 521 and FLO 528), two adult bile 
duct organoids (BDO S, DD 1125) and two adult liver organoids (LiO K, DL 1125) were 
cultured as previously described(5). The use of human organoids was approved by the 
Medisch Ethische Toetsings Commissie Erasmus MC (Medical Ethical Committee of the 
Erasmus medical center).  
Virus inoculation assay 
Virus, cell line and organoids were treated as previously described (4). Briefly, the stock of 
SA11 rotavirus (4.5*108 TCID50/ml) was used. MA104 cell line was inoculated with the 
diluted stock virus at MOI of 0.7 at 37 ̊C with 5 µg/mL of trypsin (Gibco, Paisley, UK) and 5% 
CO2 for 15 min. 
Chapter 2 
 
28 | P a g e  
 
For inoculating organoids, collected organoids were incubated with trypsin pre-activated 
rotavirus at concentration of 4.5*105 TCID50/ml for 1.5 h followed by 4 times wash with PBS. 
Afterwards, for RNA and protein detection assay, organoids with no Matrigel remain were 
spun down at 500 g for 10 min to adhered to the bottom of 24-well or 48-well plate coated 
with Collagen R solution (SERVA, Heidelberg, Germany). Culture medium was added gently 
and organoids were incubated at 37 ̊C with 5% CO2. Supernatant was harvested for 
secondary infection assay after 48 h incubation. Supernatant and organoids were harvested 
at different time points for RNA isolation or Western blot assay. Infected organoids for 
observation or staining were mixed with Matrigel and seeded back to 24-well plate for 
continues culturing. 
For secondary infection assay, Caco2 cells were washed, suspended in T75 flask and 
subsequently seeded into a 48-well plate (5×104 cells/well). Culture medium was discarded 
when cell confluence was approximately 80%, and cell monolayers were washed twice with 
PBS. 100 µL of serum-free DMEM medium, then pretreated supernatant were added and 
incubated at 37 ̊C with 5% CO2 for 60 min for infection, followed by 4 times washing with 
PBS to remove un-attached viruses. Then, cells were incubated with maintenance medium 
with 1 µg/mL of trypsin at 37 ̊C with 5% CO2. 
TCID50 assay 
The titers of rotaviruses produced by organoids were determined by calculating the 
log10TCID50/mL in Ma104 cells using the method developing by Reed and Muench in 1938(6). 
RNA isolation and sequencing, cDNA synthesis and qRT-PCR 
Total RNA was isolated using Macherey-Nagel NucleoSpin® RNA II kit (Bioke, Leiden, 
Netherlands) and quantified using a Nanodrop ND-1000 (Wilmington, DE, USA). The quality 
of RNA was measured by Bioanalyzer RNA 6000 Picochip as quality-control step, followed by 
RNA sequencing performed by Novogene with paired-end 150 bp (PE 150) sequencing 
strategy. qRT-PCR assay were performed and glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) gene was used as housekeeping gene. Relative gene expression was normalized to 
GAPDH using the formula 2-∆∆CT (∆∆CT = ∆CTsample - ∆CTcontrol). Template control and 
reverse transcriptase control were included in all qRT-PCR experiments. Primers for SA11 
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rotavirus are TGGTTAAACGCAGGATCGGA as sense and AACCTTTCCGCGTCTGGTAG as 
antisense primer. The primers for the reference gene GAPDH are 
GTCTCCTCTGACTTCAACAGCG and ACCACCCTGTTGCTGTAGTAGCCAA as sense and antisense 
primer, respectively.  
Determination of organoids cell death 
The staining and scoring process was performed as previously(3). In short, minimum of 100 
organoids were counted after 3 days of passaging. After 1.5 h incubation with SA11 
rotavirus, organoids were cultured in Matrigel for 48 h followed by staining with propidium 
iodide (PI) (red, dead cells), Hoechst (blue, nuclear), and Calcein (green, live cells). Images 
were detected using EVOS FL cell imaging system (Thermo Fisher). Under fluorescence 
version, organoids in which red signal is more than green signal and also more than 50% of 
blue signal was counted as positive. On the contrary, organoids in which green signal is more 
than red signal and also more than 50% of blue signal was treated as negative or viable. 
Three random visions in each well have been chosen and organoids have been counted by 
total number and viable number. The proportion of deteriorated organoids was calculated 
as (viable/ total).  
Western blot assay 
Lysed cells were subjected to SDS-PAGE, and proteins were transferred to PVDF membrane 
(Immobilon-FL). SA11 rotavirus VP4 (1:1000, HS-2, mouse monoclonal; provided by professor 
Harry Greenberg, Stanford University School of Medicine, USA) was detected by western 
blot analysis and β-actin protein was detected as loading control (sc-47778, 1:1000, mouse 
monoclonal; Santa Cruz). The intensity of the immunoreactive bands of blotted protein was 
quantified by the Odyssey V3.0 software. 
Immunofluorescence analysis 
After rotavirus infection, organoids were harvested and fixed in 4% paraformaldehyde in PBS 
at 4 ̊C for 10 min. Fixed organoids were added into the CytoSpin II Cytocentrifuge (Shandon 
Scientifi Ltd, Runcorn, England), then spun down at 1000 rpm for 2 min. The slides 
containing organoids were rinsed 3 times with PBS for 5 min each, followed by treatment 
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with 0.1% (vol/vol) Tritonx100 for 4 min. Subsequently, the slides were twice rinsed with PBS 
for 5 min, followed by incubation with milk-tween-glycine medium (0.05% tween, 0.5% skim 
milk and 0.15% glycine) to block background staining for 30 min. Slides were incubated in a 
humidity chamber with anti-rotavirus antibody (1:250, mouse monoclonal; Abcam) and anti-
EpCAM antibody (1:250, rabbit polyclonal; Abcam) diluted in milk-tween-glycine medium at 
4 ºC overnight. Slides were washed 3 times for 5 min each in PBS prior to 1 h incubation with 
1:1000 dilutions of the anti-mouse IgG (H+L, Alexa Fluor® 594) and the anti-rabbit IgG (H+L, 
Alexa Fluor® 488) secondary antibodies. Nuclei were stained with DAPI (4, 6-diamidino-2-
phenylindole; Invitrogen). Images were detected using Leica SP5 cell imaging system. 
Neutralization assay 
Neutralizing monoclonal antibody (MAb) HS-1 was gifted by Professor Harry Greenberg, 
Stanford University School of Medicine, USA. Neutralization assay was performed as 
previous study(7). Briefly, rotavirus were activated by 5 µg/mL trypsin, followed by adding 
Mab in series of dilution (1:1000, 1:250, 1:100), then kept neutralizing for 2 h at 37 ºC and 
overnight at 4 ºC. After 48 h inoculation with organoids, RNA was isolated and detected by 
qRT-PCR. 
Statistics 
The statistical significance of differences between means was assessed with the Mann-
Whitney test (GraphPad Prism 5; GraphPad Software Inc., La Jolla, CA). The threshold for 














Figure S1. Characterizing rotavirus infection in human intestinal organoids (HIOs). (A) Rotavirus RNA 
quantified by qRT-PCR post-inoculation. (B) Optical microscopy images of infected and un-infected 
organoids (upper). Fluorescence staining of dead cells (PI; red), live cells (Calcein; green) and nuclei 
(Hoechst; blue) (middle). Confocal immunostaining of rotavirus structural protein VP6 (red), Epcam (green) 
and nuclei (blue) (lower). (C) Quantitative analysis of the percentage of deteriorated organoids with or 
without rotavirus infection at indicated time points and calculated based on the live/dead cell staining (F, 
middle). (D) The effects of the broad-spectrum antiviral drugs on rotavirus in intestinal organoids. Ribavirin: 
Rib; mycophenolic acid: MPA; interferon alpha: IFN-α. All the data represent means ± SEM. Experiments 
were repeated 3-6 times. Mann-Whitney test; *P < 0.05, **P < 0.01. 
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Figure S2. Optical microscopy images of Caco2 cell infected with 104 times diluted rotavirus stocks 
harvested from five batches of organoids infected with rotavirus at 48 hours post-infection with the 
control at baseline inoculation (See Fig. 2D in details). In mock group, cells were all hyaline and 
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polygonous, while the other infected groups, except the control group, cells were spindle-shaped or 
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The eIF4F complex is a translation initiation factor that closely regulates translation in 
response to a multitude of environmental conditions including viral infection. How translation 
initiation factors regulate rotavirus infection remains poorly understood. In this study, the 
knockdown of the components of the eIF4F complex using shRNA and CRISPR/Cas9 was 
performed. We demonstrate that loss-of-function of the three components of eIF4F, including 
eIF4A, eIF4E and eIF4G, remarkably promotes the levels of rotavirus genomic RNA and viral 
protein VP4. Consistently, knockdown of the negative regulator of eIF4F and programmed cell 
death protein 4 (PDCD4) inhibits the expression of viral mRNA and the VP4 protein. 
Mechanically, we confirmed that the silence of the eIF4F complex suppressed the protein level 
of IRF1 and IRF7 that exert potent antiviral effects against rotavirus infection. Thus, these 
results demonstrate that the eIF4F complex is an essential host factor restricting rotavirus 
replication, revealing new targets for the development of new antiviral strategies against 
rotavirus infection. 
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INTRODUCTION 
Rotavirus is considered to be one of leading causative agent of severe diarrhea in infants 
younger than five years old [1], and it causes estimated 215,000 deaths in children each year 
globally [2]. Although rotavirus infection mainly occurs in low-income countries [3], it also 
inflicts a heavy burden in industrialized countries. For example, in the European Union, 
rotavirus infection causes more than 200 deaths, over 87,000 hospital admissions, and almost 
700,000 outpatient visits in children younger than five years of age annually [4]. Emerging 
evidence indicates that rotavirus infection causes severe complications in organ transplant 
patients irrespective to their ages [5]. Although vaccines have been developed, no approved 
antiviral treatment is available. 
The genome of rotavirus contains 11 segments encoding 12 proteins including six structural 
(VP1-4, VP6, and VP7) and six non-structural proteins (NSP1-6) [6]. Among the structural 
proteins, as a spike protein, rotavirus VP4 plays an essential role in both viral entry and exit 
[7]. VP4 was also demonstrated to be of importance in viral attachment and internalization 
[8], which is often used for the development of rotavirus vaccines [8]. VP4 contains two 
subunits including a C-terminal subunit VP5* and a N-terminal subunit VP8*, and both VP5* 
and VP8* help virus entry by interacting with several putative partners and cell surface 
receptors [7]. The rotavirus genome is a double-strand RNA containing a cap at 5’ untranslated 
regions (UTR) synthesized by the viral transcriptase but lacks a polyadenylated tail instead 
having a consensus sequence at 3’ UTR [9]. It has been reported that rotavirus NSP3 is able to 
bind to the 3’ consensus sequence of viral mRNA and interact with eIF4G to aid translation of 
viral mRNA [10]. Rotavirus NSP3 stabilizes the eIF4E–eIF4G interaction to exert an enhanced 
effect on the translation of both poly (A)- and non-poly (A)-tailed mRNAs [11]. 
There are three phases in protein synthesis including initiation, elongation, and termination 
[11]. Initiation determines translation rates [12]. Most of the eukaryotic mRNAs are 
characterized by a m7GpppX structure (where m7Gppp is the 7-methyl-guanosine-containing 
and X is any nucleotide), termed as a cap, at the 5’ ends and the poly (A) tail at the 3’ end [13]. 
The mRNA containing a cap at the 5’ ends is able to be more efficiently translated than that 
lacking this structure [14], and these mRNAs are translated in a cap-dependent manner [12]. 
The cap structure is bound by the eukaryotic translation initiation factor 4F (eIF4F) which is a 
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protein complex containing three constituent proteins: a eukaryotic translation initiation 
factor 4A (eIF4A), a eukaryotic translation initiation factor 4E (eIF4E), and a eukaryotic 
translation initiation factor 4G (eIF4G) [15]. The eIF4F complex plays a pivotal role in cap-
dependent mRNA protein translation initiated by recruiting mRNA to a ribosome [13]. As an 
RNA helicase, eIF4A makes use of ATP hydrolysis to unwind and resolve the RNA secondary 
structure [16]. The eIF4E recognizes and binds to the 7-methylguanosine (m7G) cap located 
at the 5’-UTRs of mRNA to mediate the mRNA recruitment on ribosomes, thus initiating the 
translation together with other initiation factors [17]. As a scaffold protein, eIF4G plays a 
central role in translation initiation by assembling eIF4E and eIF4A to further form the eIF4F 
complex [18]. The programmed cell death protein 4 (PDCD4) is a translation suppressor of 
mRNAs by interacting with eIF4A to suppress its helicase activity [19]. As a downstream target 
of mechanistic target of the rapamycin (mTOR) pathway, the phosphorylation of protein 
kinase S6K1 is able to phosphorylate PDCD4 to release it from eIF4A, thus allowing eIF4A to 
interact with eIF4G to form the eIF4F complex, followed by initiating translation [20]. 
Viruses require components from the host cell to replicate, assemble viral components, and 
release their new synthesized virions [14]. Viral protein synthesis completely relies on the 
translational machinery of the host due to viruses lacking this machinery themselves [21]. 
Viruses are able to exploit the translational machinery, including eIF4F, to support the 
translation of their transcripts [15]. Certain mammalian viruses are involved in targeting the 
eIF4F complex to regulate both viral and host mRNA translation; while many RNA viruses 
inhibit host protein synthesis to initiate the translation of their own mRNAs by inhibiting eIF4F 
[22]. Feline calicivirus (FCV) and mouse norovirus (MNV) have been reported to be capable of 
directly interacting with eIF4E, and viral RNA translation requires the eIF4A, indicating that 
the replication of the two viruses requires eIF4F [23]. Blocking eIF4E–eIF4G interaction has 
been demonstrated to cause inhibition of coronavirus replication, indicating that eIF4F has a 
promoting effect on the virus replication [24]. Furthermore, certain members of the eIF4G 
family were thought to be able restrict the infection of Rice yellow mottle virus (RYMV) [25]. 
Thus, the eIF4F complex has different effects on distinct viruses. 
The eIF4F complex plays an essential role in regulating interferon signaling which is considered 
to be the first line of antiviral defense [26]. The phosphorylation of eIF4E was reported to 
exert antiviral effect via regulating the production of type I interferon [27]. It was found that 
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the eIF4F complex could tightly regulate the translation of the signal transducer and activator 
of transcription 1 (STAT1) mRNA that plays a crucial role in type I interferon signaling [28]. 
Thus, in this study, we have dissected the effects of the cellular translation machinery, the 
eIF4F complex, on rotavirus infection, and we found that the eIF4F complex is an essential 




2.1. The eIF4A inhibits rotavirus infection 
We first examined the effects of rotavirus infection on the expression of the components of 
the eIF4F complex, including eIF4A and eIF4E, at indicated time points (1, 2, 4, 6, 24, and 48 
h). Although rotavirus infection did not affect the protein expression of the eIF4F complex 
(Supplementary Figure S1), it is interesting to investigate whether the components of the 
eIF4F complex regulate the course of the rotavirus infection. To this aim, we first detected the 
effects of eIF4A on rotavirus infection, by performing a lentiviral RNAi-mediated loss-of-
function assay to silence the eIF4A gene. All five short hairpin RNA (shRNA) vectors showed 
successful knockdown (Figure 1A, B). Importantly, two shRNA vectors (No 1 and 2) resulted in 
a 121.7 ± 60.6 (n = 6, P < 0.01)- and 56.7 ± 29.9 (n = 6, P < 0.01)- fold increase in SA11 rotavirus 
mRNA, respectively (Figure 1C). All shRNA vectors showed no clear cytotoxicity determined 
by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) assay 
(Supplementary Figure S2A). Western blot indicated that all five shRNA vectors increased the 
rotavirus VP4 protein level (Figure 1D). To further verify these findings, we used CRISPR/Cas9 
to knockout the eIF4A gene in Caco2 cells (Figure 1E). After eIF4A knockout, the viral mRNA 
and protein levels were remarkably reduced (Figure 1F, G). 
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Figure 1. Knockdown of eIF4A supports rotavirus infection. (A) Western blot assay detected eIF4A in Caco2 
cells transduced with lentiviral RNAi vectors against eIF4A. (B) Successful knockdown by shRNA vectors 
measured by RT-qPCR (n = 6, **P< 0.01, Mann-Whitney test). (C) Silence of eIF4A increased rotavirus 
genomic RNA level (n = 6, *P< 0.05, **P< 0.01, Mann-Whitney test). (D) Silence of eIF4A increased viral VP4 
protein level in SA11 rotavirus infected Caco2 cells. (E) Western blot detected eIF4A protein level in Caco2 
cells transduced with CRIPSRs against eIF4A, suggesting a successful knockout. (F) Silence of eIF4A by 
CRISPR/Cas9 increased rotavirus genomic RNA level (n = 6, *P< 0.05, Mann-Whitney test). (G) Silence of 
eIF4A by CRISPR/Cas9 increased viral VP4 protein level in SA11 rotavirus infected Caco2 cells. 
2.2. Blocking eIF4E promotes rotavirus infection 
Another component of the eIF4F complex, eIF4E, is responsible for binding to the cap of 
mRNA. Similarly, a lentiviral RNAi-mediated loss-of-function assay was performed to silence 
the eIF4E gene to assess its effect on rotavirus infection. One out of the four shRNAs exerted 
a potent knockdown effect on eIF4E (Figure 2A). Consistently, this shRNA vector resulted in a 
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14.5 ± 5.8 (n = 6, P < 0.01)-fold increase in SA11 rotavirus mRNA (Figure 2B). All shRNA vectors 
showed no clear cytotoxicity measured by MTT assay (Supplementary Figure S2B). This shRNA 
vector resulted in the increase in the SA11 rotavirus VP4 protein level (Figure 2C). To further 
verify this, we used CRISPR/Cas9 to knockout eIF4E in Caco2 cells (Figure 2D). After eIF4E gene 
knockout, the viral RNA and protein levels were restricted (Figure 2E, F). 
 
Figure 2. The eIF4E suppresses rotavirus infection. (A) Western blot assay measured eIF4E protein in Caco2 
cells transduced lentiviral RNAi vectors against eIF4E, indicating that one out of three shRNA vectors 
showed potent knockdown. (B) The knockdown of eIF4E significantly promoted rotavirus genomic RNA (n 
= 6, *P< 0.05, Mann-Whitney test). (C) Western blot assay confirmed eIF4E knockdown increased rotavirus 
protein level. (D) The eIF4E was knockout by crispr/cas9 assay. (E) Silence of eIF4E by crispr/cas9 increased 
rotavirus RNA level (n = 6, *P< 0.05, Mann-Whitney test). (F) Silence of eIF4E by crispr/cas9 increased 
rotavirus VP4 protein level.  
2.3. The eIF4G suppresses rotavirus infection 
As a scaffolding protein, eIF4G protein is able to physically link mRNA and the small ribosomal 
subunit via protein-protein interactions. To investigate the effects of eIF4G protein on 
rotavirus infection, a lentiviral shRNA-mediated loss-of-function assay was conducted, which 
resulted in gene silence of eIF4G by all five shRNA vectors at both the mRNA and protein level 
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(Figure 3A,B). Importantly, all these shRNA vectors resulted in a potent increase in the viral 
RNA and protein level (Figure 3C, D). The vitality of cells was not affected by these shRNA 
vectors (Supplementary Figure S2C). To further verify these findings, we performed a 
Crispr/cas9 assay to knockout eIF4G in Caco2 cells (Figure 3E). After gene knockout, the viral 
RNA and protein levels were inhibited (Figure 3F, G). 
To further verify the effect of eIF4A, eIF4E, and eIF4G on rotavirus infection, CRIPRs against 
eIF4A, eIF4E, and eIF4G were co-transfected in Caco2 cells. After puromycin selection, the 
knockout of eIF4A, eIF4E, and eIF4G was detected by western blot, indicating successful 
knockout of three genes (Figure 4A). The effect of eIF4A, eIF4E, and eIF4G on rotavirus 
infection was further detected by RT-qPCR and western blot, demonstrating that both viral 
genomic RNA and viral protein VP4 synthesis were promoted (Figure 4B, C). 
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Figure 3. Silence of eIF4G promotes rotavirus infection. (A) Western blot assay detected eIF4G in Caco2 
cells transduced with lentiviral RNAi vectors against eIF4G. (B) Successful knockdown by shRNA vectors 
detected by RT-qPCR assay (n = 6, **P< 0.01, Mann-Whitney test). (C) Silence of eIF4G showed increased 
rotavirus genomic RNA level (n = 6, *P< 0.05, **P< 0.01, Mann-Whitney test). (D) Silence of eIF4G promoted 
viral VP4 protein level in SA11 rotavirus infected Caco2 cells. (E) Western blot assay detected eIF4G in Caco2 
cells transduced with CRIPSRs against eIF4G. (F) Silence of eIF4A by CRISPR/Cas9 increased rotavirus 
genomic RNA level (n = 6, *P< 0.05, Mann-Whitney test). (G) Silence of eIF4G by CRISPR/Cas9 increased 
viral VP4 protein level in SA11 rotavirus infected Caco2 cells. 
 
 
Figure 4. Silence of eIF4A/E/G promotes rotavirus infection. (A) Western blot assay detected eIF4 A/E/G 
in Caco2 cells transduced CRIPRs against eIF4A, eIF4E and eIF4G. (B) Silence of eIF4A/E/G promoted 
rotavirus genomic RNA level detected by qPCR assay (n = 6, **P< 0.01, Mann-Whitney test). (C) Silence of 
eIF4A/E/G showed increased rotavirus protein VP4. 
2.4. Programmed cell death protein 4 (PDCD4) promotes rotavirus infection 
PDCD4 functions by inhibiting the translation by directly inhibiting the helicase activity of 
eIF4A to competitively bind to the scaffold protein eIF4G. To further verify the effects of the 
eIF4F complex on rotavirus infection, a lentiviral shRNA-mediated loss-of-function assay was 
performed to silence PDCD4, which indicated that one out of three shRNA vectors (No 1) 
exerted a potent knockdown effect (Figure 5A, B). Consistently, the shRNA vector resulted in 
a 50 ± 12 % (n= 8, P < 0.05)-fold reduction in SA11 rotavirus mRNA (Figure 5C), and remarkable 
reduction in viral VP4 protein levels (Figure 5D). All shRNA vectors have no significant 
cytotoxicity (supplementary Figure S2D). 
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Figure 5. PDCD4 sustains rotavirus infection. (A) Western blot assay detected PDCD4 in Caco2 cells 
transduced lentiviral RNAi vectors against PDCD4. (B) One out of three shRNA vectors showed successful 
knockdown detected by RT-qPCR (n = 6, **P< 0.01, Mann-Whitney test). (C) Silence of PDCD4 showed 
inhibition of rotavirus genomic RNA level (n = 8, *P< 0.05, Mann-Whitney test). (D) Silence of PDCD4 
inhibited viral VP4 protein level in SA11 rotavirus infected Caco2 cells. 
2.5. The eIF4F complex inhibits the level of antiviral proteins to exert anti-
rotavirus effect 
To further explore the underlying molecular mechanism of the antiviral effects of the eIF4F 
complex on rotavirus infection, we questioned the effect of the eIF4F complex on several 
antiviral proteins including interferon regulatory factor 1 (IRF1), IRF7, and retinoic acid-
inducible-I (RIG-I), which indicated that the knockdown of eIF4A had no obvious effect on 
these antiviral proteins. While the knockdown of eIF4E (shRNA No 2) was able to inhibit 
protein level of IRF1 and IRF7 (Figure 6B). Knockdown of eIF4G was also capable of suppressing 
the protein level of IRF1 and IRF7 (Figure 6C). To further verify this, the effect of IRF7 and IRF1 
on rotavirus replication was detected, indicating that knockout of either IRF7 (Figure 6D) or 
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IRF1 (Figure 6F) could significantly reduce the genomic mRNA of SA11 rotavirus (Figure 6E, G). 
Thus, the antiviral effect against rotavirus of the eIF4F complex may operate through 
regulating the expression antiviral proteins in the host. 
 
Figure 6. The eIF4F complex is required for IRF7 that exerts anti-rotavirus effect. (A) Western blot assay 
detected the protein level of antiviral factors including IRF1, IRF7, and RIG-I in eIF4A knockdown Caco2 cells. 
(B) Western blot assay detected the protein level of antiviral factors including IRF1, IRF7, and RIG-I in eIF4E 
knockdown Caco2 cells. (C) Western blot assay detected the protein level of antiviral factors including IRF1, 
IRF7, and RIG-I in eIF4G knockdown Caco2 cells. (D) Western blot assay detected the protein level of IRF7 
in eIF4G knockout Caco2 cells, and two out of four shRNA vectors showed successful knockdown of IRF7 
detected by western blot. (E) Silence of IRF7 increased rotavirus genomic RNA level detected by qPCR assay 
(n = 6, **P< 0.01, ***P< 0.001, Mann-Whitney test). (F) Western blot assay detected the protein level of 
IRF7 in eIF4G knockout Caco2 cells, indicating successful knockdown of IRF1 detected by western blot. (G) 
Silence of IRF1 increased rotavirus genomic RNA level detected by qPCR assay (n = 6, **P< 0.01, Mann-
Whitney test).  
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3. DISCUSSION 
Many viral mRNAs have acquired a variety of sophisticated strategies to compete with cellular 
mRNAs that are already present in the cytoplasm. This allows the selective translation of viral 
mRNAs, since they do not possess the required components to initiate the translation of 
mRNA [23,29]. The eIF4F initiation factor complex plays a vital role in initiating translation by 
recognizing the 5’ cap structure in a cap-dependent manner [23]. As the target of numerous 
cellular signaling pathways, eIF4F closely controls the translation in response to a multitude 
of environmental conditions including viral infection [30]. In contrast, viral infections often 
cause dysregulation of eIF4F expression to benefit its replication. Vesicular stomatitis virus 
(VSV) was reported to cause modifications of the eIF4F complex to inhibit host protein 
synthesis [31]. Human Cytomegalovirus (HCMV) replication was demonstrated to increase the 
overall abundance of the eIF4F components and promote assembly of the eIF4F complexes 
[32]. The cellular cap-dependent protein level was reported to be rapidly inhibited by foot-
and-mouth disease virus (FMDV) via inducing the cleavage of eIF4G [33]. However, we did not 
find remarkably altered expression levels of the components of eIF4F, including eIF4A and 
eIF4E, upon rotavirus infection (Supplementary Figure S1). 
The eIF4F is a tripartite complex composed of three components including a cap-binding 
subunit (eIF4E), an RNA helicase (eIF4A), and a large molecular scaffold (eIF4G) that is 
associated with eIF3-bound 40S ribosome subunits [30]. These three components of the eIF4F 
complex were reported to closely regulate the life cycle of various viruses either promoting or 
restricting the infection. By treating influenza virus infected cells with Hippuristanol, a sterol, 
which is able to suppress RNA binding, ATPase, and helicase activities to block eIF4A-
dependent translation, which demonstrated that eIF4A fully determines the translation of 
influenza virus mRNAs [34]; however, eIF4E does not affect influenza virus protein synthesis 
[29]. Hepatitis E virus (HEV) requires all three components of eIF4F to replicate in the host 
[35]. The protein synthesis of Junin virus (JUNV), Tacaribe virus (TCRV), and Pichinde virus 
(PICV) requires the participation of eIF4A and eIF4G but not eIF4E [36]. The eIF4F complex is 
required for maintaining translation efficiency of HCMV at the start of infection; while viral 
protein synthesis becomes increasingly insensitive to inhibition of eIF4F complex at late stage 
of virus infection [37]. Cencic et al. demonstrated that blocking the interaction between eIF4E 
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and eIF4G by a small molecule was capable of remarkably suppressing corovarius replication 
[24]. Rotavirus mRNAs are capped but not polyadenylated, and its NSP3 is capable of binding 
to eIF4G to stabilize the eIF4E–eIF4G interaction [10]. However, knockdown of NSP3 did not 
influence the synthesis of viral proteins, indicating that it is not involved in viral mRNA 
translation and virus replication [38]. We have previously confirmed that the PI3K-Akt-mTOR 
pathway sustains rotavirus infection via its downstream effector 4E-BP1 [39], which provokes 
us to further investigate the effect of eIF4E on rotavirus infection, since mTOR exerts the 
function of splitting the 4E-BP1-eIF4E dimer via phosphorylating 4E-BP1 [40]. Unexpectedly, 
we found that blocking the three components of the eIF4F complex promotes rotavirus 
infection (Figure 1, Figure 2, Figure 3, and Figure 4). This suggests that the inhibitory effect of 
eIF4F on rotavirus might be via another scenario other than the regulating of the capping 
process of viral mRNA. PDCD4 is capable of directly inhibiting the helicase activity of eIF4A by 
competing its binding to eIF4G to suppress the activity of the eIF4F complex [41]. Consistently, 
we found that blocking PDCD4 was capable of inhibiting rotavirus infection (Figure 5), which 
is in agreement with the effect of the eIF4F complex on rotavirus infection. Herein, our 
findings suggest that the eIF4F complex exerts inhibitory effects on rotavirus infection. 
Mounting evidence reveals that the eIF4F complex perverts the interferon signaling pathway 
that exerts a pivotal role in defensing various viruses. Viruses often trigger a cascade of event 
to activate certain transcription factors, such as IRF3, IRF7, and NF- B, after being recognized 
by pattern-recognition receptors (e.g., Toll-like receptors), which eventually enhances 
interferon-β (IFN-β) to exert antiviral effects [27]. It was confirmed that the 
dephosphorylation of eIF4E was able to stimulate the NF-κB pathway to promote the 
production of type I interferon [27]. The eIF4F complex was demonstrated to closely regulate 
the translation of STAT1 mRNA [28]. In 4E-BP1-/- and 4E-BP2-/- double knockout mouse 
embryonic fibroblasts (MEF), it was found that type-I IFN was strongly promoted through 
enhancing the expression of IRF7 mRNA [26]. The binding of eIF4E to eIF4G may be involved 
in the translation of IRF7 mRNA [42]. Consistently, we demonstrated that knockdown and 
knockout of eIF4E and eIF4G were capable of suppressing the protein level of IRF1 and IRF7 
(Figure 6). Importantly, we confirmed that IRF1 and IRF7 per se were able to significantly 
inhibit rotavirus replication (Figure 6). Thus, we have provided a possible novel insight into 
how the eIF4F complex regulates rotavirus replication. 
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In summary, this study has demonstrated that the three components of the eIF4F complex 
can remarkably inhibit rotavirus infection. The negative regulator of the eIF4F complex, PDCD4, 
inhibits rotavirus replication. The effect of eIF4F complex on rotavirus replication is through 
regulating the protein level of certain antiviral proteins including IRF1 and IRF7 that exerting 
remarkable antiviral effect against rotavirus. Hereto, this study revealed new insight in the 
regulation of eIF4F on rotavirus replication, and the eIF4F complex may represent as 
important targets for the development of new antivirals and antiviral therapies against 
rotavirus infection. 
 
4. MATERIALS AND METHODS 
4.1. Cell culture and Virus 
All cells used in the study were grown in Dulbecco’s Modified Eagle Medium (DMEM, Lonza, 
Verviers, Belguim) containing 20% (v/v) heat-inactivated fetal calve serum (FCS) (Hyclone, 
Lonan, Utah) and penicillin (100 IU/mL)/ streptomycin (100 mg/mL) (P/S) Invitrogen-Gibco) at 
37⁰C in a humidified 5% CO2 incubator. 
Simian rotavirus SA11 was used and prepared as described previously [39,43].  
4.2. Inoculation of SA11 Rotavirus in cells 
The inoculation method of SA11 rotavirus was described previously [6,44]. Briefly, cell 
monolayers were incubated with SA11 rotavirus (MOI = 0.7) at 37⁰C with 5% CO2 for 60 min 
for infection, followed by removing unbound viral particles by washing with cold PBS three 
times, followed by adding culture medium (FCS free) containing 5 μg/mL of trypsin and 
indicative drugs. Thereafter, cells were incubated at 37oC in a humidified 5% CO2 incubator. 
Viral titer was detected by RT-qPCR after 48 h inoculation. 
4.3. Real-time quantitative reverse transcription PCR (RT-qPCR) analyses 
Total RNA was isolated using NucleoSpin® RNA kit (MACHEREY-NAGEL, Düren, Germany) 
according to the manufacturer’s instructions. The extracted RNA was dissolved in 
diethylpyrocarbonate (DEPC)-treated water, and its concentration was measured using a 
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Nanodrop ND-1000 (Wilmington, DE, USA). The 500 ng of total RNA was used for cDNA 
synthesis using the reverse transcription system from TAKARA (TAKARA BIO INC) according to 
manufacturer’s instructions. The resultant cDNA was diluted and used for evaluating gene 
expression with corresponding primers. All RT-qPCR experiments were performed by SYBR-
Green-based (Applied Biosystems SYBR Green PCR Master Mix; Thermo Fisher Scientific Life 
Scienc; Carlsbad, CA, USA) real-time PCR with the StepOnePlus System (Thermo Fisher 
Scientific Life Sciences). The expression of target mRNAs was normalized to the 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA. The relative mRNA levels of 
target genes were expressed as 2-ΔΔCt, in which ΔΔCt = (ΔCtTarget - ΔCtGAPDH) treatment - 
(ΔCtTarget - ΔCtGAPDH) control. Gene primers for RT-qPCR were listed in supplementary 
Table S1. 
4.4. Gene knockdown by shRNA  
Lentiviral shRNA vectors, targeting eIF4A, eIF4E, eIF4B, and PDCD4 or non-targeted control 
lentivirus was prepared in 293T cells in a 6-well-plate using a standard third-generation 
packaging system (All shRNA primers were listed in supplementary Table S2). 
Cell monolayers were transfected with lentiviral vectors for three days, followed by screening 
by puromycin (8 μg/mL) to obtain stable clones, and the knockdown effect was detected by 
western blot. 
4.5. Gene knockout by clustered regularly interspaced short palindromic 
repeats (CRISPR/Cas9) assay 
The sgRNAs against eIF4A, eIF4E, eIF4G (primers were listed in supplementary Table S3) were 
designed using freely available online tools (https://www.genscript.com/gRNA-
database.html). Oligos were annealed according to the manufacturer’s protocol (37°C for 30 
min; 95°C for 5 min and then ramp down to 25°C at 5°C/min). Subsequently, annealed oligos 
were ligated into Lenti CRISPR v2, followed by transforming 10 μL of electrocomp™cells 
(ThermoFisher SCIENTIFIC, Carlsbad, USA) with 5 μL of annealed oligos, and then incubated at 
37°C for overnight. 2–3 colonies were picked up and cultured in LB medium, followed by 
performing a sequence verification. The verified colony was expanded in a LB containing 
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Ampicillin culture (100 μg/mL, SIGMA-ALDRICH, Saint Louis, USA) and DNA was isolated by 
using DNA extraction kit (ThermoFisher SCIENTIFIC) according to manufacturer’s protocol. 
CRISPR DNA was co-transfected with packaging plasmids including pVSV-G, pMD, and pREV 
into HEK293T cells and lentiviral vectors were harvested. 
Cell monolayers were transfected with lentiviral vectors for three days, followed by screening 
by puromycin (8 μg/mL) to obtain stable clones, and the knockdown effect was detected by 
western blot. 
4.6. The 3-(4, 5)-dimethylthiahiazo (-z-y1)-3, 5-di- phenytetrazoliumromide 
(MTT) assay 
MTT assay was used to evaluate cell viability, and the cells were seeded into 96-well plates 
(5000 cells/well). Then, the viable cells were quantified at indicated time points by adding 10 
μL 5 mg/mL MTT per well, and the cells were incubated for an aditional 3 h in a humidified 
incubator. Thereafter, medium containing MTT was removed, and a total of 100 μL dimethyl 
sulfoxide (DMSO) was added, followed by measuring the absorbance (490 nm) after 50 min 
inoculation. 
4.7. Western blot 
Western blot was described previously [6]. Briefly, cells were lysed using Laemmli buffer 
containing 10% dithiothreitol (DTT, Thermo Fisher Scientific, Carlsbad, USA), and then 
denatured by heating at 95⁰C for 5 min. Proteins were detected with antibodies against eIF4A 
(Cell Signaling Technology, Danvers, USA), eIF4E (Cell Signaling Technology), eIF4G (Cell 
Signaling Technology), PDCD4 (Cell Signaling Technology), and SA11 rotavirus VP4 (provided 
by professor Harry Greenberg, Stanford University School of Medicine, USA). The bound 
antibodies were visualized with Odyssey (LI-COR Biosciences, USA). The β-actin (Santa Cruz) 
was used as a loading control. 
4.8. Statistics 
All numerical results are reported as Mean ± Standard Error of Mean (SEM). The statistical 
significance of differences between means was assessed with the Mann–Whitney test using 
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GraphPad Prism 5 (stationary-pc/mac version; GraphPad Software Inc., La Jolla, CA, USA). The 
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Supplementary Information 
Supplementary table 1. qRT-PCR primers (human gene) used in the study, from 5' 
to 3'. 
Gene name Sense primer Antisense primer 
eIF4A AAGCCGTGGATTCAAGGACCAG CACCTCAAGCACATCAGAAGGC 
eIF4E ATGCCTGGCTGTGACTACTCAC GAGGTCACTTCGTCTCTGCTGT 
eIF4G GCCATTTCAGAGCCCAACTTCTC CGGAAGTTCACAGTCACTGTTGG 
PDCD4 ACTGTGCCAACCAGTCCAAAGG CCTCCACATCATACACCTGTCC 
GAPDH TGTCCCCACCCCCAATGTATC CTCCGATGCCTGCTTCACTACCTT 
 
Supplementary table 2. shRNA target sequences. 
ShRNA Sequence 
sheIF4A-1  CCGGGCCGTGTGTTTGATATGCTTACTCGAGTAAGCATATCAAACACACGGCTTTTTG 
sheIF4A-2  CCGGGCCGTAAAGGTGTGGCTATTACTCGAGTAATAGCCACACCTTTACGGCTTTTTG 
sheIF4A-3  CCGGCCTTGTATCAAGGGTTATGATCTCGAGATCATAACCCTTGATACAAGGTTTTTG 





sheIF4G-1  CCGGCCCTACAGAATTTGGGACCTACTCGAGTAGGTCCCAAATTCTGTAGGGTTTTTG 
sheIF4G-2  CCGGGCCCTTGTAGTGACCTTAGAACTCGAGTTCTAAGGTCACTACAAGGGCTTTTTG 
sheIF4G-3  CCGGGCAGATAGTATCCAACACGTTCTCGAGAACGTGTTGGATACTATCTGCTTTTTG 
sheIF4G-4  CCGGCCCAAGTAATGATGATCCCTTCTCGAGAAGGGATCATCATTACTTGGGTTTTTG 
shPDCD4-1  CCGGGCGGTTTGTAGAAGAATGTTTCTCGAGAAACATTCTTCTACAAACCGCTTTTTG 
shPDCD4-2  CCGGCTGACCTTTGTGGGACAGTAACTCGAGTTACTGTCCCACAAAGGTCAGTTTTTG 
shPDCD4-3  CCGGCTACCATTACTGTAGACCAAACTCGAGTTTGGTCTACAGTAATGGTAGTTTTTG 
 
Supplementary table 3. Sg RNA Primers (human gene) used in the study, from 5' to 
3'. 
Sg RNA Sense primer Antisense primer 
eIF4A CACCGCCCCCGATACAGGCGTGAC CGGGGGCTATGTCCGCACTGCAAA 
eIF4E CACCGGGACGTCCCCACTTGTCCG CCCTGCAGGGGTGAACAGGCCAAA 
eIF4G CACCGCTATCCAGTCGAACACCCGC CGATAGGTCAGCTTGTGGGCGCAAA 
Chapter 3 
57 | P a g e  
 
 
Supplementary Figures:  
 
 
Supplementary Fig. 1. The effect of rotavirus and mock infection (1, 2, 4, 6, 24 and 48 hr) on the 
expression level of eIF4E, eIF4A and PDCD4. Western blot assay detected the expression of eIF4E, eIF4A 
and PDCD4 after 1, 2, 4, 6, 24 and 48 hr post-infection by rotavirus and mock infection in Caco2 cells. 
 
 
Supplementary Fig. 2. Effect of shRNA against eIF4A (A), eIF4E (B), eIF4G (C) and PDCD4 (D) on host 
cell viability determined by MTT assays. 
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Abstract 
Rotavirus (RV) primarily infects enterocytes and results in severe diarrhea, particularly in 
children. It is known that the host immune responses determine the outcome of viral 
infections. Following infections, interferons (IFNs) are produced as the first and the main anti-
viral cytokines to combat the virus. Here we showed that RV predominantly induced type III 
IFNs (IFN-λ1), and to a less extent, type I IFNs (IFN-α and IFN-β) in human intestinal cells. 
However, it did not produce detectable IFN proteins and thus, was not sufficient to inhibit RV 
replication. In contrast, we revealed the essential roles of the basal IFN signaling in limiting RV 
replication by silencing STAT1, STAT2 and IRF9 genes. In addition, exogenous IFN treatment 
demonstrated that RV replication was able to be inhibited by all types of IFNs, both in human 
intestinal Caco2 cell line and in primary intestinal organoids. In these models, IFNs significantly 
upregulated a panel of well-known anti-viral IFN-stimulated genes (ISGs). Importantly, 
inhibition of the JAK-STAT cascade abrogated ISG induction and the anti-RV effects of IFNs. 
Thus, our study shall contribute to better understanding of the complex RV-host interactions 
and provide rationale for therapeutic development of IFN-based treatment against RV 
infection.  
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Introduction 
Rotavirus (RV) is a member of the Reoviridae family that primarily infects mature enterocytes 
of the small intestinal villi. However, it can spread systemically to cause viremia and infection 
of multiple organs1. RV is the most frequent agent of severe dehydrating diarrhea episodes in 
children under five years of age2. Before introduction of RV vaccines, RV caused 9.8 billion of 
severe diarrhea episodes and 1.9 billion diarrhea-related deaths worldwide, with the highest 
burden in southeast Asian and African countries3. The incidence is lower especially in countries 
that have introduced oral RV vaccination4. 
Intestinal innate immune responses are the first line of defense to battle RV infection5. 
Recognition of RV viral proteins and double-stranded RNA by the host induces the production 
of cytokines, including interferons (IFNs)6. IFNs are potent anti-viral cytokines classified into 
three different groups, type I (IFN-α, IFN-β, IFN-δ, and others), type II (IFN-γ) and type III (IFN-
λ1, IFN-λ2 and IFN-λ3) IFNs7,8. Some members are widely used in the clinic for treating viral 
infections or malignancy, whereas others are at stages of clinical development. Even though 
they bind to distinct receptors, they signal through a common, classical Janus kinase signal 
transducer and activator of transcription (JAK-STAT) pathway8,9.  
Once activated, STAT1 and STAT2 are phosphorylated and bind IFN regulatory factor 9 (IRF9) 
to form IFN stimulated gene factor 3 complex (ISGF3). ISGF3 subsequently translocates to the 
nuclues, inducing transcription of hundreds IFN-stimulated genes (ISGs) which cooperatively 
establish an anti-viral state that protects against various types of viruses10. Furthermore, IFN 
induction following RV recognition is essential to promote the development of adaptive, B-
cell-mediated immune responses11. On the other hand, however, RV has developed effective 
strategies to evade the host immune response12. RV can inhibit IFN production in the infected 
cells13 and also block the action of STAT1 and STAT2 proteins14. Viral nonstructural protein 
NSP1-mediated IFN inhibition has been shown to be associated with different levels of RV 
replication in primary mouse cells15. 
Detectable levels of IFN-α16 and IFN-γ17,18 were documented in chidlren with acute RV diarrhea, 
suggesting a role for these INFs in disease pathogenesis. Indeed, early in vitro19-21 and animal 
studies in calves22 and piglets23 demonstrated anti-RV effects of both type I and II IFNs. 
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However, in the murine models of homologous RV infection, administration of type I (IFN-α 
and IFN-β) and II (IFN-γ) IFNs failed to protect the mice against RV infection24. In addition, mice 
deficient in type I or II IFN receptor signaling controlled RV infection as well as wild-type 
mice24,25. These results suggest a minor role of type I and II IFNs in controlling RV infection in 
mice. Interestingly, a more prominent function of type III IFNs in constraining viral infection 
was suggested by experimentation in mouse models25,26. Administration of IFN-λ conferred 
better protection against RV infection than IFN-α/β25. 
Because animal models do not always recapitulate the responsiveness in human, we therefore 
comprehensively assessed the role of endogenous and the therapeutic IFNs on RV infection in 
human intestinal cell line and primary intestinal organoids. We found that the basal JAK-STAT 
cascade is effective in restraining RV infection. Furthermore, RV is sensitive to inhibition by all 
three types of IFNs in both models. Our results strengthen the evidence of essential roles of 
IFN pathway in protecting the host against viral infection.  
Results 
RV infection modulates IFN gene expression 
First, we investigated whether RV SA11 modulates the expression of the three types of IFN 
genes. Human intestinal Caco2 cells were infected with RV SA11 for 48 hours. An effective 
replication was shown by an increase in intracellular RNA level as well as secreted rotavirus in 
culture medium (Supplementary Fig. S1). In addition, immunofluorescence staining showed 
VP6-positive Caco2 cells at 48 hours after infection, indicating productive replications 
(Supplementary Fig. S2). 
Relative RNA levels of ifna, ifnb, ifng, il29 (IFN-λ1) and il28 (IFN-λ2/IFN-λ3) genes were 
examined and compared to uninfected cells at 6, 24, 36 and 48 hours post infection. As shown 
in Fig. 1, RV infection had no major effect on the gene expression at 6 and 24 hours post-
infection. At 36 hours after infection, only il29 gene expression was notably increased by 3.4 
± 1.0 (P < 0.05) fold. Importantly, at 48 hours after infection, the expression of ifna and ifnb 
genes were significantly increased by 2.8 ± 0.6 (P < 0.001) and 2.8 ± 0.5 (P < 0.01) fold, 
respectively. A profound upregulation was observed on il29 by 29.6 ± 10.7 fold (P < 0.001). No 
difference was found on il28 gene expression. The expression level of ifng gene was 
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undetectable (data not shown). Together, our findings showed that RV SA11 infection 
preferentially induced il29 (IFN-λ1) gene expression in Caco2 cells. 
 
Figure 1. RV infection modulates IFN gene expression in Caco2 cells. Caco2 cells were infected with RV 
SA11. Relative RNA levels of ifna, ifnb, il29 (IFN-λ1) and il28 (IFN-λ2 and IFN-λ3) genes were examined at 6, 
24, 36 and 48 hours post infection as compared to uninfected cells. Data were normalized to GAPDH and 
presented as means ± SEM. (n = 3 independent experiments with each of 3-4 replicates; **P < 0.01; ***P < 
0.0001)  
The increased expression of IFN genes does not result in production of 
detectable IFN protein and was not sufficient to limit RV SA11 replication 
To examine whether the increased expression of IFN genes result in IFN production in our cell 
culture system, we collected the conditioned medium (supernatant) derived from control and 
SA11-infected Caco2 cells at 48 hours post-infection. Then, we performed IFN production 
bioassay by adding the conditioned medium into two highly IFN sensitive cell lines, Huh7-
based ISRE-luciferase and HCV-luciferase reporter cell lines. As shown in Fig. 2A, the 
supernatant from SA11-infected Caco2 cells was not capable of stimulating ISRE reporter, 
while as low as 1 U/mL of IFN-α significantly induced ISRE-luc by 1.8 ± 0.2 fold (P < 0.001). 
Consistently, it was not able to diminish HCV replication, although as low as 0.1 IU/mL of IFN-
α considerably reduced HCV-luc by 40 ± 7% fold (P < 0.001) (Fig. 2B). 
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The induced expression of IFN-α and IFN-λ1 proteins can signal via autocrine and paracrine 
manner to stimulate ISGs expression. Therefore, to confirm our previous findings from ISRE-
luciferase cell lines, we also examined ISG expression in SA11-infected Caco2 cells. Despite a 
clear induction of IFN genes, we observed no upregulation of ISGs, both at 24 and 48 hours 
post-infection. At 48 hours, some ISGs were significantly downregulated by SA11 infection, 
including IRF1, IRF9, MX1 and IFIT3 (Fig. 2C).  
To rule out the possibility that endogenous IFN produced (if any) following RV infection is 
sufficient to restrict RV replication, we investigated whether the inhibition of JAK proteins, the 
downstream elements of IFN receptor, influences RV replication. Treatment of JAK I inhibitor 
at 5 and 10 μM had no effect on RV replication (Fig. 2D). At those concentrations, the drug did 
not influence the cell viability as determined by MTT assay (Fig. 2E). Collectively, our results 
demonstrate that the increased expression of IFN genes during RV infection does not result in 
IFN production and consequently appears relatively unimportant for constraining RV 
replication in intestinal epithelial cells. 
Basal IFN signaling is necessary to restrict RV replication 
As no functional production of IFN is observed following RV infection, we investigated the 
possibility that constitutive ligand independent IFN signal transduction defends intestinal 
epithelial cells against RV replication. ISGF3 that consists of STAT1, STAT2 and IRF9 is a central 
complex in IFN signal transduction. We have previously reported that in the absence of IFN 
stimulation, unphosphorylated ISGF3 drives constitutive ISG expression in homeostatic 
conditions and is critical to provide immunity against hepatitis C (HCV) and E (HEV) virus 
infections27. It is thus possible that constitutive IFN signal transduction is important for 
counteracting RV in intestinal cells as well. 
To test this possibility, we first transduced Caco2 cells with a lentiviral vector expressing 
STAT1- and STAT2-specific shRNA. A successful knockdown is shown in Fig. 3A and 3C. 
Supplementary Fig. S3 shows the quantification of knockdown efficiency. Importantly, shRNA-
mediated STAT1 and STAT2 knockdown resulted in an increased RV replication by 3.8 ± 0.6 
fold (P < 0.01) (Fig. 3B) and 13 ± 4.6 (P < 0.001) (Fig. 3D), respectively. 
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Next we investigated the role of IRF9. Two of three tested IRF9-specific shRNA (sh-2 and sh-3) 
exert a potent gene silencing capacity (Fig. 3E and Supplementary Fig. S3). Consistently, IRF9 
KD led to 4.8 ± 1.0 fold elevation of RV replication as compared to sh-CTR transfected cells (P 
< 0.001) (Fig. 3F). Altogether, these results indicate that the integrity of ISGF3 complex is 
required to provide basal immunity against RV infections. 
 
Figure 2. The increased expression of IFN genes does not result in production of detectable IFN protein 
and was not sufficient to limit RV SA11 replication. IFN production bioassay was performed in ISRE-
luciferase (A) and HCV-luciferase (B) cell lines which are highly sensitive to IFN treatment. Conditioned 
medium derived from 48 hours post-RV infection on Caco2 cells was used (n = 3 independent experiments 
with each 2-3 replicates). (C) Caco2 cells were infected with RV SA11. Relative RNA levels of IFN-stimulated 
genes (ISGs) were examined at 24 and 48 hours post-infection as compared to uninfected cells (n = 3 
independent experiments with each 2-3 replicates). (D) Pan-JAK I inhibitor had no effects on RV replication 
(n = 3 independent experiments with each 2-3 replicates).  (E) Pan-JAK I inhibitor did not affect cell viability 
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as determined by MTT assay (OD490 value) at 48 hours of treatment (n = 3 independent experiments with 





RV SA11 is sensitive to IFN treatment in human intestinal Caco2 cells and 
primary intestinal organoids 
Since we did not find a significant role of endogenous IFN in restricting RV replication, we then 
investigated whether RV was sensitive to exogenous IFN treatment (Fig. 4A). Treatment of 
SA11-infected Caco2 cells with 100 and 1000 IU/mL of IFNα resulted in a potent inhibition of 
RV replication by 79 ± 4% (P < 0.001) and 98 ± 0.7% (P < 0.001) as measured in total RNA levels. 
Similarly, IFNβ treatment at 100 and 1000 IU/mL dose-dependently inhibited total viral RNA 
Figure 3. The key component of ISGF3 
complex is necessary to restrict RV 
replication. (A) STAT1 knockdown by 
lentiviral shRNA vectors. Western blot 
analysis confirms a successful knockdown 
of total STAT1 protein. (B) 
Correspondingly, knockdown of STAT1 led 
to a significant increase of RV replication (n 
= 3 independent experiments with 3-4 
replicates each). (C) Knockdwon of STAT2 
by lentiviral shRNA vectors. Western blot 
analysis shows a potent decrease of total 
STAT2 protein level. (D) Similarly, silencing 
of STAT2 resulted in a prominent increase 
of RV RNA level (n = 3 independent 
experiments with 3-4 replicates each). (E) 
IRF9 knockdwon by lentiviral shRNA 
vectors. Western blot analysis shows a 
potent decrease of IRF9 protein level. (F) 
Knockdown of IRF9 led to a notable 
increase of RV replication (n = 3 
independent experiments with 3-4 
replicates each). Data were presented as 
means ± SEM., **P < 0.01; ***P < 0.001. 
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levels by 60 ± 9% (P < 0.01) and 73 ± 7% (P < 0.001). Type II IFNs also strongly reduced RV 
replication, although the effects were not dose-dependent. At concentration of 100 and 1000 
ng/mL, IFNγ restricted RV replication by 81 ± 6% (P < 0.001) and 68 ± 7% (P < 0.01). Analysis 
of intra and extracellular RNA levels also demonstrated the inhibition of RV replication by type 
I and II IFNs in Caco2 cells (Supplementary Fig. S4). 
Next, we investigated anti-RV effects of type III IFNs. Treatment of SA11-infected Caco2 cells 
with 100 and 1000 ng/mL of IFNλ1 resulted in a notable restriction of RV replication by 76 ± 
11% (P < 0.01) and 65 ± 6% (P < 0.001). Inhibition of RV replication was also observed with 
IFNλ2 treatment. At a concentration of 100 and 1000 ng/mL, IFNλ2 decreased RV replication 
by 61 ± 17% (P < 0.01) and 50 ± 7% (P < 0.05), respectively. At a similar concentration, IFNλ3 
significantly dimished RV replication by 52 ± 7% (P < 0.05) and 62 ± 6% (P < 0.01). Analysis of 
intra and extracellular RNA levels also demonstrated the effects of type III IFNs in limiting 
rotavirus replication in Caco2 cells (Supplementary Fig. S4).  
To further confirm the effects of various types of IFNs that we observed in the conventional 
2D cell culture system, we employed a 3D culture model of primary intestinal organoids 
derived from one individual (P1) to more closely mimick the physiological situation in vivo (Fig. 
4B). Treatment of SA11-infected organoid with 1000 IU/mL of IFNα and IFNβ led to a 
significant reduction of intracellular viral RNA levels by 73.9 ± 7.5% (P < 0.05) and 57.8 ± 7.7% 
(P < 0.05), respectively. Surprisingly, the inhibition by IFNγ was more pronounced. Treatment 
of SA11-infected organoid with 1000 ng/mL of IFNγ significantly reduced intracellular viral 
RNA levels by 99.5 ± 0.1% (P < 0.01) (Fig. 4C). Similarly, treatment with 1000 ng/mL of IFNλ1, 
IFNλ2 or IFNλ3 significantly diminished intracellular viral RNA levels by 70.2 ± 7.6% (P < 0.01), 
78.2 ± 4.2% (P < 0.01) and 79.6 ± 3.6% (P < 0.01), respectively (Fig. 4C). Quantification of 
extracellular (secreted) RNA levels also showed a notable reduction of viral production 
(Supplementary Fig. S5). To confirm these findings, we obtained primary intestinal organoids 
from the second individual (P2). Similarly, treatment of SA11-infected organoid with IFNα 
(1000 IU/mL), IFNγ (1000 ng/mL) and IFNλ1 (1000 ng/mL) significantly reduced total viral RNA 
levels by 74.6 ± 5.1% (P < 0.01), 85.5 ± 4.4% (P < 0.01) and 71.4 ± 10.5% (P < 0.01), respectively 
(Supplementary Fig. S6A). Collectively, these results suggest that all type of IFNs effectively 
inhibit RV replication, both in 2D and 3D culture model system. 
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Sensitivity of patient-derived RV strains to type I, II and III IFNs 
Next, we evaluated the sensitivity of patient-derived RV strains against different types of IFNs. 
We treated human RV (G1P[8]) with IFNα 100 IU/mL (as representative of type I IFN), IFNγ 100 
ng/mL (type II IFN), IFNλ1 and IFNλ3 100 ng/mL (as representative of type III IFN) for 48 hours. 
Three out of four samples were sensitive to the inhibition by IFNα and all samples were 
inhibited by IFNγ (Fig. 5). Interestingly, only one sample which is sensitive to type III IFN 
treatment. Collectively, our data suggest that type I and II IFN more efficiently inhibit the 




Induction of the known antiviral ISGs by all three types of IFNs 
Figure 4. Exogenous treatment 
of type I, II and III IFNs inhibits 
RV SA11 infection. Antiviral 
activity of IFNα, IFNβ, IFNγ, 
IFNλ1, IFNλ2 and IFNλ3 
treatment against RV SA11 
infection on (A) Caco2 cells (n = 
2-3 independent experiments 
with each of 3-4 replicates) and 
(C) organoids (n = 3 
independent experiments with 
each of 2-3 replicates) at 48 
hours after infection. Data were 
presented as means ± SEM., *P 
< 0.05; **P < 0.01; ***P < 0.001. 
(B) A representative picture of 
the morphology of human small 
intestinal organoid at day 4 post 
embedding in Matrigel. The 
organoid used in this 
experiment was derived from 
one individual (P1). 
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The observed anti-RV activity of type I, II and III IFNs prompted us to investigate whether all 
types of IFNs effectively induce the expression of known anti-viral ISGs in Caco2 cells and 
organoid. Although there are hundreds of ISGs, only a subset have broad or targeted antiviral 
effects28. We have selectively investigated the expression of those known antiviral ISGs. 
Indeed, treatment of Caco2 cells with recombinant human IFN-α (1000 IU/mL), IFN-γ (1000 
ng/mL) and IFN-λ1 (1000 ng/mL) for 24 hours induced the expression a panel of ISGs (Fig. 6A). 
Similarly, they also efficiently induced ISGs in organoids derived from both P1 (Fig. 6B) and P2 
(Supplementary Fig. S6B). Interestingly, we observed a variation of the type and extent of ISG 
induction with different IFN treatment. For example, IRF1 and RTP4 were more induced by 
IFN-γ as compared to IFN-α in Caco2 cells. In contrast, DDX60 and IFI6 were more induced by 
IFN-α as compared to IFN-γ (Fig. 6A). In organoid (P1), several ISGs were more efficiently 
induced by IFN-λ1 as compared to IFN-α and IFN-γ, including OASL, ISG15 and OAS1 (Fig. 6B). 
 
Figure 5. Sensitivity 
of patient-derived RV 
strains to type I, II 
and III IFNs. Caco2 
cells were infected 
with four different 
patient-derived RV 
strains (G1P[8]) and 
treated with IFNα 100 
IU/mL (as 
representative of 
type I IFN), IFNγ 100 
ng/mL (type II IFN), 
IFNλ1 and IFNλ3 100 ng/mL (as representative of type III IFN). Distinct sensitivity was observed among these 
patient-derived RV samples. Human RV RNA levels were quantified by qRT-PCR at 48 hours post-infection 
and normalized to a reference gene GAPDH. The data are derived from an experiment for multiple patient-
derived RV strains. 
Inhibition of JAK-STAT signaling abrogates the anti-RV activity of IFN-α as well 
as IFN-γ 
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The ISG induction by type I and III IFNs is mediated via a similar pathway involving ISGF3 
complex. For type II IFN, its signaling pathway involves phosphorylation and dimerization of 
STAT1 to form IFNγ activation factor (GAF)9. To investigate the role of JAK-STAT signaling 
pathway in the anti-RV effects of IFNs, we used JAK I inhibitor that predominantly inhibit JAK1 
protein, the upstream element that is responsible for STAT1 and STAT2 phosphorylation. As 
expected, JAK I inhibitor (10 μM) efficiently blocked IFNα- and IFNγ-induced ISG expression in 
Caco2 cells (Supplementary Fig. S7 and S8). Consistently, JAK I inhibitor treatment abolished 
the anti-RV effects of IFN-α and IFNγ in Caco2 cell lines (Fig. 7A and 7B, repectively). These 
data clearly indicate an important role of JAK-STAT pathway in mediating the anti-RV effects 
of IFNs. 
 
Figure 6. ISG 
induction by type I, 
II and III IFNs on 
Caco2 cells and 
organoids. Caco2 
cells (A) and 
organoids (B) were 
stimulated with 
IFNα 1000 IU/mL 
(as representative 
of type I IFN), IFNγ 
1000 ng/mL (type II 
IFN) and IFNλ1 
1000 ng/mL (as 
representative of 
type III IFN) for 24 
hours. The 
expression levels of several ISGs were measured by qRT-PCR. The organoid used in this experiment was 
derived from one individual (P1). 
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Figure 7. JAK I inhibitor blocks the anti-RV effects of IFNα and IFNγ. Caco2 cells were first infected with RV 
SA11 for 60 minutes. After four times washing, IFNα or IFNγ and Pan-JAK I inhibitor were added 
simultaneously to SA11-infected Caco2 cells and then cultured for 48 hours. Pan-JAK I inhibitor (10 μM) can 
block the anti-RV effects of IFNα 100 IU/mL (A) and IFNγ 100 ng/mL (B) in Caco2 cells. (n = 3 independent 
experiments with 2-4 replicates each) Data were presented as means ± SEM., *P < 0.05; **P < 0.01; ns, not 
significant. 
Discussion 
The in vitro study of RV biology had mainly been based on the conventional two-dimensional 
(2D) cell culture system of intestinal carcinoma-derived cell lines, including Caco2 and HT29 
cell lines14,29-31. They are homogenous immortalized cell lines that can functionally reflect the 
real biological processes in the humans intestinal epithelium However, they are lacking three-
dimensional (3D) higher order organisation present in the human intestine in vivo32. Recently, 
3D models of primary intestinal organoids were developed for studying RV biology which 
better recapitulate the architecture and cellular composition of the human intestine33-35. 
Intestinal organoids contain heterogenous and non-transformed cell types, including 
enterocytes, enteroendocrine cells, goblet cells, Paneth cells and stem cells35. Therefore, they 
enable us to investigate individual-specific response associated with histo-blood group 
antigen (HBGAs) profiles and microbiome diversity35. 
Transcriptional analysis of SA11-infected Caco2 cells revealed that RV predominantly induced 
type III (IFNλ1) rather than type I (IFNα and IFNβ) IFN responses. In other intestinal epithelial 
cells, such as HT29, RV infection induces type I IFN response (IFNβ) and subsequently regulates 
ISG expression29,30,36. However, our findings are consistent with previous studies in human 
intestinal enteroids (organoids) infected with human RV strains in which predominant type III 
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IFN responses (IFNλ1 and IFNλ2) were observed34. The relatively low induction of type I IFNs 
in these human epithelial cells is also consistent with studies in murine RV37. Following murine 
RV infection, type I IFN response was mainly produced by immune (hematopoietic) cells, not 
epithelial cells37. A predominant type III IFN response was also observed in hepatocytes upon 
HCV38 and HEV infection39. However, both type I and III IFN were similarly induced following 
influenza virus infection in lung epithelial cells40. Thus, all these findings suggest that 
preferential induction of type I and/or type III IFN response is virus- and cell type-specific and 
reflects the complex regulation of type I and III IFN induction following viral infections. 
Despite a clear induction of type III IFN responses, our IFN production bioassay found 
undetectable levels of IFN proteins in the (conditioned) culture medium from SA11-infected 
Caco2 cells (Fig. 2A and 2B). Consistently, we did not observe ISG upregulation in SA11-
infected Caco2 cells (Fig. 2C), indicating an absence of secreted IFN to stimulate ISG expression 
in an autocrine and/or paracrine manner. Further analysis by inhibiting downstream IFN 
signaling using JAK inhibitors demonstrated that RV replication levels were not altered. In 
human intestinal enteroids (organoids) infected with human RV strains, type III IFN induction 
was followed by stimulation of type III-dependent ISGs34. These discrepancies may be due to 
different RV strains as well as the different cellular composition of both models. However, 
despite this ISG induction, blockade of type I and III IFN receptor had no effects on RV 
replication34. Altogether, these findings indicate that endogenously produced IFNs (if any) 
were not sufficient to limit RV replication, even though they were able to induce ISGs in 
intestinal organoid models. These findings also suggest the ability of RV to subvert innate 
immune responses. It is known that RV have multiple ways to blunt innate IFN responses12. It 
has been shown that RV nonstructural protein 1 (NSP1) interacts with IRF3 to promote its 
degradation, leading to attenuation of IFN induction41.  
While previous studies mainly focused on the role of STAT1 in RV replication15,42, here we 
highlighted the role of basal IFN signaling in constraining RV infection. Individual knockdown 
of ISGF3 component, i.e. STAT1, STAT2 and IRF9, led to an elevated level of RV replication. 
Similarly, STAT1 knockout (KO) mice shed a significantly higher titer of RV than wild-type (WT) 
controls42. STAT1 is also shown to protect against lethal challenge of murine norovirus 
infection in mice43. In dengue virus (DENV)-infected mice, STAT2 was essentially required to 
protect against DENV-mediated diseases independently of STAT144. Our findings are also 
Chapter 4 
74 | P a g e  
 
consistent with our previous in vitro studies demonstrating that unphosphorylated ISGF3 
complex is responsible for maintaining basal transcription of ISGs in the absence of IFN 
stimulation to provide a “combat-ready” antiviral state in the susceptible host27. Thus, 
constitutive IFN signaling, ligand independent but maintained by background expression of its 
essential component, including STAT1, STAT2 and IRF9, are pivotal to restrict RV replication in 
the intestinal epithelium.  
While endogenous IFN response was not able to reduce RV replication, exogenous IFN 
treatment was effective to limit RV replication. We demonstrated that all three types of IFNs 
have notable antiviral effects against simian RV SA11 both in Caco2 cells and human organoids. 
Patient-specific organoid lines have promising implications for personalized medicine. 
Noteworthy, our study employed organoids derived from only two individuals. In this aspect, 
using organoids derived from several numbers of patients would be much better in 
recapitulating inter-individual variations, including HBGAs profiles, microbime diversity and 
genetic background32,35.  
We have also successfully cultivated four human-derived RV strains from acute diarrhea 
patients. Treatment with representative type I (IFNα), II (IFNγ) and III (IFNλ1 and IFNλ3) IFNs 
showed various sensitivity of human RV to IFNs, in which more pronounced inhibition was 
observed with type I and II rather than type III IFN treatment. In previous studies using human 
organoid models, type I IFN was more effective than type III IFN to suppress human RV 
replication34. However, conflicting results were found from in vivo studies about the relative 
contributions of type I and III IFNs during RV infections25,26,45. Type I IFN response plays a 
functional role to limit extra-intestinal spread in the mesenteric lymph node (MLN)45. On the 
other hand, RV has the capacity to attenuate the antiviral actions of IFNs14. Our study 
therefore suggests that human RV may differentially adapt in homologous host. 
While many previous studies mainly focused on the effects of type I and III IFNs, our study 
highlights the role of type II IFN (IFNγ) in limiting RV replication. Previous studies showed that 
IFNγ level in the serum was significantly higher in children with RV diarrhea than those of 
control children17. In our study, transcriptional analysis showed that IFNγ mRNA level was not 
detectable from SA11-infected Caco2 cells (data not shown). However, it has been shown that 
IFNγ was produced from human peripheral blood mononuclear cells (PBMCs) stimulated with 
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RV46. Consistently, the level of IFNγ gene expression as well as secreted level in the 
supernatant of PBMCs were significantly elevated in children with RV diarrhea as compared 
with controls18,47. These findings suggest that immune cells, and not epithelial Caco2 cells, 
were responsible for IFNγ production upon RV infection.  
RV-specific CD4+ and CD8+ IFNγ+ T cells were detected in the peripheral blood of RV-infected 
children and adults48,49. IFNγ producing T cells were also observed following experimental 
vaccines in animals and associated with disease protection21,50,51. It was previously shown that 
IFNγ inhibit RV entry into Caco2 cells20. In our study, we found that human IFNγ significantly 
reduces RV replication, suggesting that IFNγ can inhibit RV infection at various steps of the life 
cycle in the infected cells. In apparent agreement, it was suggested that IFNγ responses 
critically determine the severity of RV diseases in children52.  
ISGs are the ultimate effectors of IFN-mediated antiviral responses. Based on our findings, all 
three types of IFNs effectively induced a panel of well-known anti-viral ISGs both in Caco2 cells 
and in human organoids. However, further studies are needed to identify specific anti-RV ISGs 
to improve our understanding of immunity against RV infections. In conclusions, our study 
describes the role of both endogenous and exogenous IFN in RV infection, as well as the role 
of both basal and activated IFN signaling in limiting RV infection. These knowledge shall 
contribute to the better understanding of RV-host interactions and therapeutic development. 
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Material and Methods 
Reagents 
Type I human recombinant IFN alpha 2a (IFNα; Thermo Scientific) and IFN beta 1a (IFNβ; 
Sigma-Aldrich; Catalog Number 14151); Type II IFN gamma (IFNγ; BioLegend; Catalog# 
570202), and Type III IFNs IL29 (IFNλ1; Abnova), IL28A (IFNλ2; Abnova) and IL28B (IFNλ3; 
Abnova) were dissolved in culture medium. Stocks of Jak inhibitor I (Santa Cruz Biotech, CA) 
was dissolved in DMSO (Sigma-Aldrich, St Louis, MO, USA) with a final concentration of 5 
mg/mL. Anti-STAT1 antibody (#9172) was purchased from Cell Signaling Technology. IRF9 
antibody was obtained from LSBio (Life Span BioSciences, Inc). -actin and STAT2 (sc-476) 
antibodies were purchased from Santa Cruz Biotechnology. Anti-rabbit or anti-mouse IRDye-
conjugated antibodies were used as secondary antibodies for western blotting (Stressgen, 
Victoria, BC, Canada).  
Viruses 
Simian RV SA11, a broadly used laboratory strain, was employed. SA11 RV used in this study 
was prepared as described previously53. RV genome copy numbers were determined by 
quantitative real-time polymerase chain reaction (qRT-PCR). A plasmid template was used to 
generate a standard curve by plotting the log copy number versus the cycle threshold (CT) as 
previously described 33.  
Human-derived RV strains (G1P[8]) were obtained from fecal samples of four RV patients and 
stored at -80 oC freezer (the Erasmus MC Biobank, Department of Viroscience, Erasmus 
Medical Center, Rotterdam). These samples were collected during diarrhea period and tested 
negative for enterovirus, parechovirus, norovirus genogroup I and II, adenovirus, astrovirus 
and sapovirus by qRT-PCR. The patient characteristics were shown in Supplementary Table S1. 
Cell and human primary intestinal organoid culture 
Caco2 cell line (human caucasian colon adenocarcinoma ECACC) was cultured in Dulbecco’s 
modified Eagles’s medium (DMEM; Lonza, Verviers, Belgium) containing 20% (vol/vol) heat-
inactivated fetal calf serum (FCS; Sigma-Aldrich, St. Louis USA), 100 U/mL penicillin and 
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streptomycin (Gibco, Grand Island, USA). The cells were maintained in 5% CO2 at 37 oC in a 
humidified incubator.  
Organoid culture was performed as described previously33. Briefly, intestinal tissues taken 
from biopsy were vigorously shaken in 8 mM EDTA for 15 min at 4 oC. The EDTA solution was 
then discarded. Loosened crypts were collected by pipetting the solution up and down for 8-
10 times through a 10 mL pipette and transferred into a 50 mL tube (Greiner Bioone, the 
Netherlands). The biopsies were repeatedly used for crypts collection (2-3 times). Crypt 
suspensions were pooled and centrifuged at 300 g for 5 min. The crypt pellets were 
resuspended in 2 mL complete medium containing growth factors CMGF-: advanced 
DMEM/F12 supplemented with 1% (vol/vol) GlutaMAX™ Supplement (Gibco, Grand island, 
USA), 10 mM HEPES. The crypts were collected by centrifugation at 130g for 5 min at 4 oC, 
suspended in matrigel (Corning, Bedford, USA) and placed in the center of a 24-well plate (40 
μL per well). After the matrigel had solidified (15 min at 37 OC), organoids were maintained in 
culture medium at 37 oC, 5% CO2. Culture medium was refreshed every 2-3 days, and 
organoids were passaged every 6-7 days. 
Inoculation of SA11 and human-derived RV strains and treatment 
Caco2 cells cultured in T75 flask were suspended and subsequently seeded into 48-well plate 
(5 * 104 cells/well) in DMEM complemented with 20% (vol/vol) FCS and 100 IU/mL penicillin-
streptomycin. After 2-3 days of culture, culture medium was removed when the cell 
confluence was about 80%. The cell layers were then washed twice with 500 μL PBS. Serum-
free DMEM medium (100 μL) containing 5 μg/mL of trypsin (Gibco, Paisley, UK) and SA11 RV 
were added and incubated for 60 min at 37 oC with 5% CO2 to allow efficient infection, 
followed by four times washing with PBS (500 μL each) to remove free virus particles. 
Subsequently, culture medium containing 5 μg/mL of trypsin (and indicated treatments) were 
added to the infected cells and incubated for 24 or 48 hours at 37 oC with 5% CO2. 
For organoid infection, SA11 RV (contain 5000 genome copies) was first activated with 5 
μg/mL of trypsin at 37 oC with 5% CO2 for 30 minutes. Subsequently, organoids were infected 
with the activated SA11 for 60 minutes at 37 oC with 5% CO2, followed by four times washing 
with PBS to discard the free viruses. Organoids were then aliquoted into 48-well plates that 
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have been coated with 20% (vol/vol) Collagen R Solution (SERVA, Heidelberg, Germany) and 
maintained in culture medium containing indicated treatments at 37 oC with 5% CO2. 
Quantitative real-time polymerase chain reaction (qRT-PCR) 
Total, intracellular or extracellular (secreted) RNA was isolated by using the Machery-
NucleoSpin RNA II kit (Bioke, Leiden, The Netherlands) and quantified by a Nanodrop ND-1000 
spectrophotometer (Wilmington, DE, USA). cDNA was made from total RNA using a cDNA 
Synthesis Kit (Takara Bio Inc, Shiga, Japan) with random hexamer primers. qRT-PCR of RV RNA 
and genes of interest were performed with a SYBRGreen-based real-time PCR (MJ Research 
Opticon, Hercules, CA, USA) according to the manufacturer’s instructions with the 
StepOnePlus System (Thermo Fisher Scientific Life Sciences). Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) gene was used as a housekeeping gene to normalize (relative) gene 
expression using the 2-ΔΔCT formula. All primers used in this study are listed in Supplementary 
Table S2. 
Lentiviral vector production and transfection assays  
Lentiviral pLKO knockdown vectors (Sigma–Aldrich) targeting STAT1, STAT2 and IRF9 or 
scrambled control, were obtained from the Erasmus Center of Biomics. All shRNA sequences 
are listed in Supplementary Table S3. The lentiviral vectors were produced in human 
embryonic kidney epithelial cell line HEK 293T cells as previously described54. The shRNA 
vectors exerting optimal gene knockdown were selected. To generate the gene knockdown 
cells, Caco2 cells were transduced with the lentiviral vectors and subsequently selected by 
adding puromycin (8 μg/mL; Sigma) to the culture medium. Knockdown and control Caco2 
cells were infected with RV as previously described. 
IFN production bioassay 
The IFN production bioassay was performed to detect secreted IFN proteins in the culture 
medium as described previously55. Briefly, the culture (conditioned) medium derived from 
control and SA11-infected Caco2 cells (48 hours) were collected and filtered through 0.45 μm 
pore size membrane. Two luciferase reporter models which are extremely sensitive to IFN 
treatments were employed. Huh7.5-ET-Luc luciferase model is a hepatitis C virus (HCV) 
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replicon (I389/NS3-3V/LucUbiNeo-ET) in which the HCV-related firefly luciferase activity (HCV-
luc) can be potently inhibited by a low concentration of IFN-α treatments. Huh7-ISRE-luc is a 
luciferase reporter model in which the firefly luciferase gene was driven by multiple IFN-
stimulated response elements (ISRE) promoter. In this model, the firefly luciferase activity can 
be potently stimulated by a low concentration of IFN-α treatment. Therefore, these two 
luciferase models can be employed to sensitively detect the presence of IFN proteins in the 
conditioned medium. Huh7 HCV-luc and ISRE-luc cells were cultured in DMEM supplemented 
with 10% FCS (vol/vol), 100 U/mL penicillin and streptomycin. For Huh7 HCV-luc, 250 μg/mL 
G418 (Sigma-Aldrich) was added to the culture medium. 
Western blot assay 
Cultured cells were lysed in Laemmli sample buffer containing 0.1 M dithiothreitol (DTT) and 
heated for 5 min at 95°C. Cell lysates were subjected to 10% sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) for 100 min running at 110 V.  The proteins 
were transferred onto polyvinylidene difluoride (PVDF) membrane (Immobilon-FL) for 1.5 
hours with an electric current of 250 mA. Subsequently, the membrane was blocked with a 
mixture of 2.5 ml of blocking buffer (Odyssey) and 2.5 ml of PBS containing 0.05% Tween 20 
for 1 hour at room temperature. This was followed by an overnight incubation with the 
indicated primary antibody (1:1000 dilution) at 4°C. The membrane was then washed three 
times, followed by incubation for 1 hour with IRDye-conjugated secondary antibody (1:5000 
dilution) at room temperature. After washing three times, the protein bands were detected 
with the Odyssey 3.0 Infrared Imaging System. The intensity of the immunoreactive bands of 
blotted proteins was quantified by the Odyssey V3.0 software.  
Immunofluorescence microscope assay 
Caco2 cells were seeded on glass coverslips. After SA11 infection for 48 hours, cells were 
washed with PBS, fixed in 4% PBS-buffered formalin for 10 mins and blocked with tween-milk-
glycine medium (PBS, 0.05% tween, 5g/L skim milk and 1.5g/L glycine). Samples were 
incubated with anti-rotavirus (ab181695) antibody (Abcam) overnight at 4 °C. Subsequently, 
samples were incubated with 1:1000 dilutions of Alexa FluorTM 594 goat anti-mouse secondary 
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antibodies (Invitrogen). Nuclei were stained with DAPI (4,6-diamidino-2-phenylindole; 
Invitrogen). Images were detected using immunofluorescence microscope. 
MTT assay 
10 mM 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma) was 
added to Caco2 cells seeded in 96-well plates at indicated time points. The cells were 
incubated at 37 0C with 5% CO2 for 3 hours. The culture medium was then removed and 100 
μl of dimethyl sulfoxide (DMSO) was added to each well. The absorbance of each well was 
read on the microplate absorbance readers (BIO-RAD) at wavelength of 490 nm.  
Study Approval 
Human intestinal tissue were obtained during surgical resection. A written informed consent 
was signed by the volunteers or patients who agreed to participate. The study was approved 
by the Medical Ethical Committee of the Erasmus Medical Center (Medisch Ethische Toetsings 
Commissie Erasmus MC), and all experiments were performed in accordance with relevant 
guidelines and regulations. 
Statistical Analysis 
Statistical analysis was performed using the nonpaired, nonparametric test (Mann-Whitney 
test; GraphPad Prism software, GraphPad Software Inc., La Jolla, CA). P values <0.05 were 
considered statistically significant. 
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Supplementary Figure S1.Efficient replication of rotavirus SA11 in Caco2 cells as demonstrated by 
qRT-PCR. Intracellular (A) and secreted (extracellular) levels (B) of rotavirus SA11 were detected and 
quantified by qRT-PCR at 0 (before virus inoculation) as well as at 1, 24 and 48 hours after inoculation. 
For intracellular RNA quantification (A), RV RNA levels were shown as fold increases relative to 1 hour 
post infection. GAPDH was used as the housekeeping gene. 
 
 
Supplementary Figure S2. Efficient replication of rotavirus SA11 in Caco2 cells as demonstrated by 
immunofluorescence stainings. Representrative immunofluorescence stainings of ab181695 
(targeting VP6 rotavirus protein) (red) after 48 hours infection of Caco2 cells with rotavirus SA11. 
Nuclei were visualized by DAPI (blue).  
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Supplementary Figure S3. Western blot assays showed a successful knockdown of STAT1 (58% 
reduction), STAT2 (69% reduction) and IRF9 proteins (69% and 77% reduction). β-actin served as an 
internal reference. (means ± SEM, n = 3). 
 
 
Supplementary Figure S4. 
The effects of exogenous 
treatment of type I, II and III 
IFNs on RV SA11 replication 
in Caco2 cells. Antiviral 
activities of IFNα, IFNβ, IFNγ, 
IFNλ1, IFNλ2 and IFNλ3 
treatments against RV SA11 
infection on Caco2 cells were 
determined by quantifying 
intracellular (A) and 
extracellular (secreted) (B) 
RNA levels at 48 hours post-
infection. (n = 2-3 
independent experiment with 
each of 3 replicates) Data 
were presented as means ± 
SEM., *P < 0.05; **P < 0.01; 








Supplementary Figure S5. The effects of type I, II and III IFNs on the extracellular level of RV SA11 in 
human organoids. Antiviral effects of IFNα, IFNβ, IFNγ, IFNλ1, IFNλ2 or IFNλ3 treatment against RV 
SA11 infection in organoids were determined by quantifying extracellular (secreted) RNA levels at 48 
hours post-infection. The organoids were derived from one individual (P1). Data were presented as 
means ± SEM., *P < 0.05; **P < 0.01; ns, not significant. (n = 3 independent experiments with each of 
2-3 replicates). 
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Supplementary Figure S6. (A) Antiviral effects of representative type I (IFNα, 1000 IU/mL), type II (IFNγ, 
1000 ng/mL), and type III (IFNλ1, 1000 ng/mL) treatment against RV SA11 infection in organoids were 
determined by quantifying total RV RNA levels at 48 hours post-infection. The organoid was derived 
from individual 2 (P2). Data were presented as means ± SEM, **P < 0.01. (n = 3 independent 
experiments with each of 1-2 replicates). (B) Organoids (P2) were stimulated with IFNα 1000 IU/mL, 
IFNγ 1000 ng/mL and IFNλ1 1000 ng/mL for 24 hours. The expression levels of several ISGs were 
measured by qRT-PCR. 
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Supplementary Figure S7. JAK I inhibitor blocks IFNα-induced ISGs in Caco2 cells. JAK I inhibitor (10 
μM) abrogated IFNα- (100 IU/mL) induced ISG expression as measured by qRT-PCR. Data were 
presented as means ± SEM., *P < 0.05; **P < 0.01; ns, not significant. (n = 3 independent experiments 
with each of 2-3 replicates) 
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Supplementary Figure S8. JAK I inhibitor abolishes IFNγ-induced expression of ISGs in Caco2 cells. 
JAK I inhibitor (10 μM) abrogated IFNγ- (100 ng/mL) induced ISG expression as measured by qRT-PCR. 
Data were presented as means ± SEM., *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant. (n = 3 
independent experiments with each of 2-3 replicates) 
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Adenovirus Astrovirus Sapovirus Rotavirus 
1 74 Female Congestive 
heart failure, 
myocarditis 
No No No No No No No Yes 




No No No No No No No Yes 






No No No No No No No Yes 
4 1.5 Female Vomiting, 
watery 
diarrhea 
No No No No No No Yes Yes 
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Supplementary Table S2. Primers used in this study.  
Target Genes Sequences (5’ - 3’) 
Viruses  
RV SA11-F TGGTTAAACGCAGGATCGGA 
RV SA11-R AACCTTTCCGCGTCTGGTAG 
Human RV-F ACCATCTACACATGACCCTC 
Human RV-R CACATAACGCCCCTATAGCC 




























































IFN1 (IL-29)-F  GGAAGACAGGAGAGCTGCAACT 
IFN1 (IL-29)-R AACTGGGAAGGGCTGCCACATT 
IFN2/3 (IL-28)-F TCGCTTCTGCTGAAGGACTGCA 




Supplementary Table S3. Lentiviral sh-RNA sequences used in this study. 
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Abstract 
Rotavirus infection remains a great health burden worldwide, especially in various developing 
countries. It causes severe dehydrating diarrhea in infants, young children, as well as in 
immunocompromised and organ-transplanted patients. Viral replication heavily relies on the 
host to supply nucleosides. Thus, host enzymes involved in nucleotide biosynthesis represent 
potential targets for antiviral development. Dihydroorotate dehydrogenase (DHODH) is the 
rate-limiting enzyme in the de novo biosynthesis pathway of pyrimidines. In this study, we 
demonstrated that two specific DHODH enzyme inhibitors, brequinar (BQR) and leflunomide 
(LFM) robustly inhibited rotavirus replication in the conventional human intestinal Caco2 cell 
line model as well as in human primary intestinal organoids. The antiviral effect is conserved 
between both the laboratory strain SA11 and the rotavirus strain 2011K, isolated from clinical 
sample. Mechanistic study indicated that BQR and LFM exerted their anti-rotavirus effect 
through targeting DHODH to deplete pyrimidine nucleotide pool. Therefore, targeting 
pyrimidine biosynthesis represents a potential approach for developing antiviral strategies 
against rotavirus.  
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1. Introduction 
Rotavirus (RV), a member of Reoviridae family, is a non-enveloped virus which has a double-
stranded RNA genome of 11 segments surrounded by three concentric protein layers. It has 
been reported to cause estimated 25% of moderate-to-severe illnesses (Kotloff et al., 2013) 
and 30% of total diarrheal deaths during the first 2 years from birth (Wang et al., 2016a). The 
development and deployment of rotavirus vaccines was a breakthrough in the fight against 
diarrheal diseases. Two rotavirus vaccines, RotarixTM and Rotateq, are licensed and widely 
available in several countries (Yin et al., 2018). Nevertheless, due to limited resources, 
developing countries including India, Nigeria, Pakistan, Ethiopia and the Democratic Republic 
of the Congo bear the major burden of mortality (Groome et al., 2014). In addition, 
immunocompromised patients are also under the risk of RV infection which causes 
remarkable morbidity and mortality (Lee and Ison, 2014; Sugata et al., 2012; Yin et al., 2015c). 
For the treatment of rotavirus gastroenteritis, intravenous fluid supply has been used for 
treatment of dehydration from diarrhea. However, in the severe case of inpatients and 
immunocompromised patients who are suffering from prolonged diarrhea and fever, virus-
specific treatment is urgently required. In fact, there is still no FDA-approved medication 
available against rotavirus disease. Therefore, to ensure that the remaining burden of 
mortality and morbidity can be fully addressed in the future, research on the development of 
novel antiviral strategies is highly needed.  
Cellular nucleotides, composed of purines and pyrimidines, play a vital role in constituting 
nucleic acids RNA and DNA. De novo synthesis and salvage pathway are the two pathways for 
nucleic acid synthesis in vivo (Evans and Guy, 2004). Viral replication heavily relies on host 
supply of nucleoside biosynthesis. Therefore, host enzymes involved in nucleoside 
biosynthesis represent potential targets for antiviral development. Ribavirin, the most well-
known antiviral drug, is such an inhibitor that suppresses guanine biosynthesis via inhibition 
of cellular IMP dehydrogenase (IMPDH). Several studies have indicated that depletion of 
cellular GTP pool is the primary mechanism by which ribavirin inhibits virus replication (e.g. 
flaviviruses and hepatitis E virus) (García et al., 2018; Nicolini et al., 2018). Along this line, we 
aim to investigate whether inhibitors of the pyrimidine biosynthesis pathway could be 
targeted for potential antiviral development against rotavirus.  
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Dihydroorotate dehydrogenase (DHODH) is sequentially the fourth and the rate-limiting 
enzyme in the de novo biosynthesis pathway of pyrimidines. It is located in the inner 
membrane of mitochondria, where it plays a role of converting dihydroorotate to 
orotate(Munier-Lehmann et al., 2013). Then, the multifunctional UMP synthase uses orotate 
to produce UMP, one of the essential precursors for synthesis of all other pyrimidine 
nucleotides. Several studies have reported that inhibition of DHODH enzyme suppresses a 
range of different viruses replication (Hoffmann et al., 2011; Luthra et al., 2018; Tan et al., 
2005; Wang et al., 2011; Wang et al., 2016b).  
In this study, we report that brequinar (BQR) and leflunomide (LFM), two DHODH inhibitors, 
potently inhibit rotavirus replication in human intestinal cell line as well as three dimensional 
(3D) cultured primary intestinal organoids. Mode-of-action studies demonstrate that their 
antiviral activity is mainly achieved via the inhibition of DHODH, resulting in the depletion of 
intracellular pyrimidine pools. Collectively, our study has stressed the concept that targeting 
pyrimidine biosynthesis represents a potential approach for antiviral development against 
rotavirus. 
2. Materials and methods 
2.1 Reagents 
Brequinar (BQR) sodium salt hydrate (Method Detection Limit [MDL] no. MFCD21363375), 
leflunomide (LFM) (Chemical Abstracts Service [CAS] no. 75706-12-6) ，6-azauracil (6-AU) 
(MDL no. MFCD00006456) and uridine (CAS no. 58-96-8), were purchased from Sigma. All the 
reagents were dissolved in dimethyl sulfoxide (DMSO).  
2.2. Viruses 
Simian rotavirus SA11, a broadly used and well-studied laboratory strain (Cecílio et al., 2012), 
was a gift from Karen Knipping from Nutricia Research Utrecht, The Netherland. In the study, 
rotavirus SA11 was prepared as described (Knipping et al., 2012). Stool sample collected from 
rotavirus infected patient was obtained from the Erasmus MC biobank, Department of 
Viroscience, Erasmus Medical Center, Rotterdam. This stool sample 2011K was taken during 
patient diarrhea period and tested for enterovirus, parechovirus, norovirus genogroups I and 
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II, rotavirus, adenovirus, astrovirus and sapovirus by PCR. Sample 2011K is only positive to 
rotavirus and negative to other virus mentioned above. Sample information was also 
described in previous studies (Corless et al., 2002; Hoek et al., 2013; van Maarseveen et al., 
2010). 
2.3. Cell lines and human primary intestinal organoids 
The human colon cancer cell line Caco2 and the human embryonic kidney cell line 293T (HEK 
293T) were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Lonza, Verviers, Belgium) 
containing 20% (vol/ vol) heat-inactivated fetal calf serum (FCS, Sigma–Aldrich, St. Louis USA) 
and 100 U/ml Penicillin/ Streptomycin (P/S, Gibco, Grand Island, USA) solution. A humidified 
incubator was used for cells culturing at 37 ̊C in 5% CO2. Cells were analyzed by genotyping 
and confirmed to be mycoplasma negative. 
Human primary small intestinal organoids culture was performed as described previously (Yin 
et al., 2015a). Fragments of intestinal biopsies or surgically resected intestinal tissues were 
treated with complete chelating solution (CCS, MilliQ H2O was supplemented with 1.0 g/L of 
Na2HPO4-2H2O, 1.08 g/L of KH2PO4, 5.6 g/L of NaCl, 0.12 g/L of KCl, 15 g/L of Sucrose, 10 g/L 
of D-Sorbitol and 80 µg/L of DL-dithiothreitol) followed by 8 mM EDTA. Crypts were finally 
collected and suspended in 40 µL growth factor reduced phenol-red free Matrigel (Corning, 
Bedford, USA). Then, they were incubated at 37 ̊C with 5% CO2 with culture medium 
containing CMGF, 2% (vol/vol) of B-27® Supplements (Gibco, Grand Island, USA), 1% (vol/vol) 
of N2® Supplements (Gibco, Grand Island, USA), 500 pg/mL of EGF, 1 mM n-Acetyl Cysteine, 
10 mM Nicotinamide, 0.5 µM A83-01 (TGF-b inhibitor), 3 µM SB202190 (p38 inhibitor), 20% 
(vol/vol) of R-Spondin 1 (conditioned medium), 10% (vol/vol) of Noggin (conditioned medium) 
and 50% (vol/vol) of Wnt3a (conditioned medium). Culture medium was refreshed every 2-3 
days, and HIOs were passaged every 6–7 days. 
2.4. Inoculation of SA11 rotavirus and clinical derived strain 2011K  
Caco2 cells were washed, suspended in a T75 flask and subsequently seeded into a 48-well 
plate (5×104 cells/well). Culture medium was discarded when cell confluence was 
approximately 80%, and cell monolayers were washed twice with PBS. 100 µL of serum-free 
DMEM medium, then rotavirus (MOI=0.7) with 5 µg/mL of trypsin (Gibco, Paisley, UK) were 
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added and incubated at 37 ̊C with 5% CO2 for 60 min for infection, followed by 4 times washing 
with PBS to remove un-attached viruses Then, cells were incubated with culture medium 
containing 5 µg/ml of trypsin at 37 ̊C with 5% CO2. 
2.5. Virus production assay 
Virus, cell line and HIOs were treated as described in previous work (Yin et al., 2015b). In short, 
caco2 cells were inoculated with SA11 rotavirus (MOI=0.7) then harvested after 48h 
incubation with serum-free medium to perform assays as followed. In parallel, human primary 
intestinal organoids were infected with 10 times higher concentration of SA11 rotavirus than 
cell infection for 1.5h followed by 4 times washing with PBS. Afterwards, HIOs with no Matrigel 
remain were spun down at 500g for 10 min to adhered to the bottom of 24-well plate coated 
with Collagen R solution (SERVA, Heidelberg, Germany). Organoids culture medium was added 
gently and HIOs were incubated at 37 ̊C with 5% CO2. Culture medium and HIOs were 
harvested respectively after 48h to detect and enumerate rotavirus. Virus titers from 
supernatants were determined by calculating the log10TCID50/mL in Ma104 cells using the 
method developed by Reed and Muench(Reed and Muench, 1938). 
2.6. RNA isolation, cDNA synthesis and qRT-PCR 
Total RNA was isolated using Macherey-Nagel NucleoSpin® RNA II kit (Bioke, Leiden, 
Netherlands) and quantified using a Nanodrop ND-1000 (Wilmington, DE, USA). Total RNA 
reverse transcription was performed by using a cDNA Synthesis kit (TAKARA BIO INC.) with 
random hexamer primers. Real-time PCR reactions (50 ̊C for 2 min, 95 ̊C for 10 min, followed 
by 50 or 60 cycles of 95 ̊C for 15 s and 58 ̊C for 30 s and 72 ̊C for 10 min) were performed with 
SYBRGreen-based real-time PCR (Applied Biosystems®, Austin, USA) according to the 
manufacturer’s instruction. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene was 
used as housekeeping gene. Relative gene expressions were normalized to GAPDH using the 
formula 2-∆∆CT (∆∆CT = ∆CTsample - ∆CTcontrol). Template control and reverse transcriptase 
control were included in all RT-qPCR experiments. All qRT-PCR primers are listed in 
Supplementary table 1. 
2.7. Quantification of rotavirus genome copy numbers 
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An amplicon of the SA11 (a fragment of VP6 gene from 564-718) was cloned into the pCR2.1-
TOPO vector (Invitrogen, San Diego, CA) to generate a template for quantifying rotavirus 
genome copy number. The plasmid was extracted by Quick Plasmid Miniprep Kit (Invitrogen, 
Lohne, Germany) following manufacturer’s instructions. A series of dilutions (from 10-2 to 10-
10) were prepared and then were amplified and quantified by qRT-PCR to generate a standard 
curve. This standard curve was generated by plotting the log copy number versus the cycle 
threshold (CT) value (Fig. S1). Copy numbers were calculated by using the following equation: 
Copy number (molecules/µl) = [concentration (ng/µl) × 6.022× 1023 (molecules/mol)]/[length 
of amplicon× 640 (g=/mol) × 109 (ng/g). 
2.8. Determination of compromised organoids scoring 
The scoring process was performed as previously(Grabinger et al., 2014). In short, a minimum 
of 100 organoids were counted after 3 days following passaging. After a 1.5h incubation with 
SA11 rotavirus, HIOs were cultured in matrigel and treated with different agents for 48h, and 
HIOs were counted and defined as viable or dead via their morphological appearance in the 
optimal microscope (Axiovert 40 CFL, Zeiss, Oberkochen, Germany) in at least three random 
visions in different parallel wells, the description of this scoring system is showed in Fig. S3. 
The proportion of deteriorated organoids was calculated as (viable/ total) %. 
2.9. Gene knockdown assays 
Lentiviral shRNA vectors, targeting dihydroorotate dehydrogenase (DHODH) gene or non-
targeted control lentivirus were produced in 293T cells as previous work (Qu et al., 2018). 
Caco2 cells were inoculated with lentivirus to generate stable gene knockdown cells. Cells 
were subsequently selected with 5 µg/mL puromycin (Sigma). After pilot study, two shRNA 
vectors exerting optimal gene knockdown were selected. Knockdown and control Caco2 cells 
were incubated with rotavirus as described above. All shRNA primers were listed in 
supplementary table 2. 
2.10. Western blot assay 
Lysed cells were subjected to SDS-PAGE, and proteins were transferred to PVDF membrane 
(Immobilon-FL). DHODH (ab 54621, 1:1000, mouse monoclonal, Abcam), SA11 rotavirus VP4 
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(1:1000, HS-2, mouse monoclonal; provided by professor Harry Greenberg, Stanford 
University School of Medicine, USA) was detected by western blot analysis and β-actin protein 
was detected as loading control (sc-47778, 1:1000, mouse monoclonal; Santa Cruz). The 
intensity of the immunoreactive bands of blotted protein was quantified by the Odyssey V3.0 
software. 
2.11. Immunofluorescence analysis 
After rotavirus infection and BQR treatment, HIOs were harvested and fixed in 4% 
paraformaldehyde in PBS at 4 ̊C for 10 min. Fixed HIOs were added into the CytoSpin II 
Cytocentrifuge (Shandon Scientifi Ltd, Runcorn, England), then spined down at 1000 rpm for 
2 min. The slides containing HIOs were rinsed 3 times with PBS for 5 min each, followed by 
treatment with 0.1% (vol/vol) Tritonx100 for 4 min. Subsequently, the slides were twice rinsed 
with PBS for 5 min, followed by incubation with milk-tween-glycine medium (0.05% tween, 
0.5% skim milk and 0.15% glycine) to block background staining for 30 min. Slides were 
incubated in a humidity chamber with anti-rotavirus antibodies (1:250, mouse monoclonal; 
Abcam) diluted in milk-tween-glycine medium at 4 ºC overnight. Slides were washed 3 times 
for 5 min each in PBS prior to 1h incubation with 1:1000 dilutions of the anti-mouse IgG (H+L, 
Alexa Fluor® 594) secondary antibody. Nuclei were stained with DAPI (4, 6-diamidino-2-
phenylindole; Invitrogen). Images were detected using EVOS FL cell imaging system (Thermo 
Fisher). 
2.12. MTT assay 
The CC50 values of BQR and LFM (1613µM for BQR and 372µM for LFM) were determined by 
MTT assay (Fig. 1C) as previous study (Qu et al., 2018). Approximately 1×104 Caco2 cells were 
seeded per well in 96-well plate. After 48h, cells were incubated with 10 µL 5 mg/ml MTT for 
3 h, then replaced with 100 ml dimethyl sulfoxide (DMSO) medium (Sigma). Absorbance (490 
nm) was analyzed accordingly.  
2.13. Statistics 
All numerical results reported represent at least two technical replicates obtained in two 
independent biological replicates and are reported as Mean ± SEM. The statistical significance 
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of differences between means was assessed with the Mann-Whitney test (GraphPad Prism 5; 
GraphPad Software Inc., La Jolla, CA). The threshold for statistical significance was defined as 
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3. Result 
3.1. BQR and LFM potently inhibit the replication of SA11 and patient-derived 
rotavirus strain 2011K.  
BQR is an immunosuppressive and anti-proliferative compound which has been evaluated in 
multiple clinical trials as a potential treatment for cancer (Madak et al., 2017; Makowka et al., 
1993). Similarly, LFM is also an immunosuppressive drug used in active moderate-to-severe 
rheumatoid arthritis and psoriatic arthritis (Davis et al., 1996). So we tried to investigate 
whether these two inhibitors of the pyrimidine biosynthesis pathway have potential anti-
rotavirus effect. After infection by simian rotavirus SA11, Caco2 cells were treated with various 
concentrations of BQR and LFM for 48h. BQR and LFM potently inhibited SA11 rotavirus 
replication in a dose-dependent manner as measured in both RNA and protein levels (Fig. 1A 
and B), while cell viability was not affected (Fig. 1C). The IC50 values of BQR and LFM are 
0.04917 µM and 48.98 µM respectively, while the CC50 values are 1613 µM and 372 µM, 
indicating a high specificity of these two compounds on rotavirus (Fig. 1C and Fig. S2).  
Consistently, SA11 rotavirus titer was also significantly decreased by BQR and LFM treatment 
(Fig. 1D). Indirect fluorescence microscopy analysis further confirmed that BQR and LFM could 
inhibit rotavirus replication (Fig. 2A and B). 3D cultured primary human intestinal organoids 
(HIO) represent a state-of-art model for investigating intestinal physiology and pathology. 
Therefore, we further tested the antiviral activity of BQR and LFM in the HIO model. 
Importantly, BQR and LFM reduced the levels of cellular viral RNA and inhibited virus 
production significantly, while no cytotoxicity effects were observed (Fig. 3A and B, Fig. S3A). 
For instance, with 5μM of BQR, cellular viral RNA was decreased by 65% (n=6, p<0.01), and 
virus production was inhibited by 76% (n=6, p<0.01). Since rotavirus infection causes 
pathological and morphological changes on organoids, we randomly selected three scopes 
and quantified the proportion of compromised organoids upon different treatments. Both 
BQR and LFM could strongly decrease the proportion of compromised organoids (Fig. 4 A-C). 
This notion was further supported by the evidence that BQR and LFM treatment led to 
decreased levels of rotavirus VP6 protein (Fig. 4D). Next, we expand our study to patient-
derived rotavirus strain 2011K. Consistently, BQR and LFM profoundly inhibited virus 
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replication of this rotavirus strain (Fig. 5). Collectively, these results demonstrated that BQR 
and LFM could potently inhibit rotavirus replication. 
 
Figure 1. BQR and LFM exert potent antiviral activity against rotavirus SA11 on Caco2 cells. Caco2 cells 
were infected with SA11 rotavirus. After infection, cells were treated with various concentrations of BQR 
or LFM. (A) qRT-PCR analysis indicated that BQR (n=6) and LFM (n=6) exerted potent antiviral effect against 
rotavirus replication. Data were normalized to housekeeping genes GAPDH and presented relative to the 
control (CTR) (set as 1). Data represent means ± SEM. *, P < 0.05; **, P < 0.01. (B) Western blot analysis 
showed that BQR (n=4, 0.05 to 5 µM) and LFM (n=4, 50 µM) inhibited rotavirus replication. Data represent 
means ± SEM. *, P < 0.05. (C) 50% cytotoxic concentration (CC50) curves of BQR (left panel) and LFM (right 
panel) were determined by MTT assays. (D) The supernatant of each well was harvested after freeze and 
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thaw for three times, virus titer from different groups was measured (n=4. Data represent means ± SEM. 
***, P < 0.001). 
 
 
Figure 2. BQR and LFM inhibit the expression of rotavirus VP6 protein. (A)Indirect fluorescence 
microscope analysis of viral structural protein VP6 (red) upon treatment with BQR (0.05 µM) and LFM (5 
µM). Nuclei were visualized by DAPI (blue). (B) The ratio of VP6 positive cells/ total cell number was 
quantified (n=4). Data represent means ± SEM. *, P < 0.05. 
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Figure 3. BQR and LFM exert potent antiviral activity against rotavirus SA11 on human intestinal 
organoids. (A) Representative microscopy of cultured human small intestinal organoids. (B) BQR (n=6) as 
well as LFM (n=6) inhibit SA11 replication and virus production after 48h incubation. The relative rotavirus 
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RNA and genomic copy number were analyzed by qRT-PCR. Data represent means ± SEM. *, P < 0.05; **, P 
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Figure 4. Microscopy image analysis indicated that BQR and LFM exert potent antiviral activity against 
rotavirus SA11 on human intestinal organoids (HIOs). (A) Microscopy image analysis of HIOs treated with 
5µM BQR and 50µM LFM. (B) Microscopy image analysis of HIOs infected by rotavirus SA11 and treated 
with CTR, 5µM BQR or 50µM LFM. (C) Scoring of proportion of deteriorated HIOs in different random visions, 
n=6. Data represent means ± SEM. **, P < 0.01. (D) 5µM BQR and 50µM LFM inhibited rotavirus SA11 
replication on HIOs. Rotavirus structural protein VP6 (red). Nuclei were visualized by DAPI (blue). 
 
Figure 5. BQR and LFM showed antiviral effect against clinical-derived rotavirus strains. (A) qRT-PCR 
analysis indicated that BQR (n=6) and LFM (n=6) exerted strong antiviral effect against rotavirus 2011K. 
Data were normalized to housekeeping genes GAPDH and are presented relative to the control (CTR) (set 
as 1). Data represent means ± SEM. *, P < 0.05; **, P < 0.01. (B) Virus titer of rotavirus 2011K were measured 
upon BQR and LFM treatment respectively (n=4). Data represent means ± SEM. ***, P < 0.001.  
3.2 BQR and LFM, two DHODH inhibitors, inhibit rotavirus replication through 
depletion of the cellular pyrimidine nucleotide pool 
Classically, BQR and LFM are two well-established DHODH inhibitors. Upon inhibition of 
DHODH, cellular pyrimidine biosynthesis pathway will be blocked, resulting in the depletion 
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of pyrimidine nucleotide pool. To investigate whether these two compounds exert a similar 
mode-of-action against rotavirus, we employed both BQR and LFM for further mechanistic 
study. We first used an RNAi-based loss-of-function assay to study the role of DHODH. Two 
successful knock-down clones were confirmed by both qRT-PCR and western blot (Fig. 6A). 
Silencing of DHODH resulted in compromised rotavirus replication (Fig. 6B). The specificity of 
the effect was further confirmed when we added BQR and LFM to DHODH knockdown or 
control cell lines infected with SA11. Knockdown of DHODH abrogated the anti-rotavirus 
effect rate of BQR from 53% to 37% and 38% respectively. As for LFM, the effect decreased 
from 72% to 50% in both knockdown cell lines (Fig. 6C). To further validate whether the 
antiviral effect of BQR and LFM was achieved via the depletion of pyrimidine pool, exogenous 
uridine was supplemented to cell culture medium. Of note, supplementation of pyrimidine 
dose-dependently abolished the anti-rotavirus effect of BQR and LFM. At the concentration 
of 2000μM, the BQR and LFM-provoked anti-rotavirus effect was totally abolished (Fig. 6D). 
Taken together, these results indicated that BQR and LFM exerts their anti-rotavirus effect 
through targeting DHODH to deplete pyrimidine nucleotide pool. Orotidine 5'-
monophosphate decarboxylase (ODCase) serves as the downstream enzyme of DHODH, which 
catalyzes OMP to UMP. 6-azauracil (6-AU), a potent inhibitor of ODCase, was evaluated for its 
potential effect on rotavirus replication. Consistently, 6-AU also inhibits rotavirus replication 
(Fig. 7A). Conceptually, targeting pyrimidine biosynthesis represents a potential approach for 
antiviral development against rotavirus. 
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Figure 6. BQR and LFM exert its anti-rotavirus effect through targeting DHODH to deplete pyrimidine 
nucleotide pool. (A) qRT-PCR and western blot analysis confirmed the knockdown of DHODH in Caco2 cells 
(n=9). Data represent means ± SEM. ***, P < 0.001. (B) Knockdown of DHODH significantly inhibits SA11 
rotavirus replication in Caco2 cells (n=6). Data represent means ± SEM. **, P < 0.01. (C) Anti-rotavirus effect 
of BQR and LFM was partially blocked in two clones of DHODH knockdown cells (n=6). Data represent means 
± SEM. *, P < 0.05. (D) Supplementation of exogenous uridine attenuates the anti-rotavirus effect of BQR 
and LFM in Caco2 cells (n=6). Data represent means ± SEM. **, P < 0.01. 
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Figure 7. Depleting pyrimidine nucleotide pool inhibits rotavirus replication. (A) qRT-PCR analysis showed 
that 6-AU, a specific inhibitor of ODCase, inhibited rotavirus replication (n=6). Data represent means ± SEM. 
*, P < 0.05. (B) Schematic overview of de novo pyrimidine biosynthesis pathway. 
4. Discussion 
Though rotavirus vaccines have been introduced, and the vaccines remarkably reduced the 
burden of rotavirus gastroenteritis in many developed countries, due to prevalence and 
diversity of the virus, one third to half of the children is subject to vaccination failure in some 
developing countries (Macartney et al., 2000). Antiviral treatment may serve as complement 
to vaccination. A drug repurposing approach offers many advantages for the identification of 
new antiviral strategies over the development of new drugs, since safety and pharmacology 
in humans are already well known. Therefore, if a drug, currently in clinical use, demonstrates 
considerable antiviral activity against rotavirus, there should be great potential to expand its 
application to combating rotavirus infection.  
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Of note, BRQ and LFM are two well-known immunosuppressive agents (Batt, 1999). As for 
LFM, it was reported as immunosuppressive therapy for bone marrow (Avery et al., 2004) and 
renal (Chon and Josephson, 2011) transplantation. Accumulating evidence indicates that 
organ transplant patients, irrespective of their age, are more vulnerable to rotavirus infection. 
Thus, the potential clinical prospects of BQR and LFM or their analogues may be to achieve a 
“one stone two birds” effect: exerting immunosuppressive function and anti-rotavirus effect 
at the same time. Of note, BQR was reported to have some side effects, such as 
leukocytopenia ,thrombocytopenia, reduced body weight gain or body weight loss, thymic 
atrophy, cellular depletion of bone marrow and splenic white pulp, and villous atrophy in 
jejunum (Pally et al., 1998). Similarly, LFM also has side effects, including gastrointestinal 
symptoms, rash or allergic reactions and alopecia (Emery et al., 2000; Mladenovic et al., 1995; 
Smolen et al., 1999; Strand et al., 1999). These kinds of clinical observations should be seen in 
the light of that all drugs come with side effects.  Importantly, the drug dosages of both drugs 
used in our study for inhibition of rotavirus are much lower than their previous clinical trial 
dosages (Maroun et al., 1993; Natale et al., 1992; Smolen et al., 1999). This might make BQR 
or LFM a preferable option for treating rotavirus infection, achieving high efficacy with less 
side effects. In addition, pyrimidine biosynthesis (Figure 7B) represents a potential host 
pathway for novel antiviral drug development. These specific inhibitors of this pathway may 
represent as a starting point for the development of efficient anti-rotavirus drugs with more 
broad applications. 
Intestinal carcinoma-derived cell lines such as Caco2 cell line are widely used as in vitro models 
to investigate rotavirus infection (Cuadras et al., 2002; Frias et al., 2012). Compared to such 
two-dimensional (2D) single cell type culture systems, the three-dimensional (3D) model of 
human primary intestinal organoids surpasses 2D models in cell diversity and spatial structure 
for mimicking rotavirus infection (Yin et al., 2015a). Specifically, these primary intestinal 
organoids consist of many undifferentiated and heterogeneous cell types with similar 
functions as in the organ/tissue of origin (Sato and Clevers, 2012, 2013; Sato et al., 2011; Sato 
et al., 2009), including enterocytes, enteroendocrine cells, goblet cells, Paneth cells and stem 
cells (Saxena et al., 2015). We have validated our results observed in conventional cell culture 
model also in the primary human organoids. Moreover, the use of rotavirus strains isolated 
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from clinical samples leads our study one step closer to eventual improved clinical therapy for 
rotavirus infection. 
Nucleotides play an important role in host cell metabolism and are essential for virus infection. 
Many inhibitors targeting de novo pyrimidine biosynthesis (Fig. 7B) have been well studied on 
dengue virus, HBV, HEV and other virus infection models (Beardsley et al., 1989; Greene et al., 
1995; Hoppe‐Seyler et al., 2012; Nelson et al., 1975; Qing et al., 2010; Silva et al., 1997; Wang 
et al., 2011; Wang et al., 2016b). In this study, we demonstrated that both BQR and LFM, 
inhibitors of DHODH enzyme, have potent antiviral activity against rotavirus infection. 
Mechanistic study demonstrated that BQR and LFM exert their anti-rotavirus effect through 
targeting DHODH to deplete pyrimidine nucleotide pool. Therefore, targeting pyrimidine 
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 Supplementary information 
Supplementary table 2. qRT-PCR primers (human gene) used in the study, from 5' to 3'. 













   
 
 
Supplementary table 2. shRNA target sequences. 
ShRNA Sequence 
shDHODH-1  CCGGCGATGGGCTGATTGTTACGAACTCGAGTTCGTAACAATCAGCCCATCGTTTTT 
shDHODH-2  CCGGGTGAGAGTTCTGGGCCATAAACTCGAGTTTATGGCCCAGAACTCTCACTTTTT 
 
y = -0.2993x + 11.39 R
2
=0.9986 P<0.0001
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Supplementary Fig. S1. Standard curve for quantifying rotavirus genome copy numbers. An amplicon of the 
SA11 was cloned into the pCR2.1-TOPO vector. The plasmid was extracted, followed by a series of dilutions, 
from 10-2 to 10-10, were prepared and then were amplified and quantified by qRT-PCR. Standard curve was 
generated by plotting the cycle threshold (CT) value regarding the log copy number.   
 
 
Supplementary Fig. S2. 50% cytotoxic concentration (CC50) curves of BQR (A) and LFM (B) determined by 
MTT assays. Caco2 cells treated with two agents for 48h respectively. 
 
Supplementary Fig. S3. 50% inhibitory concentration (IC50) curves of BQR (A) and LFM (B) against SA11 
rotavirus on Caco2 cell line. 
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Supplementary Fig. S4. Description of the organoid scoring system. (A) Fluorescence microscopy images 
analysis of HIOs treated with BQR, LFM and various concentration of DMSO after 48h incubation and then 
stained by PI(red) which represented as dead cell, Hoechst(blue) which represented as nuclear, and 
Calcein(green) which represented as live cell. (B) After 48h, in 2% DMSO group, we define the upper right 
HIO(which red signal is more than green signal and also more than 50% of blue signal) as positive HIO, on 
the contrary, HIOs like lower left one, will be counted as negative HIO, in optimal microscopy image, positive 
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ABSTRACT 
Rotavirus infection has emerged as an important cause of complications in organ 
transplantation recipients and might play a role in the pathogenesis of inflammatory bowel 
disease (IBD). 6-thioguanine (6-TG) has been widely used as an immunosuppressive drug for 
organ recipients and treatment of IBD in the clinic. This study aims to investigate the effects 
and mode-of-action of 6-TG on rotavirus replication. Human intestinal Caco2 cell line, 3D 
model of human primary intestinal organoids, laboratory rotavirus strain (SA11) and patient-
derived rotavirus isolates were used. We have demonstrated that 6-TG significantly inhibits 
rotavirus replication in these intestinal epithelium models. Importantly, gene knockdown or 
knockout of Rac1, the cellular target of 6-TG, significantly inhibited rotavirus replication, 
indicating the supportive role of Rac1 for rotavirus infection. We have further demonstrated 
that 6-TG can effectively inhibit the active form of Rac1 (GTP-Rac1), which essentially 
mediates the anti-rotavirus effect of 6-TG. Consistently, ectopic over-expression of GTP-Rac1 
facilitates but an inactive Rac1 (N17) or a specific Rac1 inhibitor (NSC23766) inhibits rotavirus 
replication. In conclusion, we have identified 6-TG as an effective inhibitor of rotavirus 
replication via the inhibition of Rac1 activation. Thus, for transplantation patients or IBD 
patients infected with rotavirus or at risk of rotavirus infection, the choice of 6-TG as a 
treatment appears rational. 
 
Keywords: Rotavirus; 6‐thioguanine; Rac1; intestinal organoids 
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INTRODUCTION 
Rotavirus, a double stranded RNA (dsRNA) virus in the Reoviridae family, is a major cause of 
gastroenteritis, particularly in children younger than 5 years of age. As a major global health 
problem, this virus causes 114 million diarrhea episodes, 2.4 million hospitalizations, and an 
estimated 215,000 deaths worldwide annually (Grimwood and Buttery, 2007; Tate et al., 2016). 
Although rotavirus infection mainly occurs in developing countries, it also results in over 200 
deaths and more than 87,000 hospital admissions in infants in European Union (Vesikari et al., 
2007). Besides young children, organ transplantation patients are also susceptible to rotavirus 
infection irrespective of their age, causing long-term diarrhea and even death due to graft failure 
(Yin et al., 2015b). Although two global licensed rotavirus vaccines have been launched, no 
specific antiviral treatment is available.  
A thio analogue of the naturally occurring purine base guanine, 6-thioguanine (6-TG), has been 
used in the clinic since the early 1950s (Munshi et al., 2014). 6-TG was initially developed to treat 
cancer; whereas currently it is widely used as an immunosuppressive agent in organ 
transplantation. It is also used as treatment for acute lymphoblastic leukemia in children and for 
autoimmune diseases (Bourgine et al., 2011). In particular, 6-TG is often used to treat 
inflammatory bowel disease (IBD) (de Boer et al., 2006). IBD including Crohn’s disease (CD), 
ulcerative colitis (UC) and indeterminate colitis (IC) represent a heavy burden in Western 
countries (Kolho et al., 2012). Although the causes of exacerbations of IBD remain poorly 
characterized, gastrointestinal infections including rotavirus might induce flares in IBD (Masclee 
et al., 2013). Thus, preventing or treating rotavirus infection in these patients is of importance. 
Upon ingestion, 6-TG is first metabolized into 6-thioguanosine monophosphate (6-TGMP), and 
subsequently into 6-thioguanosine diphosphate (6-TGDP), and finally into 6-thioguanosine 
triphosphate (6-TGTP) (Chouchana et al., 2012). Among these metabolites, 6-TGDP and 6-TGTP 
are able to compete with endogenous guanosine phosphates for Rac1 binding and to form 6-
TGNP•Rac1 complexes. These complexes are in turn incapable to support the formation of the 
active configuration of Rac1, a process that Rac1 interacts with GTP. Thus, 6-TG indirectly 
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provokes inhibition of Rac1-dependent signaling (Shin et al., 2016), which has substantial 
consequences for cellular physiology. As a member of the Ras superfamily of Rho GTPases, GTP-
bound Rac1 mediates a myriad of cellular processes including actin reorganization and gene 
transcription. Intriguingly, IBD is characterized by hyperactivation of Rac1 in the phagocyte 
compartment. This is associated with reduced effector function of Rac1, which is sensitive to 6-
TG treatment (Parikh et al., 2014). The inhibition of Rac1 resulting from 6-TG treatment restores 
innate immune functionality of phagocytes in IBD patients, contributing to disease remission 
(Parikh et al., 2014). Thus, Rac1 hyperactivation appears an important immunosuppressive 
effector in human pathophysiology, at least in the phagocyte compartment.  
Given the clinical relevance and the potential in revealing mechanistic insight, we have 
investigated the effects and mechanism-of-action of 6-TG on rotavirus replication. To this end, 
we have demonstrated that 6-TG effectively combats rotavirus replication through inhibition of 
Rac1 activation.  
MATERIALS AND METHODS 
Viruses and reagents 
Simian rotavirus SA11 strain and patient-derived rotavirus isolates (G1P[8]) were prepared as 
previously described (Yin et al., 2015a; Yin et al., 2016).  
Stocks (0.1 mg/mL) of 6-TG (Sigma-Aldrich) were dissolved in alkali solution (1 M NaOH, 50 mg/ml), 
and NSC23766 (Merck Millipore) was dissolved in H2O (2 mM). All chemicals were stored in 25 µL 
aliquots and frozen at -80 ºC.  
Conventional enterocyte culture and human primary intestinal organoid culture 
Human colon cancer cell line Caco2 and human embryonic kidney cell line 293T (HEK 293T) cells 
were grown in Dulbecco's modified Eagle medium (DMEM) (Invitrogen-Gibco, Breda, The 
Netherlands) supplemented with 20% (vol/vol) heat-inactivated fetal calve serum (FCS) (Hyclone, 
Lonan, Utah) and Penicillin (100 IU/mL)/streptomycin (100 mg/mL) (Invitrogen-Gibco) at 37°C in 
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a humidified 5% CO2 incubator. Rac1 knockout mouse embryonic fibroblast (MEF) cells were 
cultured in DMEM supplemented with 10% FCS, Penicillin (100 IU/mL)/streptomycin (100 mg/mL), 
L-Glutamine (Gibco® by Life Technologies), non-essential amino acids (Gibco® by Life Technologies) 
and sodium-pyruvate (Gibco® by Life Technologies). Caco2 cells with stable knockdown of Rac1 
were generated by transduction of lentiviral shRNA (produced in HEK293T cells) targeting Rac1 
and selected with puromycin (6 µg/mL) as described previously (Yin et al., 2016). The shRNA 
targeting sequences used in this study were listed in Table S1. 
Rotavirus inoculation and drug treatment 
Inoculation and treatment of Caco2 cells and human intestinal organoids with SA11 and patient-
derived rotavirus were performed as previously described (Yin et al., 2016).  
Viability assay of cells or organoids 
The viability of cells or organoids was determined by 3-(4, 5-Dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT) assay. Briefly, Caco2 cells (1x104 cells/well) or organoids were seeded 
into a 96-well culture plate and incubated with various concentrations of 6-TG or NSC23766 for 
48 h, followed by adding 500 µg/mL of MTT (solution to each well and incubation at 37 °C for 3 
hrs. Subsequently, the medium was removed, and replaced with 100 µL DMSO and incubated at 
37 °C for 50 min. Then, the absorbance was measured at 490 nm in an enzyme-linked 
immunosorbent assay reader (BIO-RAD). The effects of 6-TG, NSC294002, IFNα and ribavirin on 
host cell viability were determined by MTT assay (Fig. S1).  
Transfection of plasmids 
A constitutively active Rac1V12 and dominant inactive Rac1N17 plasmids were prepared as 
previously described (Apolloni et al., 2013). HEK 293 cells were seeded into 6-well plates for Rac 
activation assay or 48-well plates for infection assay with ~70% confluence. The cells were washed 
with PBS, followed by adding 500 µL of Opti-MEM® reduced serum medium with 2 µg Rac1V12 or 
Rac1N17 plasmids and 10 µg polyethylenimine (PEI) per well of a 6-well plate, or 100 µL of Opti-
MEM® reduced serum medium (Thermo Fisher Scientific) with 0.25 µg Rac1V12 or Rac1N17 
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plasmids and 1.25 µg polyethylenimine (PEI) (Sigma-Aldrich) per well of a 48-well plate. After 4 to 
5 hrs of incubation, 2 mL or 0.5 mL of DMEM containing 10% FCS was added to each well of 6-
well plate or 48-well plate, respectively. Transfected cells were infected with rotavirus for 24 hrs. 
Quantitative real-time PCR (qRT-PCR) 
Total cellular RNA was isolated using a NucleoSpin® RNA kit (MACHEREY-NAGEL, Düren, Germany) 
following the manufacturer’s protocol, and quantified with a Nanodrop ND-1000 (Wilmington, 
DE, USA). cDNA was synthesized using the reverse transcription system from TAKARA according 
to manufacturer’s instructions (TAKARA BIO INC). The resulting cDNA was diluted 1:10, and 2 µL 
of the diluted cDNA was used for qRT-PCR with primers listed in Table S1. All qRT-PCR experiments 
were performed by SYBR-Green-based (Applied Biosystems SYBR Green PCR Master Mix; Thermo 
Fisher Scientific Life Science) real-time PCR with the StepOnePlus System (Thermo Fisher Scientific 
Life Sciences). The expression of target mRNA was normalized to the glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) mRNA. Gene expression analysis was performed by the ΔΔCT method 
(Yin et al., 2015a; Yin et al., 2016).  
Rac activation assay 
The levels of Rac1-bound GTP were detected using Rac interactive binding (CRIB) domain of PAK 
(aa56-272) as described previously (Fuhler et al., 2008). In brief, GST-PAKcrib protein was pre-
coupled to glutathione-Sepharose beads (Sigma-Aldrich) for 45 min at 4 °C. Caco2 cells treated 
with various concentrations of 6-TG or NSC23766 (48 h, seeded in 6-well-plate) were lysed for 10 
min in lysis buffer (50 mM Tris, pH 7.4, 10% glycerol, 200mM NaCl, 1% NP-40, 2mM MgCl2, 2 mM 
sodium orthovanadate, and protease inhibitors). Cell lysates were incubated with pre-coupled 
beads for 45 min. Then, agarose beads were washed 3 times with 1x lysis buffer, followed by 
boiling in Laemmli buffer, and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE, 15%) analysis.  
Western blotting 
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Cell lysates were subjected to SDS-PAGE, and proteins were transferred to PVDF membrane 
(Immobilon-FL). Rac1 monoclonal antibody (1:1000, rabbit; cell signaling) and SA11 rotavirus VP4 
[1:1000, HS-2, a mouse monoclonal antibody (provided by Professor Harry Greenberg, Stanford 
University School of Medicine, USA)] were detected by Western blotting analysis. Detection of β-
actin was served as loading control (1:1000, mouse monoclonal; Santa Cruz) as previously 
described (Versteeg et al., 2002).  
Serial passaging of rotavirus with 6-TG treatment 
To investigate whether rotavirus can develop resistance to 6-TG treatment, viruses were 
passaged in both MA104 and Caco2 cells in the absence of drug (vehicle control) or in the 
presence of gradually increasing concentrations of the drug (1000 ng/mL of 6-TG for passage 1-
10 and 2000 ng/mL of 6-TG for passage 11-20). In brief, MA104 or Caco2 cells in 24-well plate 
were inoculated with 200 µL virus (MOI=0.7) at 37 °C for 1 hr, followed by adding 6-TG or without 
drug (as control). After 48 hrs, both cells and supernatant were harvested, subsequently frozen, 
thawed once, and centrifuged. The supernatant containing passaged viruses was stored at -80 °C 
until used for the next passage. Viruses were serially passaged by using 1 aliquot of viral stock 
from the preceding passage to infect fresh MA104 or Caco2 cells. The effect of each passage of 
virus (same titer) was quantified by qRT-PCR. 
IC50 and CC50 calculation 
IC50 and CC50 calculation were described previously (Yin et al., 2016).  
Statistics 
Data are presented as means, and statistical comparison between different groups was 
performed by Mann-Whitney test (two-tailed) using GraphPad Prism 5. Error bars represent the 
SEM, and P value <0.05 was considered statistically significant.  
RESULTS 
6-TG remarkably inhibits rotavirus replication 
Chapter 6 
129 | P a g e  
 
To assess the effects of 6-TG on rotavirus replication, we treated SA11 rotavirus-infected Caco2 
cells with various concentrations (0.001 – 10000 ng/mL) of 6-TG for 48 hrs. This resulted in dose-
dependent inhibition of rotavirus RNA replication (Fig. 1A, n = 3-17, *P<0.05, ***P<0.001). The 
IC50 value of 6-TG against SA11 rotavirus was 3.0×10-13 M, which is substantially below the 
concentrations reached in patients undergoing 6-TG or azathioprine therapy. CC50 of 6-TG to 
Caco2 cells was 9.8×10-6 M and selectivity index (SI, CC50/IC50) was 3.3×107 (Table S2). This was 
further confirmed at the infectious virus production levels and protein levels of the rotavirus VP4 
protein (Fig. 1B and 1C). To further verify the effect of 6-TG on rotavirus replication, SA11 
rotavirus-infected Caco2 cells were treated with 6-TG at different time points (6, 12, 24 and 48 
hrs), indicating that 6-TG significantly inhibited rotavirus RNA replication in time-dependent 
Manner (Fig. 1D, n = 4-8, *P<0.05, ***P<0.01). These results were substantiated by experiments 
in human primary intestinal organoids, a model system that recapitulates many aspects of the 
intestinal epithelium, including the presence of a villus domain and a crypt domain (Fig. 1E) (Sato 
and Clevers, 2013). 6-TG significantly inhibited SA11 rotavirus replication and virus production in 
these organoids (Fig. 1F and G, n = 6, *P<0.05, **P<0.01). Our results were essentially repeated 
using five patient-derived rotavirus isolates in Caco2 cells but also in human intestinal organoids 
(Table S3). Treatment with 100 ng/mL 6-TG inhibited patient-derived isolates in both Caco2 cells 
(Fig.1H) and human intestinal organoids (Fig.1I). Hence, 6-TG significantly counteracts rotavirus 
replication at clinically relevant concentrations.  
Development of resistance to 6-TG is uncommon for rotavirus 
Rotavirus was serially passaged in the presence of escalating concentrations of 6-TG to assess the 
potential of drug resistance development. As a control, wild-type SA11 rotavirus was passaged in 
the absence of the drug. During the initial ten passages, infected cultures were exposed to 1000 
ng/mL of 6-TG; whereas the drug concentration was increased to 2000 ng/mL at the subsequent 
later passages. After 20 passages, the effects of 6-TG (100 ng/mL) on each representative passage 
(both drug treated and untreated) of rotavirus was quantified by qRT-PCR. Our results indicate 
that rotavirus remains sensitive to 6-TG treatment in MA104 cells (Fig. 2A) and Caco2 cells (Fig. 
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2B). Therefore, rotavirus does not easily develop 6-TG resistance, suggesting that the antiviral 
effects of 6-TG likely depend on a cellular target but not a direct interaction with the virus itself.  
 
Fig. 1. 6-TG effectively inhibits rotavirus replication. (A) Treatment with 6-TG (48 hrs) significantly inhibited 
viral genomic RNA in SA11 rotavirus infected Caco2 cells (MOI = 0.7) in a dose-dependent manner (n = 6-17, 
means ± SEM, *P < 0.05, ***P < 0.001, Mann-Whitney test, A.U. denotes artificial unit). (B) Effects of 6-TG on 
the production of infectious viral particles determined by TCID50 method. Each bar represents the TCID50/mL 
(mean ± SEM) (n = 3, P < 0.05, Mann-Whitney test). (C) Treatment with 6-TG (48 h) significantly inhibited viral 
VP4 protein in SA11 rotavirus infected Caco2 cells in a dose-dependent manner (the densitometric analysis of 
immunoreactive bans in western bots was quantified by ImageJ software, and the ratio of VP4/β-actin was 
expressed in arbitrary units). (D) Treatment with 6-TG (6 - 48 hrs) significantly inhibited viral genomic RNA in 
SA11 rotavirus infected Caco2 cells (MOI = 0.7) in a time-dependent manner (n = 4-8, means ± SEM, *P < 0.05, 
***P < 0.01, Mann-Whitney test, p.i.h denotes hour of post infection). (E) The morphology of human primary 
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small intestinal organoids with clear villus domain and crypt domain. (F) Treatment with 6-TG (48 hrs) 
significantly inhibited genomic RNA in SA11 rotavirus (MOI = 7) infected human intestinal organoids (n = 6, 
means ± SEM, *P < 0.05, Mann-Whitney test). (G) Treatment with 6-TG (48 hrs) significantly inhibited viral 
production in SA11 rotavirus infected human intestinal organoids (n = 6, means ± SEM, **P < 0.01, Mann-
Whitney test). (H) Treatment with 100 ng/mL of 6-TG (48 hrs) inhibited viral RNA of patient-derived rotavirus 
isolates in Caco2 cells. (I) Treatment with 100 ng/mL of 6-TG (48 hrs) inhibited viral RNA of patient-derived 
rotavirus isolates in human intestinal organoids.  
Rac1, the cellular target of 6-TG, sustains rotavirus replication 
Although initially characterized as a nucleotide synthesis inhibitor, in the last decade it has 
become clear that many of the effects of 6-TG, at least in gastrointestinal pathophysiology, 
depend on its potency to inhibit Rac1 (Shin et al., 2016). Thus, we investigated the potential role 
of Rac1 on rotavirus replication. To this end, we performed a lentiviral RNAi-mediated loss-of-
function assay to silence the Rac1 gene. Two (no. 9689 and 9691) out of five RNAi vectors showed 
potent knockdown of the target gene (Fig. 3A). Importantly, these two RNAi vectors resulted in 
65.0 ± 0.1% (n = 10, P < 0.001) and 61.8 ± 0.2% (n = 6, P < 0.05) reduction of SA11 rotavirus viral 
RNA, respectively (Fig. 3B). In apparent agreement, we obtained Rac1 knockout mouse embryonic 
fibroblasts cells (MEFs), and their status as a bona fide knockout was confirmed by western blot 
assay (Fig. 3C). Rotavirus replication in Rac1 knockout MEFs (-/-) was significantly less efficient 
(62.4 ± 0.2%; n = 4; P < 0.05), compared with the replication in wild type MEF (lf/lf) (Fig. 3D). Thus, 
decreased Rac1 levels correlate with increased resistance towards rotavirus replication. 
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Fig. 2. 6-TG has a high barrier to drug resistance development. Rotavirus was serially passaged in MA104 or 
Caco2 cells exposed to no 6-TG (as control) and increasing concentrations of 6-TG until 20 passages (infected 
cultures were exposed to 1000 ng/mL of 6-TG in passage 1-10; whereas the drug concentration was increased 
to 2000 ng/mL at the subsequent later passages). The effect of 6-TG (100 ng/mL) on passage 5, 10, 15 and 20 
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(the drug treated and untreated) of rotavirus was quantified using qRT-PCR. 6-TG retained its anti-rotavirus 
activity even with continuous exposure to 6-TG for 20 passages in MA104 cells (A) and Caco2 cells (B).  
Efficient rotavirus replication requires Rac1 activation 
Rac1 acts as binary switch in cellular biochemistry, and it is only capable of provoking signaling in 
the active GTP-bound form (Shin et al., 2016). NSC23766, a specific GTP-Rac1 inhibitor was able 
to effectively inhibit GTP-Rac1 accumulation in Caco2 cells, as evident when tested in GTP-Rac1 
specific pull-down assay (Fig. 4A and B). Importantly, treatment with either 5 or 25 µM NSC23766 
for 48 hrs resulted in 58.8 ± 0.1% (n = 8; P < 0.05) and 77.48 ± 0.1% (n = 10; P < 0.001) reduction 
on viral RNA levels, respectively (Fig. 4C). The IC50 value of NSC23766 against SA11 rotavirus was 
1.1×10-8 M, the CC50 of NSC23766 to Caco2 cells was 3.1×10-4 M, and the SI was 2.8 ×104 (Table. 
S2). The inhibitory effect of NSC23766 on the rotavirus infectious was further verified by a 
western blot assay, revealing that treatment with either 1, 5 or 25 µM NSC23766 significantly 
inhibits rotavirus VP4 protein synthesis in Caco2 cells (Fig. 4D). The effect of this drug was further 
confirmed by experiments in human primary intestinal organoids, which indicated 91.1 ± 0.1% (n 
= 6; P < 0.05) reduction of viral RNA in the organoids (Fig. 4E) following treatment with NSC23766.  
Next, we tested the effects of constitutively active and dominant negative forms of Rac1 on 
rotavirus replication. This was done by transfection of the active Rac1V12 plasmid or the 
dominant negative Rac1N17 plasmid. Expression of both plasmids was successful when tested by 
flow cytometry (Fig. 4F). Accordingly, Rac1V12-transfected cells displayed abundant GTP-Rac1, 
which in contrast is low in Rac1N17-transfected cells, as determined in a Rac pull-down assay (Fig. 
4G). These results were confirmed by analyzing abundance of phospho-PAK2 status (Fig. 4H). 
Importantly, Rac1V12 promoted, but Rac1N17 inhibited rotavirus replication (Fig. 4I). Taken 
together, activation of Rac1 supports rotavirus replication.  
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Fig. 3. Rac1, the drug target of 6-TG, sustains rotavirus replication. (A) Western blot assay detected Rac1 in 
transduced Caco2 cells transduced lentiviral RNAi vectors against Rac1 (The ratio of Rac1/β-actin was expressed 
in arbitrary units). (B) Three (No. 9687, 9689 and 9690) out of five lentiviral shRNA vectors inhibited rotavirus 
genomic RNA (n = 6-10, means ± SEM, *P < 0.05, ***P < 0.001, Mann-Whitney test). (C) Western blot assay 
confirmed knockout of Rac1 in Rac1 knockout (-/-) MEF cells. (D) SA11 rotavirus replication was significantly 
attenuated in Rac1 knockout (-/-) MEF cells (n = 4, means ± SEM, *P < 0.05, Mann-Whitney test).  
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Fig. 4. The activation form of Rac1 is required for supporting rotavirus replication. (A) Schematic depicting the 
pull-down assay. (B) NSC23766 inhibited GTP-Rac1 detected by pulldown assay (The ratio of GTP-Rac1/Rac was 
expressed in arbitrary units). (C) Treatment with NSC23766 (48 hrs) significantly inhibited viral genomic RNA in 
SA11 rotavirus infected Caco2 cells in a dose-dependent manner (n = 8-10, means ± SEM, *P < 0.05, ***P < 
0.001, Mann-Whitney test). (D) Treatment with NSC23766 (48 hrs) significantly inhibited viral VP4 protein in 
SA11 rotavirus infected Caco2 cells in a dose-dependent manner (The ratio of VP4/β-actin was expressed in 
arbitrary units). (E) Treatment with NSC23766 (48 hrs) significantly inhibited viral RNA in SA11 rotavirus infected 
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human intestinal organoids (n = 6, means ± SEM, *P < 0.05, Mann-Whitney test). (F) Flow cytometric analysis 
of green fluorescence indicated the percentages of transduced cells with Rac1V12 and Rac1N17 plasmids. 
Median fluorescence identity (MFIs) of control, N17 and V12 are 3.43, 35.5 and 84.3, respectively. (G) Pull-down 
and western blot assays showed higher level of GTP-Rac1 with transduction of Rac1V12 but lower level of GTP-
Rac1 with Rac1N17 plasmids (The ratio of GTP-Rac1/Rac was expressed in arbitrary units). (H) Detection of 
phospho-PAK2 indicated successful transduction of Rac1V12 and Rac1N17 plasmids. (I) Rac1V12 transduction 
facilitates but Rac1N17 inhibits rotavirus replication (n = 10, means ± SEM, *P < 0.05, Mann-Whitney test). 
6-TG inhibits rotavirus via suppression of Rac1 GDP/GTP cycling 
The inhibition of the activation of Rac1 by 6-TG was reported in many cell types (Fuhler et al., 
2008; Shin et al., 2016; Tiede et al., 2003). Employing the Rac1 pull-down assay (Fig. 4A), we 
observed that 6-TG potently inhibited GTP-Rac1 accumulation; whereas corresponding western 
blots did not show reduced overall Rac1 levels in Caco2 cells following 6-TG treatment (Fig. 5A). 
Functional studies using Rac1 knockdown Caco2 cells (Fig. 5B and 5C) were performed to 
demonstrate that both 6-TG and NSC23766 require Rac1 to combat rotavirus replication. In 
agreement, pharmacological Rac1 inhibitors did not inhibit rotavirus replication in Rac1 knockout 
MEF cells (Fig. 5D). Thus 6-TG inhibits rotavirus via suppression of Rac1 activation. 
6-TG has no combination effect with IFNα, but moderately antagonistic effect with 
ribavirin on rotavirus replication 
Interferon-alpha (IFNα) and ribavirin are widely used as general antivirals, being confirmed to 
significantly inhibit rotavirus replication in vitro (Yin et al., 2015a). Consistently, we again 
demonstrated the inhibitory effects of IFNα and ribavirin on rotavirus RNA (Fig. 6A, and 6E) and 
viral protein (Fig. 6B and 6F) in a dose-dependent manner. The IC50 value of IFNα against SA11 
rotavirus was 3.1×10-5 IU, CC50 of IFNα to Caco2 cells was 18706 IU, and SI was 6.0×108 (Table S2). 
The IC50 value of ribavirin against SA11 rotavirus was 1.6×10-7 M, CC50 of ribavirin to Caco2 cells 
was 3.02×10-2 M and SI was 1.9×105 (Table S2). Next, we assessed the combinatory antiviral 
effects of 6-TG with IFNα or ribavirin. The combination of 6-TG and IFNα resulted in no 
combination (no synergy or antagonism) antiviral effect, with a synergy volume of -2.8 µM2% (Fig. 
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6C and 6D). However, the combination of 6-TG and ribavirin resulted in moderately antagonistic 
antiviral effect, with a synergy volume of -26.02 µM2% (Fig. 6G and 6H). 
 
Fig. 5. 6-TG inhibits rotavirus via suppression of Rac1 activation. (A) Anti-rotavirus effect of 6-TG (100 ng/mL) 
was attenuated in Rac1 knockdown Caco2 cells (The ratio of VP4/β-actin was expressed in arbitrary units). (B) 
6-TG inhibited GTP-Rac1 detected by pull-down assay. (C) Anti-rotavirus effect of NSC23766 (25 μg ng/mL) was 
attenuated in Rac1 knockdown Caco2 cells. (D) The anti-rotavirus effect of 6-TG (100 ng/mL) was attenuated in 
Rac1 knockout (-/-) MEF cells (n = 6-8, means ± SEM, *P < 0.05, **P < 0.01, Mann-Whitney test). 
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Fig. 6. The effects of the combination of 6-TG with IFNα, or ribavirin on rotavirus replication. (A) Treatment 
with IFNα (48 hrs) significantly inhibited viral genomic RNA in SA11 rotavirus infected Caco2 cells in a dose-
dependent manner (n = 4, means ± SEM, **P < 0.01, Mann-Whitney test). (B) Treatment with IFNα (48 hrs) 
remarkably inhibited viral VP4 protein in SA11 rotavirus infected Caco2 cells in a dose-dependent manner (The 
ratio of VP4/β-actin was expressed in arbitrary units). (C) Effect of the combination of various concentrations 
of 6-TG and IFNα on rotavirus replication in Caco2 cells. (D) Synergy plot representing the percentage of antiviral 
activity above/below the expected activity for the 6-TG-IFNα combination based on the data shown in C. (E) 
Treatment with ribavirin (48 hrs) significantly inhibited viral genomic RNA in SA11 rotavirus infected Caco2 cells 
in a dose-dependent manner (n = 4-7, means ± SEM, *P < 0.05, **P < 0.01, Mann-Whitney test). (F) Treatment 
with ribavirin (48 hrs) remarkably inhibited viral VP4 protein in SA11 rotavirus infected Caco2 cells in a dose-
dependent manner (The ratio of VP4/β-actin was expressed in arbitrary units). (G) Effect of the combination of 
various concentrations of 6-TG and ribavirin on rotavirus replication in Caco2 cells. (H) Synergy plot 
representing the percentage of antiviral activity above/below the expected activity for the 6-TG-ribavirin 
combination based on the data shown in G. 
DISCUSSION 
In this study, we have demonstrated that 6-TG effectively inhibits rotavirus replication via 
inhibition of the Rac1 activity. This is particularly interesting in view that rotavirus replication is 
especially an issue in organ transplantation recipients and in patients with IBD. 6-TG is a 
therapeutic option for both groups of patients. Based on the findings presented in the current 
study, the choice of 6-TG for these patients appears rational, in particular when they are at risk 
of rotavirus infection (Yin et al., 2015b). 
Our results fit well with the momentum of studies that document antiviral activity of 6-TG. For 
instance, it has been reported that 6-TG can combat Middle East respiratory syndrome 
coronavirus infection by augmenting interferon responses (Cheng et al., 2015) and it has also 
reported that Simian virus 40 DNA replication is antagonized by 6-TG (Maybaum et al., 1987). 
Interestingly, it was reported that vaccinated IBD patients had lower titers of hepatitis B surface 
antibody (HBsAb), which might be influenced by the use of immunosuppressants including 6-TG 
(Watts et al., 2017).  
As a 6-thiopurine (6-TP) prodrug, 6-TG is converted into pharmacologically active deoxy-6-
thioguanosine phosphate (also called 6-thioguanine nucleotide) and 6-thioguanosine phosphate 
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(6-TGNP). 6-TGNP can bind to Rac1 to form the 6-TGNP•Rac1 complex inactivating Rac1 (Shin et 
al., 2016). As a major player of the Rho family of small GTPases, Rac1 plays a vital role in various 
cellular signaling pathways to regulate a wide variety of cell functions including gene transcription, 
cell proliferation, apoptosis, motility, and redox signaling (D'Ambrosi et al., 2014). The expression 
of Rac1 is ubiquitous, but it has two conformational states including an inactive GDP-bound form 
and an active GTP-bound form (Bosco et al., 2009). It exerts biological functions mainly through 
activation of Rac1 (i.e. GTP-bound form) (Bosco et al., 2009). Many viruses interfere with or 
employ the conformational states of Rac1 to regulate their infection. At early stages of African 
swine fever virus (ASFV) infection, Rac1 is activated, and inhibition of Rac1 is able to suppress 
production of this virus (Quetglas et al., 2012). Rac1 is found to be activated during intracellular 
mature virus (MV) of Vaccinia virus entry (Mercer and Helenius, 2008).  
Although rotavirus replication per se does not affect the activation of Rac1 (Fig. S4), we have 
demonstrated that the loss-of-function of Rac1 by gene knockdown or knockout significantly 
impairs rotavirus replication, which is in line with the previous finding that knockdown Rac1 could 
significantly inhibit Enterovirus 1 (EV1) infection (Karjalainen et al., 2008). More specifically, the 
activation of Rac1 is required as shown by the opposing effects of ectopic over-expression of the 
active or inactive forms of Rac1 on rotavirus replication. This mechanistically explains the potent 
anti-rotavirus effects of the GTP-Rac1 inhibitors, 6-TG and NSC23766. Of note, NSC23766 has 
been shown to inhibit the replication of several influenza viruses including a human virus strain 
from the 2009 pandemic and highly pathogenic avian virus strains (Dierkes et al., 2014).  
Despite the absence of approved medications for treating rotavirus, the widely used general 
antivirals including ribavirin and IFNα have been studied on rotavirus in experimental models (Yin 
et al., 2015a). Here, we have evaluated the combinatory effects of 6-TG with IFNα or ribavirin. 
Consistently, we confirmed that ribavirin and IFNα inhibit rotavirus replication at both RNA and 
protein levels (Fig. 6A and 6B). We found increased potency of IFNα in the presence of 6-TG. 
However, whether the combination of IFNα and 6-TG could be used to treat rotavirus infected 
patients remains to be further investigated.  
In conclusion, this study has demonstrated that 6-TG effectively inhibits rotavirus replication with 
a high barrier to drug resistance development. We further identified the active form of Rac1 as 
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an important host factor supporting rotavirus replication. 6-TG exerts its anti-rotavirus effects via 
the specific inhibition of Rac1 activation. Herein, this study provided important references for 
clinicians to optimize medications for organ recipients or IBD patients who are infected with 
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Supplementary Information 
Table S1. Primers and shRNA sequences used in the study 
Sequence of rotavirus primers 
 SA11 Rotavirus Human Patient Rotavirus 
Sense  TGGTTAAACGCAGGATCGGA ACCATCTACACATGACCCTC 
Anti-sense AACCTTTCCGCGTCTGGTAG CACATAACGCCCCTATAGCC 
 
Primer sequences of GAPDH 
Primers Human Mouse 
GAPDH-F GTCTCCTCTGACTTCAACAGCG TTCCAGTATGACTCCACTCACGG 
GAPDH-R ACCACCCTGTTGCTGTAGTAGCCAA TGAAGACACCAGTAGACTCCACGAC 
 








Table S2. 50% inhibition concentration (IC50) of 6-TG, NSC23766, IFNα and ribavirin 
against SA11 rotavirus, 50% cytotoxic (CC50) of against Caco2 cells, and corresponding 
selectivity index (SI, CC50/IC50).  
Drugs  IC50 against SA11 
rotavirus (M) 




6-TG 3.0×10-13 M 9.8×10-6 M 3.3×107 
NSC23766 1.1×10-8 M 3.1×10-4 M 2.8 ×104 
IFNα 3.1×10-5 IU 18706 IU 6.0×108 
Ribavirin  1.6×10-7 M 3.02×10-2 M 1.9×105 
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Table S3. Patient characteristics. 
Patient Age 
(yrs) 
Gender Symptoms  Virus Detection 






Adenovirus Astrovirus Sapovirus Rotavirus 
1 3.5 Female Fever  No No No No No No No Yes 
2 74 Female Congestive heart 
failure, myocarditis 
No No No No No No No Yes 
3 27 Female Fever, diarrhea, 
nausea, vomiting 
No No No No No No No Yes 
4 67 Male Fever, stomachache, 
watery diarrhea 
(Kidney transplant) 
No No No No No No No Yes 




No No No No Yes No No Yes 
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Fig. S1. Effect of 6-TG (A), NSC23766 (B), IFNα (C) and ribavirin (D) on host cell viability 
determined by MTT assays. Caco2 cells treated with all four drugs for 48 h.   
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Fig. S2. The effect of inactive rotavirus by UV treatment, rotavirus and mock infection (1 and 8 h) 
on the expression of GTP-Rac1. (A) Western blot assay detected the expression of GTP-Rac1 after 
1 and 8 h post-infection by inactive rotavirus (UV treatment), rotavirus and mock infection in Caco2 
cells. (B) Quantification of the intensity of the immunoreactive bands of Rac1 (n = 4, means ± SEM, 
Mann-Whitney test) using Odyssey V 3.0 software. 
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ABSTRACT 
Although rotavirus infection is usually acute and self-limiting, it can cause chronic infection 
with severe disease phenotypes in immunocompromised patients, including organ 
transplantation recipients and cancer patients and irrespective of whether this concerns 
pediatric or adult patients. Clinical management is complicated by the absence of approved 
medication against rotavirus infection. Here we screened a library of safe-in-man broad-
spectrum antivirals. We identified gemcitabine, a widely used anti-cancer drug, as a potent 
inhibitor of rotavirus infection. We confirmed this effect in 2D cell cultures and 3D cultured 
human intestinal organoids with both laboratory-adapted rotavirus strains and five clinical 
isolates. Supplementation of UTP or uridine largely abolished the anti-rotavirus activity of 
gemcitabine, suggesting its function through inhibition of pyrimidine biosynthesis pathway. 
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Rotavirus infection is the leading cause of severe dehydrating gastroenteritis among children 
under five-year-old (Greenberg and Estes, 2009). Although rotavirus infection is usually acute 
and self-limiting, it can cause chronic infection with severe diseases in immunocompromised 
patients, in particular organ transplantation recipients irrespective of whether these are 
pediatric or adult patients (Yin et al., 2015b). In addition, cancer patients have 
compromised immune system especially when undergoing chemotherapy or 
radiotherapy treatment, which make them prone to infections with worse outcomes 
(Hotchkiss and Moldawer, 2014). Rotavirus infections have been widely reported in 
pediatric or adult cancer patients causing prolonged diarrhea (Akhtar et al., 2018; Ghosh et 
al., 2017). Therefore, specific and effective antiviral treatment is urgently needed for these 
special populations when infected with rotavirus. Unfortunately no FDA-approved 
medications against rotavirus infection are available.  
Developing new drugs usually takes more than ten years with enormous investment and high 
risk of failure. Given that only the specific population with rotavirus infection require antiviral 
treatment, the pharmaceutical industry will likely not develop new anti-rotavirus drugs. We 
propose that repurposing existing drugs represents a cost-effective approach to identify 
antiviral treatment that can readily benefit patients (Qu et al., 2019). In this study, we 
screened a library of safe-in-man broad-spectrum antiviral agents (BSAAs, 
https://drugvirus.info) (Andersen et al., 2020; Ianevski et al., 2018) on rotavirus infection in 
experimental models. These compounds are known to target viruses belonging to two or more 
viral families and have passed phase 1 clinical trials. This greatly enhances the probability of 
identifying novel activities of some of these agents against rotavirus infection and facilitates 
their clinical translation.  
We first screened 94 BSAAs in the human intestinal Caco2 cell line infected with simian 
rotavirus SA11 strain (Table S1). To minimize non-specific effects on host cells, we used low 
concentration of 1 µM and treated for 48 hours. By qRT-PCR (primers listed in Table S2) 
quantification of rotavirus genomic RNA, we identified 43 candidates exerting over 50% 
inhibitory effects, and 17 with inhibition over 70% (Fig. 1A). Among these, gemcitabine was 
one of the most effective candidates (Fig. 1A). It is a cytidine analog that has been widely used 
for cancer treatment (Cerqueira et al., 2007; Zhang et al., 2019). It has been shown to inhibit 
a broad range of RNA viruses including severe acute respiratory syndrome coronavirus (SARS-
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CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), Zika virus and hepatitis C 
virus (HCV) in experimental models (Beran et al., 2012; Dyall et al., 2014; Kuivanen et al., 2017). 
Nucleotide and nucleoside analogues are excellent examples of BSAAs that have been widely 
used in the clinic for treating infections of RNA and DNA viruses (Ianevski et al., 2018). We 
have previously demonstrated that nucleotides, including purine and pyrimidine, biosynthesis 
pathways are essential in the rotavirus infection process and can be pharmacologically 
targeted (Chen et al., 2019; Yin et al., 2018a; Yin et al., 2016). As a cytidine analog, gemcitabine 
has been reported to inhibit pyrimidine biosynthesis, resulting in nucleotide depletion (Lee et 
al., 2017). Therefore, we focused on the effects and mode-of-action of gemcitabine on 
rotavirus infection in this study. 
We next tested a series of gemcitabine concentrations (0.01-10 µM) in the Caco2 cell model 
to assess both antiviral and cytotoxic effects. We confirmed the potent anti-rotavirus effect 
and observed a large therapeutic window between cytotoxic and antiviral activities, as shown 
the CC50 value of 13.58 mM and IC50 value of 0.12 µM (Fig. 1B, 1C). We performed same 
experiments in the monkey MA104 cell line that is widely used for propagating rotavirus in 
laboratory. Similar trends were observed with CC50 value of 0.36 mM and IC50 value of 3.98 
µM (Supplementary Fig. S1). By harvesting supernatant of Caco2 cells at 48-hour post-
treatment, we performed TCID50 assay to determine the titers of secreted viruses. 
Consistently, the titers of produced rotavirus with infectivity were significantly reduced by 
gemcitabine treatment (Fig. 1D). At the protein level, we found potent inhibition of viral 
protein 4 (VP4) expression determined by Western blotting (Fig. 1E). Furthermore, 
immunofluorescent staining of viral capsid protein (VP6) showed significant reduction of the 
number of infected Caco2 cells by gemcitabine treatment (Fig. 1F, 1G, Supplementary Fig. S2). 
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Figure 1. Screening BSAAs identified gemcitabine as a potent inhibitor of rotavirus infection. (A) Human 
intestinal Caco2 cells were infected with SA11 rotavirus. After infection, cells were treated with 94 BSAAs 
at 1 µM for 48 hours. qRT-PCR analysis of viral RNA revealed that 43 reagents exerted ≥ 50% inhibitory 
activity, and 17 of them exerted ≥ 70% inhibitory activity against rotavirus replication. Gemcitabine (GCT) 
inhibited rotavirus replication by 70%. (B) 50% cytotoxic concentration (CC50) curves of GCT were 
determined by MTT assays on Caco2 cell line. (C) Dose-dependent inhibitory activity of GCT on rotavirus 
infected Caco2 cell line. qRT-PCR data were normalized to housekeeping gene GAPDH and presented 
relative to the control (CTR) (set as 1) (n = 6). (D) The supernatant of each well under GCT treatment was 
harvested after freezing and thawing for three times, virus titer from different groups was measured by 
TCID50 assay (n = 6). (E) Rotavirus infected Caco2 cells were treated by different concentrations of GCT, and 
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protein samples were harvested after 48 hours. The expression of viral structural protein VP4 was stained 
and quantified by western blot assay (n = 4). (F) Indirect fluorescence microscope analysis of viral structural 
protein VP6 (red) upon treatment with GCT. Nuclei were visualized by DAPI (blue). (G) The ratio of VP6 
positive cells/ total cell number was quantified under 40* vision field (Supplementary Fig. S2) (n = 6). Data 
represent means ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001. 
The responsiveness to antiviral therapy can vary dramatically in patients. This mainly 
attributes to host and viral factors. The nucleoside analog ribavirin has been used for treating 
HCV infection for decades. Reduced cellular uptake by the host and mutagenesis of the viral 
genome have been linked to treatment resistance in chronic HCV patients (Ibarra et al., 2011). 
As recently repositioned for treating chronic hepatitis E virus (HEV) infection (Kamar et al., 
2017), viral mutagenesis during ribavirin treatment or pre-deposition of resistance mutations 
are thought to contribute to treatment failure (Ikram et al., 2018). Our previous studies have 
evaluated the effects of the nucleoside analog ribavirin and mycophenolic acid (MPA), and the 
antiviral cytokine interferon alpha (IFN-α) on rotavirus in cell culture models. We found the 
responsiveness to these agents dramatically vary among different clinical isolates from potent, 
moderate, minimal to even pro-viral effects (Yin et al., 2015a; Yin et al., 2016). This imposes 
major challenges for clinical application as how to personalize the selection of potential 
responders. Thus, we extended our evaluation of gemcitabine to different rotavirus 
strains/isolates. We found that gemcitabine significantly inhibits the replication of rhesus 
rotavirus RRV strain (Fig. 2A) and five clinical isolates (Fig. 2B-2F). Based on these results, we 
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Figure 2. Antiviral effect of gemcitabine against RRV rotavirus strain and clinical isolates. qRT-PCR analysis 
of rotavirus RNA upon treatment of gemcitabine (GCT) at 1 µM for 48 hours in laboratory rotavirus strain 
RRV (A), clinically isolated rotavirus strain 026k (B), 1758k (C), 1934 (D), 664k (E), and 2011k (F). Data were 
normalized to housekeeping gene GAPDH and are presented relative to the control (CTR) (set as 1). Data 
represent means ± SEM; n = 6; *P < 0.05; **P < 0.01.  
We have previously established that modeling of rotavirus infection in intestinal organoids 
allows the study of virus-host interactions and assessment of antiviral drugs efficacy (Yin et al., 
2015a; Yin et al., 2018a; Yin et al., 2018b; Yin et al., 2016). Intestinal organoids, also called 
mini-guts, are stem cell-derived epithelial 3D cultures. These organoids are much better in 
recapitulating the architecture, composition, diversity, organization and functionality of cell 
types of the intestine when compared to more conventional model systems. Treatment with 
gemcitabine in rotavirus inoculated human intestinal organoids potently inhibited viral RNA 
synthesis and secretion of rotaviruses with approximately 80% inhibitory effects for both at 1 
µM concentration treated for 48 hours (Fig. 3A; Supplementary Fig. S3). This effect was 
further confirmed at the VP4 protein level by western blot assay (Fig. 3B). Importantly, 
rotavirus infection led to morphological and pathological changes in organoids. Based on 
optical imaging, we observed that rotavirus infected organoids without gemcitabine 
treatment showed opaque, wizened and disorganized morphology. In contrast, gemcitabine 
treated groups, in particular with 1 µM concentration, most of the organoids were hyaline and 
in a spheroidal shape (Fig. 3C upper panel). In confocal immunostaining, VP6 protein was 
detected in all groups, but the intensity and frequency of the viral protein were lower in 
treatment groups (Fig. 3C middle panel). Fluorescence staining of cell viability by Propidium 
Iodide (PI) showed that cell death (determined as described in Supplementary Fig. S4) in un-
treated group is more obvious, and dead cells were diffused in almost all organoids (Fig. 3C 
lower panel). This is consistent with the percentage of  organoids in a deteriorated condition 
(Fig. 3D). Thus, inhibition of rotavirus replication by gemcitabine can protect organoids from 
rotavirus induced cytopathogenesis.  
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Figure 3. Antiviral activity of gemcitabine against rotavirus SA11 in human intestinal organoids . (A) 
Human intestinal organoids (HIOs) were inoculated with SA11 rotavirus strain and treated with gemcitabine 
(GCT) for 48 hours. The relative cellular rotavirus RNA and secreted viruses calculated as genomic copy 
number were analyzed by qRT-PCR (n = 6). Standard curve for calculation of genomic copy number is 
included in Supplementary Fig. S3. (B) The expression of viral structural protein VP4 was stained and 
quantified by western blot assay (n = 4). (C) Optical microscopy images, confocal images and indirect 
fluorescence microscope images of HIOs from mock group and GCT treated groups. In confocal images, VP6 
protein was stained in red, green signal represents Epcam, and nuclei were visualized by DAPI (blue). In 
fluorescence microscope images, HIOs were stained by PI (red) indicating dead cells, Hoechst (blue) for 
nuclear, and Calcein (green) as live cells. (D) Rate of deteriorated HIOs was calculated as dead organoids/ 
total organoids (n = 6). Data represent means ± SEM; *P < 0.05; **, P < 0.01. 
The antiviral activity of gemcitabine has been linked to the inhibition of pyrimidine 
biosynthesis pathway, especially the salvage pathway (Lee et al., 2017). We thus 
supplemented UTP or uridine to rotavirus infected Caco2 cell model when treated with 
gemcitabine. We found that exogenous supplementation of pyrimidine dose-dependently 
abolished the anti-rotavirus effect of gemcitabine. The anti-rotavirus effect was almost 
completely abolished by addition of 1000 μM UTP or uridine (Fig. 4A, 4B). Hence, the anti-
rotavirus activity of gemcitabine was largely dependent on the salvage pyrimidine 
biosynthesis pathway. Combination approaches are often used in clinic to achieve optimal 
antiviral efficacy and avoid resistance development. We finally assessed the combinatory 
effects of gemcitabine with ribavirin, MPA or IFN-α, as we previously have demonstrated the 
anti-rotavirus effects of these three agents (Yin et al., 2015a; Yin et al., 2016). We found 
enhanced anti-rotavirus activity when combined with ribavirin or IFN-α, but not MPA (Fig. 4C).  
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Figure 4. The effects of nucleotide supplementation and combination with other antivirals on the anti-
rotavirus activity of gemcitabine. Supplementation of exogenous uridine (A) and UTP (B) attenuates the 
anti-rotavirus effect of gemcitabine (GCT) in Caco2 cell model (n = 6). (C) The combinatory effects of 1 µM 
GCT with 1000 U IFN-α, 1 µg/ml ribavirin (Rib) or 0.1 µg/ml mycophenolic acid (MPA), respectively (n = 6). 
Data represent means ± SEM; *P < 0.05; **P < 0.01.  
In summary, we have identified gemcitabine as a potent inhibitor against rotavirus infection 
through screening of a BSAA library. The antiviral activity was largely dependent on the 
pyrimidine biosynthesis pathway. Because gemcitabine has been widely used as 
chemotherapy for cancer patients, and these patients are at risk of infections (Hotchkiss and 
Moldawer, 2014), the use of gemcitabine in cancer patients as chemotherapeutic drug 
probably mitigates the risk of viral infections in general. Our results support a repositioning of 
gemcitabine for treating rotavirus infection, especially in infected cancer patients. 
Furthermore, the approach of discovering new antiviral therapy from BSAAs bears essential 
implications in combating emerging viral pathogens, such as the ongoing coronavirus disease 
COVID-19 pandemic (Mahase, 2020).  
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Supplementary information 
Materials and methods 
Reagents 
All the compounds used in this study were from broad-spectrum antiviral agents (BSAs) library. 
Names of all BSAs are listed in Supplementary table 1. All the reagents were dissolved in 
dimethyl sulfoxide (DMSO) or milli-Q water.  
Viruses 
Simian rotavirus SA11 and rhesus rotavirus RRV were gifted by Karen Knipping from Nutricia 
Research Utrecht, The Netherland. Stool samples collected from rotavirus infected patient 
were obtained from the Erasmus MC biobank, Department of Viroscience, Erasmus Medical 
Center, Rotterdam.  
Cell lines and human primary intestinal organoids 
Human colon cancer cell line Caco2 and African green monkey kidney cell line MA104 were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM; Lonza, Verviers, Belgium) containing 
20% or 10% (vol/ vol) heat-inactivated fetal calf serum (FCS, Sigma–Aldrich, St. Louis USA) 
respectively and 100 U/ml Penicillin/ Streptomycin (P/S, Gibco, Grand Island, USA) solution. A 
humidified incubator was used for cells culturing at 37 ̊C in 5% CO2. Cells were analyzed by 
genotyping and confirmed to be mycoplasma negative. 
Human intestinal organoids culture was performed as described previously (Yin et al., 2015). 
Culture medium was refreshed every 2-3 days, and HIOs were passaged every 5–7 days. 
Virus inoculation and production assay 
Virus, cell line and human intestinal organoids (HIOs) were maintained and treated as in 
previous work (Chen et al., 2019; Yin et al., 2015; Yin et al., 2018a; Yin et al., 2018b; Yin et al., 
2016). In short, Caco2 cells and MA104 cells seeded into a multi-well plate (5×104 cells/well). 
Culture medium was discarded when cell confluence was approximately 80%, followed by 
Chapter 7 
163 | P a g e  
 
twice PBS washing. Then 100 µL of serum-free DMEM medium, rotavirus (MOI=0.7) with 5 
µg/mL of trypsin (Gibco, Paisley, UK) were added and incubated at 37 ̊C with 5% CO2 for 60 
min for infection, followed by 3 times washing with PBS to remove un-attached viruses. Then, 
cells were incubated with culture medium containing 5 µg/ml of trypsin at 37  ̊C with 5% CO2. 
In parallel, human primary intestinal organoids were infected with 10 times higher 
concentration of SA11 rotavirus than cell infection for 1.5 h followed by 4 times washing with 
PBS. Afterwards, HIOs with no Matrigel remain were spun down at 500g for 10 min to adhered 
to the bottom of 24-well plate coated with Collagen R solution (SERVA, Heidelberg, Germany). 
Organoids culture medium was added gently and HIOs were incubated at 37  ̊C with 5% CO2. 
Culture medium and HIOs were harvested respectively after 48h to detect and enumerate 
rotavirus. Virus titers from supernatants were determined by calculating the log10TCID50/mL 
method. 
RNA isolation, cDNA synthesis and qRT-PCR 
Total RNA was isolated using Macherey-Nagel NucleoSpin® RNA II kit (Bioke, Leiden, 
Netherlands) and quantified using a Nanodrop ND-1000 (Wilmington, DE, USA). Total RNA 
reverse transcription was performed by using a cDNA Synthesis kit (TAKARA BIO INC.) with 
random hexamer primers. Real-time PCR reactions (50 ̊C for 2 min, 95 ̊C for 10 min, followed 
by 50 or 60 cycles of 95 ̊C for 15 s and 58 ̊C for 30 s and 72 ̊C for 10 min) were performed with 
SYBRGreen-based real-time PCR (Applied Biosystems®, Austin, USA) according to the 
manufacturer’s instruction. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene was 
used as housekeeping gene. Relative gene expressions were normalized to GAPDH using the 
formula 2-∆∆CT (∆∆CT = ∆CTsample - ∆CTcontrol). Template control and reverse transcriptase 
control were included in all RT-qPCR experiments. All qRT-PCR primers are listed in 
Supplementary table 2. 
Quantification of rotavirus genome copy numbers 
An amplicon of the SA11 (a fragment of VP6 gene from 564-718) was cloned into the pCR2.1-
TOPO vector (Invitrogen, San Diego, CA) to generate a template for quantifying rotavirus 
genome copy number. The plasmid was extracted by Quick Plasmid Miniprep Kit (Invitrogen, 
Lohne, Germany) following manufacturer’s instructions. A series of dilutions (from 10-2 to 10-
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10) were prepared and then were amplified and quantified by qRT-PCR to generate a standard 
curve. This standard curve was generated by plotting the log copy number versus the cycle 
threshold (CT) value (Supplementary figure. S2). Copy numbers were calculated by using the 
following equation: Copy number (molecules/µl) = [concentration (ng/µl) × 6.022× 1023 
(molecules/mol)]/[length of amplicon× 640 (g=/mol) × 109 (ng/g). 
Determination of organoids cell death 
The scoring process was performed as previously (Chen et al., 2019; Grabinger et al., 2014). In 
short, a minimum of 100 organoids were counted after 3 days of passaging. After 1.5 h 
incubation with SA11 rotavirus, HIOs were cultured in matrigel and treated with different 
agents for 48 h, then HIOs were stained by PI (red) which represented as dead cell, 
Hoechst(blue) which represented as nuclear, and Calcein (green) which represented as live 
cell. We define the HIOs with red signal more than green signal and also more than 50% of 
blue signal as positive, otherwise HIOs will be counted as negative. Detailed example is shown 
in Supplementary figure. S4. In optical microscopy imaging, positive HIOs were opaque and 
disorganized while negative HIOs were hyaline and in a spheroidal shape. The proportion of 
organoids apparently deteriorated was calculated as (viable/ total) %. 
Western blot assay 
Lysed cells were subjected to SDS-PAGE, and proteins were transferred to PVDF membrane 
(Immobilon-FL). DHODH (ab 54621, 1:1000, mouse monoclonal, Abcam), SA11 rotavirus VP4 
(1:1000, HS-2, mouse monoclonal; provided by professor Harry Greenberg, Stanford 
University School of Medicine, USA) was detected by western blot analysis and β-actin protein 
was detected as loading control (sc-47778, 1:1000, mouse monoclonal; Santa Cruz). The 
intensity of the immunoreactive bands of blotted protein was quantified by the Odyssey V3.0 
software. 
Immunofluorescence analysis 
After rotavirus infection, organoids were harvested and fixed in 4% paraformaldehyde in PBS 
at 4 ̊C for 10 min. Fixed organoids were added into the CytoSpin II Cytocentrifuge (Shandon 
Scientifi Ltd, Runcorn, England), then spun down at 1000 rpm for 2 min. The slides containing 
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organoids were rinsed 3 times with PBS for 5 min each, followed by treatment with 0.1% 
(vol/vol) Tritonx100 for 4 min. Subsequently, the slides were twice rinsed with PBS for 5 min, 
followed by incubation with milk-tween-glycine medium (0.05% tween, 0.5% skim milk and 
0.15% glycine) to block background staining for 30 min. Slides were incubated in a humidity 
chamber with anti-rotavirus antibody (1:250, mouse monoclonal; Abcam) and anti-EpCAM 
antibody (1:250, rabbit polyclonal; Abcam) diluted in milk-tween-glycine medium at 4 ºC 
overnight. Slides were washed 3 times for 5 min each in PBS prior to 1h incubation with 1:1000 
dilutions of the anti-mouse IgG (H+L, Alexa Fluor® 594) and the anti-rabbit IgG (H+L, Alexa 
Fluor® 488) secondary antibodies. Nuclei were stained with DAPI (4, 6-diamidino-2-
phenylindole; Invitrogen). Images were detected using Leica SP5 cell imaging system. 
MTT assay 
The CC50 values of GCT were determined by MTT assay (Fig. 1B, 1D) as previous study {Qu, 
2018 #156}. Approximately 1×104 Caco2 cells were seeded per well in 96-well plate. After 48h, 
cells were incubated with 10 µL 5 mg/ml MTT for 3 h, then replaced with 100 ml dimethyl 
sulfoxide (DMSO) medium (Sigma). Absorbance (490 nm) was analyzed accordingly.  
Statistics 
All numerical results are reported as Mean ± SEM. The statistical significance of differences 
between means was assessed with the Mann-Whitney test (GraphPad Prism 5; GraphPad 
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Supplementary table 3. List of broad-spectrum antiviral agents (BSAs) library. 
1 Abamectin 25 Cyclosporine 49 Hydroxychloroquine 73 Novobiocin 
2 ABT-263 26 Dasatinib 50 Imatinib 74 Obatoclax 
3 Acetylsalicylic acid 27 Dibucaine 51 Indomethacin 75 Omeprazole 
4 Aciclovir 28 Diphyllin 52 Itraconazole 76 Pentosan polysulfate 
5 Amiloride 29 Doxycycline 53 Ivermectin 77 Pirlindole 
6 Amiodarone 30 DFMO 54 Kasugamycin 78 Quinine 
7 Amodiaquine 31 Emetine 55 Lamivudine 79 Raloxifene 
8 Apilimod 32 Emodine 56 Leflunomide 80 Rapamycin 
9 Arbidol 33 Erlotinib 57 Lanatoside C (Isolanid) 81 Ribavirin 
10 Artesunate 34 Esomeprazole 58 Lobucavir 82 Ritonavir 
11 Azacitidine 35 Ezetimibe 59 Lopinavir 83 Regorafenib 
12 Azithromycin 36 Famciclovir 60 Lovastatin 84 Simvastatin 
13 BDA-366 37 Favipiravir 61 Luteolin 85 Sofosbuvir (PSI-7977) 
14 Bepridil 38 Fenretinide (4-HPR) 62 Manidipine 86 Suramin 
15 Berberine 39 Flavopiridol 63 Maribavir 87 Tamoxifen 
16 Bortezomib 40 Fluoxetine 64 Memantine 88 Teicoplanin 
17 Brequinar 41 Fluvastatin 65 Metformin 89 Tenofovir 
18 Bromocriptine 42 Formoterol 66 Minocycline 90 Topotecan 
19 Caffeine 43 Foscarnet 67 Mitoxantrone 91 Trifluridine 
20 Camostat 44 Ganciclovir 68 Mycophenolic acid 92 Valacyclovir 
21 Camptothecin 45 Gefitinib 69 Nafamostat 93 Verapamil 
22 Chloroquine 46 Gemcitabine 70 Nelfinavir 94 Vidarabine 
23 Cidofovir 47 Glycyrrhizin 71 Nitazoxanide   
24 Clofarabine 48 Homoharringtonine 72 Niclosamide   
 
 
Supplementary table 2. qRT-PCR primers (human gene) used in the study, from 5' to 3'. 
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Supplementary Fig. S1. Antiviral effect of gemcitabine (GCT) on MA104 cell line and its 50% inhibitory 
concentration (IC50) curves. (A) 50% cytotoxic concentration (CC50) curves of GCT on MA104 cell line. 
(B) Dos-dependent inhibitory activity of GCT on MA104 cell line. (C) On Caco2 cell line, IC50 is 3.977 µM. 
(D) On MA104 cell line, IC50 is 0.1161 µM. 
 
 
Supplementary Fig. S2. Indirect fluorescence microscopy for Caco2 cell line under 40* vision field. 
The ratio of VP6 positive cells/ total cell number was quantified under these visions of field (n=6).  
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Supplementary Fig. S3. Standard curve for quantifying rotavirus genome copy numbers. An amplicon 
of the SA11 was cloned into the pCR2.1-TOPO vector. The plasmid was extracted, followed by a series 
of dilutions, from 10-2 to 10-10, were prepared and then were amplified and quantified by qRT-PCR. 
Standard curve was generated by plotting the cycle threshold (CT) value regarding the log copy number.   
 
 
Supplementary Fig. S4. Determination of organoids cell death. Fluorescence microscopy images 
analysis of human intestinal organoids (HIOs) treated with gemcitabine (GCT) then stained by PI (red) 
which represented as dead cell, Hoechst (blue) which represented as nuclear, and Calcein (green) 
which represented as live cell. We define the lower left HIO (with red signal more than green signal 
and also more than 50% of blue signal) as positive HIO; on the contrary, HIOs like upper right one, will 
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The development of rotavirus vaccines has made huge impact on global burden of rotavirus 
infection (1). This positive development has however diminished attention to quest for 
successful combat against rotavirus infection. However, the mortality of rotavirus disease 
remains considerably high in developing countries, especially in sub-Saharan Africa and south-
east Asia (2). Additionally, some organ transplanted patients and IBD patients are still under 
the risk of contracting rotavirus infection (3). Moreover, recent research and case reports 
showed that rotavirus might be one of the viral causes of biliary atresia (4). So, investigation 
on rotavirus and focusing on antiviral treatment is still needed. This consideration led me to 
start research described this thesis, and here I want to summarize the result and outline my 
comprehension as what these results tell us. 
Rotavirus infection and cytopathogenesis in development of biliary atresia 
One important issue with respect to rotavirus is that the full extent of clinical complications 
provoked by the virus may have been underestimated. Biliary atresia (BA) is a neonatal liver 
disease characterized by progressive fibro-inflammatory obliteration of both intrahepatic and 
extrahepatic bile duct. The etiologies of BA remain largely unknown, and although some 
hypotheses as to how BA may come about, there is little actual data. Intriguingly, rotavirus 
infection might be a viral factor provoking this condition as a rotavirus-induced biliary atresia 
mouse model is a wildly established model for research on BA. In the present work I exploit 
liver organoids culture platforms to obtain more insight (5).  
Results of my study indeed bolstered the case of a connection between rotavirus and BA. In 
total seven batches of biliary organoids from 3 different origins allowed productive infection 
with rotavirus, as evidenced by the generation of infectious viral particles, strongly suggesting 
that at least some type of cell in liver or bile duct is susceptible to rotavirus. Although I think 
this is an important step in making the case that rotavirus causes BA, I feel much more work 
is necessary  and more research is now warranted: firstly, more rotavirus strains, and 
especially clinical isolated should be tested in more batches of organoids from different origins. 
Secondly, we should apply more differentiated organoids to test the infection, so that we can 
find out which type of cells are susceptible to rotavirus infection. Thirdly, mouse 
experimentation and infection of mouse biliary organoids may help us to get better 
understanding of the mechanism rotavirus-induced BA in vivo. Last but not the least, more 
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clinical evidence will help to reveal how rotavirus gets into neonatal bile duct. Does occur 
during gestation and can the virus overcome the placenta barrier or does infection occur in 
the birth canal?  
Interferon mediated antiviral strategies 
The Eukaryotic Translation Initiation Factor 4F (eIF4F) complex, containing a eukaryotic 
translation initiation factor 4A (eIF4A), a eukaryotic translation initiation factor 4E (eIF4E), and 
a eukaryotic translation initiation factor 4G (eIF4G), is a translation initiation factor that tightly 
regulates translation in response to a multitude of environmental conditions including viral 
infection (6). In our study, we found that blocking PDCD4 (a negative regulator of the eIF4F 
complex) elevates the activity of the three components of eIF4F complex and thereby inhibits 
rotavirus replication in host cells. Mounting evidence indicates that such inhibitory activity is 
the result of more efficient expression of antiviral proteins from the interferon signaling 
pathway. Thus, the eIF4F complex may become a promising target for development of new 
antiviral agents. 
In line with this notion are especially the results of my studies in cell lines and intestinal 
organoids, which show that the interferon (IFNs) production, which follows rotavirus infection, 
can upregulate the expression of Interferon-stimulated genes (ISGs), but that cell autonomous 
endogenously produced IFNs are not able to limit rotavirus replication. This is mainly due to 
the ability of rotavirus to subvert the host innate immune response. However, exogenous 
treatment all three existing types of IFN treatment are effective in inhibiting rotavirus 
infection, and I also observed that combining IFNs with antiviral drugs also has a remarkable 
performance in limiting rotavirus infection, both in conventional cell lines and in the organoid 
model. Although further study should be done to identify which specific ISGs mediate the anti-
rotavirus effect to complement the understanding of immunity against rotavirus, I feel my 
results indicate that IFN-mediated or IFN combined antiviral medication therapy should now 
be considered for managing problematic cases of rotavirus infection. 
Nucleotides based anti-rotavirus strategies 
Nucleotides play an important role in host cell metabolism but are obviously also essential for 
virus replication. Thus, targeting on purine or pyrimidine biosynthesis pathway might 
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effectively inhibit rotavirus replication and thus constitute a novel approach for potential 
novel anti-rotavirus therapy. Intriguingly, especially for organ transplanted patients, who are 
under the risk of rotavirus infection after surgery (3), a need for taking immunosuppressive 
drug exist and these drugs can be inhibitors of enzymes located in nucleotide producing 
pathways or be poorly metabolizible analogues of some intermediate products. Indeed such  
drugs have been described to exert potent antiviral activity against various types of virus (7-
10). Therefore, taking this type of drugs would be a “kill two birds with one stone” solution, 
limiting rejection as well as virus infection at the same time. However, mechanisms of antiviral 
activity should be evaluated before clinical use, take 6-thioguanine (6-TG) and leflunomide 
(LFM) for instance, in my study, 6-TG exerts its antiviral activity through impairing Rac1 
activation, and LFM can inhibit activity of the DHODH enzyme to limit rotavirus replication. 
However, in a previous HEV study, those two drugs have pro-viral effects on HEV infection in 
the Huh7 cell line (11). So, when considering using nucleotides based antiviral therapy, more 
comprehensive tests are required for specific drugs before clinical use is appropriate. 
Broad-spectrum antiviral reagents screening strategy 
Developing new drugs usually takes a long period of time require massive investments while 
risk of failure is high. Specifically, for rotavirus drug development, the potentially low return 
on investment ratio discourages widespread investment in the development of novel antiviral 
drugs. Faced with this problem, I proposed that repurposing existing drugs represents a cost-
effective approach to identify antiviral treatment  (12). In this line of thinking, screening of 
already clinically approved drugs screening should be a good way to reduce development 
costs. Among all kinds of drugs, broad-spectrum antiviral agents should be in the first round 
of the screening process. To be noticed in this respect, many antiviral drugs my host laboratory 
investigated are from the broad-spectrum antiviral agents (BSAAs) library. Setting drug 
libraries like BSAAs library is highly needed for humankind in order to have broader range of 
candidate drug options when viral pandemic (like the ongoing global COVID-19 pandemic) 
occurs.  
Overall conclusions and future perspectives 
In this thesis, I first established that rotavirus may be one of the causal factors with respect to 
biliary atresia, which also emphasized the importance of investigating rotavirus infection and 
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further illustrates the desperate need of novel antiviral treatment. Consequentially, we aimed 
at discovering anti-rotavirus strategies through targeting the interferon pathway, by inhibition 
of the nucleotide synthesis pathways and through broad-spectrum antiviral agents screening, 
respectively. These strategies provided insight to new antiviral drug development and provide 
a window to better treatment.  
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Het rotavirus vormt een gesel die de mensheid hard treft. Deze ziekteverwekker infecteert 
onze darmen en veroorzaakt daar diarree, met als gevolg ziekte, uitdroging en kindersterfte. 
Ofschoon, eerst door verbeterde hygiëne en daarna door de introductie van vaccins de 
situatie sterk verbeterde, blijft rotavirusinfectie een groot probleem. In grote delen van de 
Derde Wereld is het nog steeds één van de belangrijkste oorzaken  van kindersterfte. 
Daarnaast is het rotavirus ook gevaarlijk voor kwetsbare bevolkingsgroepen zoals 
transplantatiepatiënten en patiënten die immuunsysteemonderdrukkende medicijnen 
gebruiken. Tenslotte zou het zo kunnen zijn dat er klinische beelden bestaan die wel 
veroorzaakt worden door rotavirusinfectie, maar die niet als zodanig herkend worden. Zoals 
ik in hoofdstuk 1  uitleg dreven deze overwegingen mij het onderzoek zoals beschreven in dit 
proefschrift uit te voeren, waarbij ik mij met name heb geconcentreerd op het geven van een 
aanzet met betrekking tot het ontwikkelen van nieuwe geneesmiddelen voor de behandeling 
van rotavirus infectie. Zulke geneesmiddelen bestaan namelijk momenteel niet en artsen zijn 
dus gedwongen om bij de behandeling van rotavirusinfectie zich grotendeels te beperken tot 
geven van vocht en zout, dit om uitdroging van de slachtoffer(tje)s tegen te gaan, terwijl er 
gehoopt wordt op spontaan herstel. 
In hoofdstuk 2 kijk naar afsluitingen van de galgang (zogenaamde biliaire atresie), een 
zeldzame ziekte bij pasgeborenen. Verlittekening van de galwegen veroorzaakt het ophopen 
van gal en indien er niet geopereerd wordt leidt dit tot steeds verder voortschrijdend 
leverfalen en uiteindelijk tot overlijden op jonge leeftijd. De oorzaak is onbekend, maar in dit 
hoofdstuk laat ik zien dat de cellen die galwegen bekleden geïnfecteerd kunnen worden met 
rotavirus (dit was nog niet bekend) en daar effecten veroorzaken die overeenstemming zijn 
met een rol voor het rotavirus bij het ontstaan van biliaire atresie. Ik kon deze resultaten 
publiceren in het vooraanstaande vaktijdschrift mBio. Ik laat dus zien dat problematiek 
geassocieerd met het rotavirusinfectie zelfs nog groter is dan gedacht. 
In Hoofdstuk 3 en Hoofdstuk 4 kijk ik naar hoe ons aangeboren immuunsysteem 
rotavirusinfectie onder de duim kan houden. In hoofdstuk 3 doe ik daarbij een interessante 
observatie. Rotavirus heeft de eiwit-producerende machinerie van de cel nodig om zichzelf te 
kunnen vermenigvuldigen. Ik zie echter dat ons aangeboren immuunsysteem dezelfde eiwit-
producerende machinerie nog harder nodig heeft om het virus effectief te kunnen bestrijden. 
Het remmen van de eiwit-producerende machinerie is dus een heilloze weg bij het ontwerpen 
van nieuwe therapie. Deze resultaten heb ik gepubliceerd in het vooraanstaande 
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wetenschappelijke tijdschrift Nature Scientific Reports. Vervolgens heb ik verder gekeken naar 
hoe het aangeboren immuunsysteem nog geholpen zou kunnen worden bij effectieve 
remming van virusvermenigvuldiging. Ik zie daarbij dat het geven van antivirale cytokinen 
(cytokinen zijn enigszins vergelijkbaar met hormonen) het aangeboren immuunsysteem zo 
sterk aanspoort dat het nu effectief het virus gaat bestrijden. Omdat dergelijke antivirale 
cytokinen ook echt aan mensen kunnen worden gegeven, geeft dit een duidelijk handvat bij 
het ontwerpen van nieuwe mogelijke therapie, gebaseerd op het aanjagen van de activiteit 
van ons eigen immuun systeem in haar gevecht met het rotavirus. Deze resultaten werden 
gepubliceerd in het vooraanstaande vaktijdschrift Antiviral Research. 
Ofschoon dus bleek dat het remmen van de eiwitproductie niet de oplossing is bij het 
bestrijden van het rotavirus, bleef de mogelijkheid openliggen dat remming op RNA niveau 
wel effectief zou kunnen zijn. Rotavirussen bevatten hun genetische informatie in een dubbele 
RNA streng en als de aanmaak van de betrokken nucleotiden geremd wordt, zou dat heel wel 
een oplossing kunnen bieden bij indectie. Nucleotiden komen in twee smaken, pyrimidines en 
purines. Inderdaad zag ik dat remmers van pyrimidine biosynthese een sterk effect hadden 
tegen rotavirus (Hoofdstuk 5). Ook een remmer van purines (6-thioguanine) was effectief 
tegen rotavirus, maar dit effect bleek niet via purine biosynthese te lopen, maar via de 
immuunsysteemregulator p21Rac (Hoofdstuk 6). Onder voorwaarden kunnen zowel 
pyrimidine synthese inhibitoren alsook 6-thioguanine veilig aan patiënten worden gegeven en 
dus twee middelen zijn ook nieuwe mogelijkheden voor de behandeling van rotavirus infectie. 
Ik wist beide studies dan ook te publiceren als twee artikelen in het vooraanstaande 
vaktijdschrift Antiviral Research. 
Belangrijke overwegingen bij de ontwikkeling van medicijnen zijn de kosten en moeite die 
men zich moet getroosten om vast te stellen dat de betreffende medicijnen veilig zijn. Bij 
bestaande medicatie, die reeds getest is, speelt dit uiteraard niet. Medicatie heeft vaak 
meerdere werkingen in het lichaam en het zou zo maar kunnen dat er bestaande medicatie is 
die toevallig ook effectief rotavirusinfectie kan bestrijden. Daarom besloot ik een grote 
bibliotheek van bestaande en reeds geteste medicijnen te onderzoeken op hun vermogen 
rotavirusinfectie te remmen. In Hoofdstuk 7 beschrijf ik de resultaten en laat ik zien dat het 
antikanker medicijn gemcitabine heel krachtig is tegen rotavirus. Vooral voor kankerpatiënten 
die veel risico lopen op rotavirusinfectie zou dit wel eens een belangrijke overweging kunnen 
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vormen in de beslissing met welke medicatie zij behandeld moeten worden. Een publicatie is 
in voorbereiding. 
Al met al heb ik het gevoel dat ik met dit proefschrift een aantal belangrijke nieuwe 
handvatten heb gevonden met over wanneer en hoe behandeling van het rotavirus 
uitgevoerd moet gaan worden. Ik hoop dan ook met dit proefschrift een bijdrage te hebben 
geleverd in het gevecht van de mensheid tegen dit virus. 
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